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Abstract
Aneuploidy, an abnormal complement of chromosomes, is present in approximately 90% of human
malignancies. Despite over 100 years of research, many questions remain regarding the contribution
of aneuploidy to the cancer phenotype. In this thesis, we develop computational methods to infer the
presence and specific patterns of aneuploidy across thousands of primary cancer tissue specimens. We
then combine these inferences with clinical and genomic features of the cancer samples to refine our
understanding of both the clinical implications of aneuploidy, and how it evolves in various human
cancers. We identified a signature of chromosomal instability from specific genes whose expression
was consistently correlated with aneuploidy in several cancer types, and which was predictive of
poor clinical outcome multiple cancer types. Current genomic characterization techniques measure
somatic alterations in a cancer sample in units of genomes (DNA mass). The meaning of such
measurements is highly dependent on the tumors purity and its overall ploidy; they are hence
complicated to interpret and compare across samples. Ideally, copy-number should be measured in
copies-per-cancer-cell. Such measurements are straightforward to interpret and, for alterations that
are fixed in the cancer cell population, are simple integer values. We develop two computational
methods to infer tumor purity and malignant cell ploidy directly from allelic analysis of DNA.
First we describe HAPSEG, a probabilistic method to interpret bi-allelic marker data in cancer
samples in order to produce genome-wide estimates of homologue specific copy-ratios. Second, we
describe ABSOLUTE, a method that infers purity, ploidy, and absolute copy-numbers from the
estimates produced by HAPSEG. In addition, ABSOLUTE can analyze point mutations to detect
subclonal heterogeneity and somatic homozygosity. We used ABSOLUTE to analyze ovarian cancer
data and discovered that 54% of somatic point mutations were, in fact, subclonal. In contrast,
mutations occurring in key tumor suppressor genes, TP53 and NF1 were predominantly clonal
and homozygous. Analysis of absolute allelic copy-number profiles from 3,155 cancer specimens
revealed that genome-doubling events are common in human cancer, and likely occur in already
aneuploid cells in many cancer types. By correlating genome-doubling status with mutation data,
we found that homozygous mutations in NF1 occurred predominantly in non-doubled samples. This
finding suggests that genome doubling influences the pathways of tumor progression, with recessive
inactivation being less common after genome doubling.
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Chapter 1
Introduction
Scott L. Carter
Effective treatment of cancer requires a margin of therapeutic specificity, whereby cancer
cells are selectively killed (or inactivated) with sufficient specificity so as to be
physiologically tolerated by the patient. Following the early success of Farber
developing chemotherapy for childhood leukemia, the history of cancer treatment is
strewn with gruesome examples of pushing such tolerance to its limits, and beyond[1].
Targeted approaches to treating cancer
Decades of research have culminated in the modem understanding of cancer [2]. By
identifying the genetic alterations unique to cancer cells, which drive the cancer
phenotype, modem science has produced cancer treatments precisely targeting cancer
cells, offering the promise of cancer eradication with minimal toxicity to the patient.
The first example of such treatment is the use of Imatinib to treat chronic myelogenous
leukemia (CML). Nearly all such neoplasms are driven by the BCR-Abl fusion protein,
formed by a recurrent chromosomal translocation (the "Philadelphia chromosome") [3],
[4]. This success was followed in 2004 by reports describing gain-of-function mutations
in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR)
which conferred sensitivity to pharmacologic EGFR inhibition [5], [6], [7]. Notably, lung
adenocarcinomas harboring KRAS mutations exhibit primary resistance to these therapies
[8].
Collectively, the dependence of cancer cells on specific mutations which drive the cancer
phenotype has been termed "oncogene addiction" [9]. An additional example is the
BRAF gene, which is mutated in 50-70% of malignant melanomas[10], predicting
enhanced sensitivity to pharmacologic MAP kinase inhibition (e.g., RAF or MEK
inhibitors). Pharmacological inhibition of mutant, activated, BRAF [11] was
demonstrated to be effective in treatment in metastatic melanoma[1 2].
Resistance mutations
Unfortunately, all efforts to directly target oncogene addiction in human cancer patients
have resulted in the eventual outgrowth of resistant cancer clones, many of which are
refractory to the available targeted and cytotoxic treatment. For example, in CML
treatment with BCR-Abl many patients eventually relapse. In 2001, Charles Sawyers and
colleagues showed that many such relapses were associated with a single amino acid
substitution in the Abl kinase domain, known to form a critical hydrogen bond with the
drug [13].
Similar resistance mutations have been reported in the treatment of EGFR-driven cancers
with EGFR inhibitors. For example, the mutation EGFR (T790M), which occurs in the
kinase domain, is associated with resistance to Gefitinib [14], [8], [15]. Alternately,
resistance in these tumors may also be driven by amplification of the MET oncogene
[16], which may co-occur with the T790M mutation[1 7].
Finally resistance to the PLX4720 pharmacologic inhibitor of MEK/BRAF is associated
with both MEKl(P124L) and MEKl(Q56P) mutations [18]. In 2010, MAP3K8 (the gene
encoding COT/Tpl2) was identified as a MAPK pathway agonist, the amplification of
which drives resistance to RAF inhibition in B-RAF(V600E) cell lines[1 9]. Also in
2010, another group identified induction of PDGFRb expression and tyrosine
phosphorylation as a dominant feature of acquired resistance in human melanoma-
derived cells [20].
Thus, in all cases, a single mutational event allows the cancer cells to escape targeted
inhibition of driver oncogenes.
Non-oncogene addiction
Another approach to achieve selective killing of cancer cells is to target normal cellular
processes that are of greater importance to the survival of cancer cell, relative to normal
cells. This concept has been labeled "non-oncogene addiction" [21]. Notably, because
such pathways may be targetable by general means, acquired mutations affecting a single
gene may be less likely to confer resistance to the cancer cell. Such intervention might
therefore be less predisposed to the development of resistance mutations than targeting
oncogene addiction directly.
A paradigmatic example of non-oncogene addiction was the demonstration by Susan
Lindquist and colleagues in 2007 that the heat shock factor 1 (HSF1) gene is a potent
modifier of carcinogenesis[22]. HSF1 encodes the master regulator of eukaryotic heat
shock response [22], and controls the expression of heat-shock proteins that promote
protein refolding, prevent protein aggregation, and target mis-folded proteins for
destruction. The authors demonstrated that HSF1 deficiency in mice protects against
tumorigenesis driven either by mutations of the RAS oncogene or a recurrent mutation in
the tumor suppressor p53 (p53Rl 72H) [22],[21].
In contrast to expression of mutant Ras alleles, over-expression of HSF1 was unable to
transform immortalized mouse embryonic fibroblasts [22]. In addition, the viability of
multiple human cancer cell lines was decreased following knockdown of HSF 1 by short
hairpin RNAs (shRNAs). However, HSF1 knockdown had only minimal impact on the
viability of normal cells such as primary mammary epithelial cells and WI-3 8 human
lung fibroblasts. The heat-shock response thus fulfills the criteria for a targetable non-
oncogene addiction in human cancer [21].
The DNA damage repair pathway represents another aspect of normal cellular function
which becomes essential to the viability of cancer cells. This has been exploited in
BRCA deficient cells by inhibition of the poly(ADP-ribose) polymerase (PARP) enzyme
involved in base excision repair, a key pathway in the repair of DNA single-strand
breaks. Genetic and pharmacologic inhibition of PARP results in chromosomal
instability, cell cycle arrest and subsequent apoptosis in human embryonic stem-cells
deficient for BRCA1 or BRCA2, but not in their wild-type counterparts[23]. Both MCF7
(wild-type p53) and MDA-MB-231 (mutated p53) human breast cancer cell lines display
a similar sensitivity to PARP inhibition upon depletion of BRCA2 with short interfering
RNAs [24]. Furthermore, pharmacologic PARP inhibition is effective in mouse
xenografts seeded with the BRCA2-deficient V-C8 cell-line, but not with the BRCA2
reconstituted V-C8-B2 cell-line [24]. Because patients carrying germline cancer risk
alleles in BRCA2 (BRCA2+') are likely to become BRCA2- by somatic deletion of the
wild-type allele, PARP inhibition offers a selective window to treat such tumors [24],
[25]. Indeed, several follow-up studies have shown clinical efficacy of such inhibitors
[26], [27], [28].
Thus PARP inhibition in BRCA incompetent cancers represents a distinct aspect of non-
oncogene addiction, whereby a specific pathway (BRCA-mediated homologous repair)
facilitating cancer development causes increased reliance of the cancer cells on the
normal function of a protein (PARP). The demonstration by systematic RNA
interference that oncogenic KRAS-driven cancers require TBK1 [29] provides another
example of this type of synthetic interaction with a cancer pathway.
The role of aneuploidy in cancer development
In the early 2 0 th century, Theodore Boveri observed that aneuploidy, a chromosome
complement that is not a multiple of haploid, is a frequent feature of cancer cells and
suggested that it might represent a causal mechanism [30]. Recent studies have
confirmed that aneuploidy is one of the most ubiquitous features of human cancer,
present in greater than 90% of cases [31], [32].
What roles might aneuploidy have in the evolution of human cancers? It has previously
been proposed that the distribution of age at cancer diagnosis is consistent with a
requirement of genetic instability to generate the number of serial transformations
required to evolve the mature cancer clone [33]. A classic model holds that, after an
initial period of genetic instability, a stable aneuploid karyotype emerges[34], which may
then evolve further by punctuated evolution[35]. Despite its ubiquity in cancer,
aneuploidy is not tolerated by normal human cells [36], suggesting that alterations
specific to the cancer phenotype may confer viability to aneuploid cells.
How does this frequent aneuploidy arise and what evidence supports a causal role for
aneuploidy in cancer? Several mechanisms have been demonstrated by which
chromosomal instability and resulting aneuploidy may be generated.
Experimental data have shown that chromosomal instability is functionally associated
with defects in mitotic spindle checkpoints [37],[38]. Such defects allow mitoses to
proceed in settings of improper chromosomal alignment, kinetochore attachment, or
kinetochore tension, [39], [40] thus leading to variable distribution of chromosomes
among daughter cells. Despite earlier reports of somatic mutations in spindle-checkpoint
genes resulting in chromosomal instability and aneuploidy[38], [41], [42], efforts to
attribute chromosomal instability in many human cancers to defects in these genes have
been lacking. For example, the BubR1 mutations identified in a small number of
colorectal cancers [38] have not been demonstrated in subsequent genome sequencing
studies of colorectal or other human cancers[43]. Thus it remains doubtful whether
chromosomal instability is caused by specific genetic alterations in a large fraction of
human cancers, as has been previously suggested [41].
Another potential source of genetic instability during tumor evolution is telomere crisis,
whereby the normal telomeric 'caps' at the ends of chromosomes erode to critically short
length, at which point they trigger DNA double-stranded break (DSB) response, which
can result in the free DNA ends being randomly joined together. This can lead to the
creation of chromatids bearing multiple centromeres, which can then attached to opposite
spindle poles during the next cell division. This can result in the di-centric chromosome
being broken again, leading to additional DSB repair, exacerbating the process.
Importantly, this process may be terminated by expression of the telomerase gene, which
can stabilize free DNA ends and halt this cycle [34]. Telomere crisis has been shown to
induce genetic instability and tumorigenesis in mouse models [44].
An additional potential source of genetic instability in human cancer could be due to the
excess centrosome number sometimes observed in cancer cells. Normal human cells
contain 2 centrosomes, which function during cell division to nucleate the assembly of
microtubules forming the mitotic spindle. Normally, the replication of centrosomes is
controlled by licensing factors permitting duplication only once per cell cycle. Excess
centrosome content has been shown to lead to multipolar spindles, typically with
disastrous consequences for the resulting cell. One obvious way for a cell to obtain an
excess centrosome complement would be to undergo an abortive mitosis, where both the
DNA and centrosomes are duplicated, but the cell fails to complete cytokinesis. Indeed,
the frequent observation of chromosome complements far in excess of the diploid number
in human cancers has lead to much speculation that tetraploidization is a common event
in human cancer[36], [45], [46].
Tetraploidization, because it produces rampant aneuploidy, was first proposed as a
carcinogenic mechanism by Theodor Boveri in 1914 [30]. Multiple lines of evidence are
consistent with the view that tetraploidization has a role in the development of at least
some human cancers: (i) Many mature cancers display chromosome complements far in
excess of diploid [46], [47]; (ii) 4N populations of cells have been demonstrated in
precancerous lesions, and correlated with p53 loss and increased genetic instability [48],
[49]; (iii) A number of cancer causing genetic events - for example Rb loss and APC loss
- are known to cause cytokinesis failure and thus genome doublings [36], [50], and
additional mechanisms have been demonstrated in vitro [51], [52]; (iv) Finally, the
principal that cytokinesis failure can promote tumorigenesis has been directly
demonstrated using animal models [53], [54].
Recent results have shown that excess centrosomes can occasionally cluster into two
poles at mitosis to form a reasonably normal bi-polar spindle [54]; however, excess rates
of chromosome mis-segragation were observed in such mitoses. These results suggest a
means by which excess centrosomes could contribute to the genetic instability during
cancer development.
Despite these insights, several fundamental questions remain regarding the evolution of
aneuploidy in human cancer: (i) Is aneuploidy a cause or consequence of the cancer
phenotype? (ii) At what stage of cancer development might aneuploidy emerge? (iii) Are
specific mutations required to trigger chromosomal instability? (iv) Do specific genes or
pathways become essential to viability in the aneuploid cellular state? (v) How does a
genetically unstable cell stabilize its karyotype, generating the predominantly
monogenomic cancer clones observed in most mature cancers? (vi) How might
aneuploidy be related to polyploidization or genome-doubling?
The advent of high throughput technologies with which to characterize thousands of
tumor samples has shed light on some of these questions. For example, previous analysis
of cancer karyotypes relied on spectral karyotyping (SKY), a laborious technique to
visualize stained metaphase chromosomes. The low resolution and difficulty of
analyzing these data have led to some misconceptions about somatic copy alterations
(SCNAs) in cancer. For example, it has previously been stated that:
One barrier to defining the role of aneuploidy in tumour biology is the genetic
complexity of aneuploid cells. Like Tolstoy's unhappy families, each aneuploid
tumour is aneuploid in its own way[36].
In fact pan-cancer analysis of several thousand tumor copy-profiles using high-density
DNA SNP microarrays has revealed that many chromosome-arm level SCNAs are
remarkably recurrent within cancer types and lineages [55]. This suggests that selection
for gain and loss of specific chromosome arms plays a prominent role in shaping the
stable cancer karyotype emerging from chromosomal instability. On the other hand, this
also complicates the analysis of aneuploidy observed in human cancers, since it may be
difficult or impossible to separate the phenotypic contributions of aneuploidy per se from
its downstream consequences on proliferation, etc.
Model systems to study the effects of aneuploidy
Over the past several years, Angelika Amon and colleagues have created model systems
in which cellular phenotypes associated with specific aneuploidies can be dissected. By
engineering yeast strains lacking the karyogamy gene KAR1 and mating them with wild-
type, nuclear fusion is prevented, resulted in abortive matings, in which individual
chromosomes are occasionally transferred from one cell to another. By placing different
selectable markers in each mating partner at the same genomic location, the authors were
able to selectively isolate these rare events and generate strains ("disomics") carrying 13
of the 16 possible single chromosome gains [56]. In order to further discern whether the
phenotypes associated with aneuploidy are dependent on gene dosage effects, these
experiments employ yeast artificial chromosomes (YACs), which are constructed from
human DNA and do not contain transcribed genes [56].
Characterization of these strains revealed that disomics share a number of phenotypes,
including defects in cell cycle progression, increased glucose uptake, and increased
sensitivity to conditions interfering with protein synthesis and protein folding (e.g. high
temperature)[56]. Importantly, these defects were not observed in the strains bearing one
of more YACs, indicating that they result from alterations in gene-dosage, and not due to
physiological consequences of abnormal DNA content, such as altered spindle
geometry)[56]. Interestingly, the YAC-bearing strains shared a common transcriptional
response with several of the disomic lines, suggesting the existence of transcriptional
programs induced solely by excess DNA content[56]. Using analogous experimental
methods, similar results have been obtained in mouse cells [57].
Recently, it was demonstrated that these same disomic yeast strains display many
features of genetic instability, including increased rates of point-mutation and
chromosomal mis-segregation[58]. These results suggest that there may not be a hard
distinction between aneuploidy and chromosomal instability (i.e. a 'state' vs. a 'rate'), as
had previously been proposed [59].
Aneuploidy as a potential non-oncogene addiction
Because of its ubiquity in human cancer, aneuploidy would make a highly attractive type
of non-oncogene addiction to target. It is possible that genetic instability is required for
generation of the mutational diversity needed for the evolution of the cancer phenotype
[33]. While aneuploidy may be an important prerequisite to the development of many
cancers, it may also confer specific weaknesses, which may be exploited for cancer
treatment. This leads to the question of which normal cellular functions unique to the
aneuploid cell-state might be exploited to obtain a therapeutic window. Because it
creates stoichiometric imbalances among the components of many protein-complexes,
aneuploidy may produce an excess burden for protein folding chaperones and
proteosomal degradation mechanisms; these conditions can induce a partial heat-shock
response [60]. As reported by Angelika Amon and colleagues in 2007, aneuploidy of
each individual yeast chromosome is sufficient to induce the heat-shock response and
proteotoxic stress [56]. Furthermore, these cells are especially sensitive to proteosomal
inhibition or high-temperature stresses [56], [32]. These results are consistent with the
demonstration by Susan Lindquist and colleagues in 2007 that HSF 1 deficiency in mice
protects against tumorigenesis driven either by mutations of the RAS oncogene or a
recurrent mutation in the tumor suppressor p53 [22],[21].
In 2010, Angelika Amon and colleagues reported the evolution of specific genetic
adaptations to tolerate aneuploidy in yeast strains[61]. In particular, a loss-of-function
mutation in the gene encoding the deubiquitinating enzyme Ubp6 resulted in increased
proliferation of several aneuploid yeast strains [62]. In 2011, the same group reported the
identification of chemical compounds with aneuploidy-specific lethality [63].
Targeting of the proteosome has been a successful means to treat malignancies in the
past, with demonstrated induction of apoptosis specifically in cancer cells [64].
Clinically therapeutic responses have been obtained in the treatment of multiple myeloma
with Bortezomib (Velcade), which targets the 26S proteasome [65]. In addition, the anti-
cancer effects of the antibiotic geldanamycin are mediated by its ability to specifically
bind an evolutionarily conserved 'pocket' domain of the protein-folding chaperone
HSP90 [66]; this pocket likely plays an important role in the binding of HSP90 to its
client substrates.
A more thorough of the clinical and genomic correlates of aneuploidy in human cancer
might allow for additional insight into mechanisms by which this cancer hallmark might
be therapeutically exploited.
Thesis summary
Chapter 2: Gene expression correlates of aneuploidy in human cancer samples
Chapter 2 describes work done in 2005-2006 in collaboration with Dr. Zoltan Szallasi at
the Children's Hospital Informatics Program (CHIP). Although increased expression in a
panel consisting of 8 major mitotic checkpoint genes in human breast cancer cells with
chromosomal instability was reported in early 2006 [67], no systematic evaluation of
gene expression associated with aneuploidy had been performed. Because many gene
expression datasets were becoming publically available, we used gene expression
measurements to infer segmental DNA copy-number alterations. These imbalances could
then be directly correlated with the expression of individual genes. This approach was
attractive because very few datasets existed with DNA copy-number and mRNA
profiling of the same samples.
Inferences of segmental copy-change were performed at fixed resolution, set arbitrarily to
cytological sub-bands. The resulting measurements of genome-imbalance were
summarized in each sample as a scalar estimate, termed 'functional aneuploidy". This
score was used as a bait to indentify genes co-expressed with aneuploidy over diverse
cancer expression profiles. The set of genes with the highest CIN-score over all samples
comprised a coherent module of genes, including many known regulators of cytokinesis,
spindle checkpoint, DNA damage response2.
Characterization of aneuploidy is not part of standard clinical practice for most human
cancers3 . Due to the interest in developing clinically prognostic gene expression
signatures around 1998 - 2006, many of these samples were annotated with clinical
1 A term coined by Dr. Szallasi, which was inspired by the term 'functional genomics',
used to describe analysis of mRNA profiles at the time).
2 It is the author's opinion that the coherence of this gene-expression module made the
limitations of the SCNA detection irrelevant.
3 An important exception is neuroblastoma, in which hyperdiploidy is closely associated
with improved relapse-free survival in some patient groups [42]. Ploidy is thus often
evaluated in such cases to inform treatment.
outcome data. We noted that the mean expression of the top CIN-score genes was
broadly prognostic of cancer recurrence, consistent with the association between clinical
grade and aneuploidy. We demonstrated that the CIN-score was a superior predictor of
breast-cancer prognosis than tumor grade however, showing that 'intermediate' grade 2
patients split into two groups by CIN signature, with outcomes equivalent to grade 1 and
grade 3. These results were published in 2006, and are included in this thesis as Chapter
2. In the discussion section (Chapter 5), further results based on the CIN signature paper
published over the last 5 years are summarized.
Chapter 3: Statistical analysis of DNA SNP-microarray data
In order to better characterize genomic copy-number alterations in human cancer
samples, we turn to direct measurement of somatic DNA copy-number alterations
(SCNAs) using DNA microarrays. Specifically, we developed a technique to measure
the copy-ratio of both homologous chromosomes. This is accomplished by
computational identification and quantization of heterozygous loci in the cancer-derived
DNA.
Human genomes are normally diploid, with one copy of each homologous chromosome
derived from either parent in each cell4 . Due to pervasive aneuploidy in human cancers,
many genomic regions have homologous copy-imbalances. This implies that germline
heterozygous loci in the cancer sample may be present at two distinct concentration
bands in the measured allelic copy-ratios (for a segment with constant total copy-
number).
Chapter 3 describes work done in 2008-2010 in collaboration with Dr. Gad Getz. We
developed rigorous statistical methodology (HAPSEG) for analysis of allelic copy data at
polymorphic loci in cancer-derived DNA. HAPSEG was originally developed in order to
4 Although it is becoming increasingly apparent that polyploid cells also play a role in
normal physiological processes [33], notably, as a response to genotoxic stress in mature
hepatocytes [43].
produce highly accurate estimates of homologue-specific copy ratios (HSCRs) in cancer
samples. As we point out, gross genomic aberrations common in cancer samples require
specialized inference methods. Specifically, we estimate the germline genotypes and
genome-wide copy-ratios of both parental homologues. This is accomplished by
statistical analysis of bi-allelic DNA concentration measurements at many polymorphic
loci using either SNP microarray or massively parallel sequencing technology, in order to
infer germline genotypes, phase of imbalanced heterozygous markers, and copy ratio of
both homologues in the cancer clone. We develop specialized error-models for use with
DNA microarrays.
Accurate inference of homologous copy-ratios is crucial for interpretation of absolute
copy-number states in cancer-cell populations, which may be obscured by unknown
tumor purity and ploidy. Indeed, HSCR estimates from HAPSEG formed the input data
for subsequent joint inference of tumor purity, ploidy, and absolute allelic copy-numbers
(described in Chapter 4).
The use of HSCRs reduces the ambiguity of observed copy- profiles with regard to their
interpretation as fixed SCNAs having simple integer copy-numbers. For example, the
total copy ratio profile of a sample without SCNAs would be equivalent for ploidy values
of 1,2,3, etc., however the HSCR profile would rule out odd ploidy values, since these
would not be consistent with equal allelic copy-numbers. In addition, since subclonal
alterations will affect only a single HSCR value in a given genomic segment, the ratio of
clonal to subclonal SCNAs genome-wide is generally higher than when only total copy-
numbers are considered.
Because recombination at meiosis is highly non-random[68], and tends to occur at
'hotspots' along the genome where recombination is much more likely, the genotypes of
adjacent SNPs are not statistically independent of one another. Rather, they show
patterns of linkage disequilibrium, whereby nearby genotypes are correlated.
When the phase of adjacent heterozygous markers is known, the resulting haploid
genotypes (or, haplotypes), display an even stronger statistical dependency, the structure
of which is intimately connected to the recombination rate and the evolutionary history of
the patient population. Specifically, it is possible to statistically describe phased
haplotypes involving common SNPs as a 'mosaic model' [69], which summarizes each
sequence of phased markers as a 'mosaic' of reference haplotypes, with occasional jumps
from one chromosome to another; the probability of such jumps is governed by the local
recombination rate, which is often estimated using family-trio genotyping[70].
Such a panel of reference genotyped chromosomes were produced by the international
HAPMAP project[70]. Because only a few hundred such chromosomes are needed to
describe the genetic variation in a given population (down to 5% MAF), this provides a
more powerful way to summarize human population-genetic variation than can be
obtained using minor allele frequencies, or the commonly used r2 metric of correlation
between nearby SNP genotypes.
These dependencies between phased adjacent genotypes are exploited by HAPSEG to
obtain optimized estimates of HSCR and germline genotypes. This is useful to accurately
recover the germline genotypes when they have become obscured in the cancer sample,
as can happen in regions of somatic LOH when the cancer sample is very pure5 . Because
estimation of HSCRs requires jointly estimating marker genotypes, exploiting genotype
dependencies also improves the HSCR estimates; specifically the additional genotype
information is invaluable in preventing spurious over-fitting of the HAPSEG statistical
model at regions of allelic-balance, which can occur in some samples. Because the
haploid genotypes implied by such over-fitting are not at all consistent with a plausible
mosaic of phased chromosomes, HAPSEG will reject the spurious phasing and converge
at allelic balance for such regions.
5 In this scenario, the concentration of (germline) heterozygous alleles is nearly identical
to that of germline homozygous alleles.
The separation between the allelic concentrations of each homologous chromosome
provides a means of direct haplotyping within such regions, which we demonstrate
anecdotally. Implications of this capability for medical and population genetic analysis
are discussed further in Chapter 3 and in the discussion section (Chapter 5).
Chapter 4: Resolution of integral copy numbers for fixed SCNAs
Chapter 4 describes work done in 2007-2011 in collaboration with Drs. Gad Getz and
Matthew Meyerson. We developed a novel method, called ABSOLUTE, which can
accurately infer the number of copies per-cancer-cell of somatic DNA alterations
detected in (commonly impure) tumor tissue samples. In order to accomplish this,
ABSOLUTE performs joint inference of tumor purity and ploidy, based on the HSCR
profiles produced by HAPSEG (Chapter 3).
The shift from the currently used relative measurements to absolute per-cancer-cell
measurements greatly enhances our ability to analyze cancer samples because absolute
units reflect the true underlying discrete nature of the DNA alterations that occurred
during cancer evolution (e.g. amplifications, deletions, point mutations), and enables us
to distinguish clonal from subclonal events.
Although we and others have been attempting to solve this problem for several years, no
currently described methods are capable of large-scale deployment to the analysis of
thousands of tumor samples. The key improvements that contributed to increasing the
accuracy were: (i) Enhancing our model to allow for a small fraction of copy-number
events to be subclonal; and, most importantly, (ii) Disambiguation of several equally-
likely candidate solutions by comparison to a large set of tumor absolute allelic copy-
profiles (these were constructed directly from the input dataset of 3,155 cancer samples,
by using the least ambiguous profiles in a 'boot-strapping' fashion.)
We present the results of the systematic application of ABSOLUTE to 3,155 cancer
copy-profiles and 214 paired whole-exome sequencing samples, revealing several novel
insights regarding human cancer evolution. Analysis of absolute allelic copy-profiles
from a diverse panel of human cancers revealed that whole genome doubling events
occur frequently during somatic evolution, ultimately resulting in mature cancers
descended from doubled cells, bearing complex karyotypes.
In addition to the discussion of our use of ABSOLUTE to characterize human cancer
evolution with respect to aneuploidy and genome doubling in Chapter 4, additional
scientific context and future directions are presented in Chapter 5.
Statistical inference techniques
Formal coursework in graduate school statistics consisted of Machine learning at MIT
with Professor Leslie P. Kaelbling, Introduction to Computational Biology at MIT with
Professors Tommi Jaakkola, Richard Young, and David Gifford, and attendance of
Bayesian statistics lectures by Professor Jun Liu at Harvard. Starting in the fall of 2007, I
began working with Dr. Gad Getz who served as an invaluable mentor in translating
statistical ideas covered in this coursework into practically applicable research tools. Dr
Getz's background in the physical sciences naturally inclined him towards Bayesian
methods, an inclination shared by his new student.
Classical statistical analysis allows for inference of unknown parameters underlying the
generation of observed data by a modeled stochastic process. These inferences may be
expressed as point-estimates (e.g. maximum likelihood estimates), or as confidence
intervals, the interpretation of which is restricted to thefrequentist definition of
probability as the limiting distribution of a sampling process, (e.g., as the frequency of a
'heads' in an infinite number of coin-tosses). The classic application of frequentist
statistics is to answer questions of the form: what is the probability of a obtaining a test-
statistic of this magnitude or greater, given a specific parameter setting? Where the test-
statistic is computed from a probability distribution over the data with parameter set to
model the 'null effect' hypothesis, to be rejected if this probability (or P-value) falls
below 0.05.
While this definition is often useful for simple statistical tests,6 it does not easily support
the integration of uncertainty from multiple sources, which can be invaluable in
leveraging all available data to obtain optimally sensitive inferences. For a
demonstration of inconsistencies implied by the frequentist interpretation of probability,
as well as a historical perspective explaining its dominance in 20t century statistics, see
the 1986 paper by B. Efron, "Why isn't everyone a Bayesian?" [71].
If data Xrepresent random variables generated from a probability distribution
parameterized by 0, then the likelihood of the data P(X |0) can be directly calculated.
By inversion of this conditional probability using Bayes' rule we obtain:
P(9 I X) =P(X I 6)P(6)
P(X I 6)P(9)d9
Where P(6 |X) gives the posterior probability distribution on 6, summarizing the state of
uncertainty on the value of 6 given the prior specified as P(9) and observed data X7. The
key innovation of Bayesian statistical analysis is the modeling of parameters specifying
random processes as themselves generated from additional probability distributions of
specified form. In this formulation, the interpretation of probability is ultimately
subjective, rather than as the limiting sampling distribution of the frequentist'. This
difference in interpretation has no bearing on the mathematical properties of probability,
however. At the end of the day, it is up to the practitioner to decide what the resulting
probabilities mean, although this is certainly not unique to Bayesian inference.
6 in which cases it is generally equivalent to a Bayesian procedure, e.g. the Student's t-
test.
7 Although it is often assumed that the use of Bayes' rule is equivalent to Bayesian
statistics, this is incorrect, as the use of Bayesian statistics in the modem technical sense
precedes Bayes himself, with the marquis de Laplace generally acknowledged as the first
Bayesian.
8 Arguments related to this particular difference in interpretation have reportedly resulted
in several brawls among professional statisticians.
Although it may seem like a this difference is therefore a subtle semantic point, this shift
in viewpoint allows for the development of complex statistical models, in which
probabilistic dependencies among multiple variables are linked together to optimally
exploit all available data. This process is formalized in the modem technique of
probabilistic modeling with graphical models [72].
In particular, Hierarchical Bayesian models (HBMs), as described in [73], allow pooling
of information from many instances of a phenomenon in order to estimate parameters
which are modeled as shared among them. This strategy is employed directly to estimate
parameters quantifying the extent of cross-hybridization between probes to either allele in
SNP microarray data (Chapter 3) and in various aspects of the modeling described in
Chapter 4.
In addition, we favor the 'Occam Factor' interpretation of Bayesian evidence [74], which
naturally embodies the scientific precept that simpler models should be favored over
more complex models with equivalent explanatory power. This principle can be used to
quantitatively evaluate the evidence supporting models of differing complexity, given the
available data (another major advantage of the Bayesian framework). This technique was
used in the HAPSEG method (Chapter 3) in order to choose whether adjacent genomic
segments truly had differing copy-number. For further ease of computation, the Laplace
approximation[74] was used to approximate the posterior volume of the parameter space
of the locations in each model. In addition, the formulation proposed by
Spiegelhalter[75] is attractive, although we have not yet implemented such techniques.
An attractive feature of explicit modeling using HBMs is quantification of the requisite
amount of prior belief required for acceptance of a given inference from the model. This
allows for a rigorous examination of the importance of one's prior assumptions on the
conclusions drawn from a given dataset. That being said, in the case of the work with
ABSOLUTE presented in Chapter 4, there is very little doubt as to the robustness of the
main biological conclusions, which are qualitatively consistent with many aspects of
cellular biology and prior cytological analysis of cancer samples.
An important aspect of using complex probabilistic models is that they be calibrated, that
is, the posterior certainty obtained by fitting to the data truly reflects the probability of the
modeled event (e.g., a parameter value lying within a 95% posterior-fit confidence
interval should contain the true value 95% of the time). We note that this is only
generally possible when the model describes the exact stochastic process by which the
data were generated. We note that this condition describes the ideal modeling situation,
whereby all sources of uncertainty can be normalized to universally interpretable
probability distributions, which can then be combined for optimal inference. While this
condition is never truly satisfied in practice, it is often the case that models accurate
enough to be useful can be readily constructed and fit to datasets using modem Bayesian
methods, which involve various types of approximation to aid computation.
Importantly, if the a given model under consideration is inadequate to produce calibrated
estimates of the uncertainty in fit parameters, then the construction of an elaborate
computational scheme to estimate posterior distributions of these parameters will not
result in useful inferences. Rather, in such cases effort should be directed at refining the
model specification to capture more of the relevant variation in the data, leveraging as
much prior information regarding the processes generating the data as is possible.
The use of hierarchically constructed karyotype models to regularize the inference of
tumor purity/ploidy (Chapter 4) is an example of this philosophy. The mode-finding
algorithm used to find all possible interpretations of sample allelic copy-profiles9 finds
maximum likelihood solutions; estimation of the uncertainty around these modes is
irrelevant to the inference of main interest: which of the modes represents the unique
correct solution. This is because the likelihood used in the mode-finding is based on a
Gaussian mixture-model describing the generation of observed HSCRs from fixed
SCNAs, which are simple integer values, with some allowance for subclonal alterations
(modeled with uniform density over a moderate copy-ratio range). Such models are
9 Formed from the homologue-specific copy-ratios (HSCRs) estimated using HAPSEG
(Chapter 3).
vastly simpler than the biological processes which generated the data, and likely leave
much of the relevant variation in the data un-modeled.
Early versions of purity/ploidy inference used Markov chain Monte Carlo (MCMC)
sampling to fit an HBM with many parameters (including shared parameters among
samples) to large tumor datasets (details of the implementation are presented as Appendix
B of this thesis). Although this approach was successful, it was computationally
cumbersome to use, and the stochastic nature of the MCMC sampling process made some
results difficult to interpret. By further consideration of the problem, it was discovered
that many of the parameters represented in this model could be fixed for the purpose of
mode-finding, resulting in a simple two-dimensional optimization problem which was
solved using numerical coordinate ascent of the model likelihood, initiated at points in
regular lattice over the purity/ploidy domain (Chapter 4). Importantly, this process can
be performed for each sample independently, dramatically simplifying the fitting
procedure.
Instead of explicit hierarchical modeling, we incorporated pooling of sample-level
parameters by clustering cancer karyotypes to construct a database of recurrent motifs.
This was accomplished using the Expectation Maximization method on multinomial
mixture models (Chapter 4, Online methods). This database was constructed directly
from the input data itself in a boot-strapping manner, whereby less ambiguous copy-
profiles were used to seed models producing provisional priors, which further reduced the
ambiguity of remaining profiles, and so on. This process was analogous the use of an
HBM, even though it was not necessary to explicitly construct such a model to perform
the relevant inferences. In some sense, the fitting of hierarchical parameters took place in
the minds of the researchers [76], [77].
Statistical excursions
In addition to the above mentioned MCMC-sampling of the multi-sample HBM for purity
/ ploidy inference mentioned above (and described in Appendix B), collaboration with
Dr. Gad Getz resulted in several other statistical excursions over the course of my Ph.D.
In 2007-2008, we worked on a mutually devised project to predict SCNA status in
genomic regions pre-defined as being significantly recurrent in human cancer using
GISTIC[78] using gene expression data. We adopted a Bayesian factor analysis model,
with missing indicators for each gene modeling its status as copy-dependant or notlo.
This model was fit using Gibbs sampling, which resulted in predictive models with
average sensitivity and specificity of-85% for modeled GISTIC regions (not shown).
Although these results were encouraging, the production of large-scale datasets by The
Cancer Genome Atlas consortium made the need to infer DNA SCNAs from gene
expression data less compelling. Furthermore, although the dissection of gene-expression
correlation with copy-number has since been exploited to identify putative targets of
multi-genic SCNAs [79], we felt it was more pressing at the time to develop methods for
absolute copy-number inference (Chapter 4).
In 2008-2009, we investigated the Dirichlet Process (DP) model [80], [81], [82], [83],
and its use to integrate over all clusterings of genomic segments by copy-ratio. This led
to what we believe is a novel extension of the DP to the case whereby data atoms have
variable 'weights' in the clustering process. These weights corresponded to genomic
segment sizes, and were allowed reweighting of the DP clustering process to favor large
segments (details are given in Appendix B). These techniques may become useful for the
future analysis of tumor copy-profiles, particularly in the case where several clones are
superimposed in the cancer cell population.
During the same time period, we investigated extended ensemble MCMC sampling [84]
for use in fitting HBMs with strongly interacting degrees of freedom. In particular,
multicanonical MCMC sampling, as previously described [85], [86],[87] was
implemented on several real and 'toy' problems. Although this technique is extremely
powerful, and has been used to estimate key parameters of model systems in statistical
physics[87], the problems addressed in this thesis did not require this level of
10 For example, many genes expressed at or below the detection limit of the microarrays
used would be better modeled as uninformative of copy-number.
sophistication. These techniques may be useful for future computational problems in
cancer genomics, however.
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Chapter
A signature of chromosomal instability inferred
from gene expression profiles predicts clinical
outcome in multiple human cancers
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Szallasi
This chapter is presented in the context of its contemporary science and originally appeared in
Nature Genetics 38, 1043 - 1048 (2006).
Corresponding Supplementary Material can be found in Appendix A.
A signature of chromosomal instability inferred from gene expression profiles
predicts clinical outcome in multiple human cancers
Scott L Carter, Aron C Eklund, Isaac S Kohane, Lyndsay N Harris & Zoltan Szallasi
We developed a computational method to characterize aneuploidy in tumor samples based
on coordinated aberrations in expression of genes localized to each chromosomal region.
We summarized the total level of chromosomal aberration in a given tumor in a univariate
measure termed total functional aneuploidy. We identified a signature of chromosomal
instability from specific genes whose expression was consistently correlated with total
functional aneuploidy in several cancer types. Net overexpression of this signature was
predictive of poor clinical outcome in 12 cancer data sets1-" representing six cancer types.
Also, the signature of chromosomal instability was higher in metastasis samples than in
primary tumors and was able to stratify grade 1 and grade 2 breast tumors according to
clinical outcome. These results provide a means to assess the potential role of chromosomal
instability in determining malignant potential over a broad range of tumors.
One of the most consistent characteristics of human solid tumors is chromosomal instability
(CIN)'3 . Despite its fundamental importance in cancer biology, the molecular mechanisms
underlying CIN are poorly understood1'4"5 , and it is rarely measured in the clinic owing to the
technical difficulty of ascertainment and a lack of clear therapeutic application 6 .
Because aneuploidy is a consequence of CIN, genes with expression levels consistently
associated with aneuploidy might provide insight into molecular mechanisms underlying CIN.
Currently, few clinical tumor samples exist for which the extent of aneuploidy has been directly
observed and for which high-resolution gene expression data are available. However, significant
correspondence has been observed between chromosome copy number alterations and gene
expression changes in the affected regions 17,18. Therefore, we used gene expression data to infer
chromosomal imbalance at sub-band resolution (Fig. 1). This 'functional aneuploidy' profile
describes the net deviation in expression of genes contained in each chromosomal region relative
to the remainder of the sampled transcriptome (see Methods).
As a measure of overall chromosomal imbalance, we defined the 'total functional
aneuploidy' (tFA) of a sample as the sum of the magnitudes of its functional aneuploidy features.
We assessed tFA across the NCI60 cell line panel, for which gene expression profiles, DNA
copy number profiles (SNP-chip)' 9 and spectral karyotyping (SKY) data2 0 are available,
providing independent DNA-based characterization of chromosomal aberrations. The tFA
measure correlated with the total number of structural chromosomal aberrations as assessed by
SKY (P = 0.0009) and with total aneuploidy measures derived from DNA copy number
measurements (P = 0.0004; Supplementary Fig. 1 online). Thus, tFA is a proxy for the overall
level of aneuploidy assessed at the transcriptional level (Fig. 1b,c).
We analyzed 18 gene expression data sets'-12 (Supplementary Fig. 2 online) of various
cancer types and found that high tFA was a significant predictor of poor clinical outcome in four
data sets profiling breast, lung and brain tumors2,4,6, 7 (Supplementary Fig. 2). Given this
association with poor prognosis, we reasoned that genes associated with tFA might uncover
specific molecular mechanisms connecting high levels of CIN with increased tumor malignancy.
Within each data set, we calculated the correlation between tFA and expression level for each
gene. The correlation of expression of each gene to tFA was similar across data sets
(Supplementary Fig. 3 online), suggesting the existence of a common mechanism involved in
the generation or maintenance of aneuploidy.
We derived a 'CIN score' for 10,151 genes present on multiple platforms by combining
the ranked level of correlation of each gene to tFA in multiple data sets from diverse tumor types
(see Methods). The gene with highest CIN score, TPX2, has a key role in chromosomal
segregation and causes polyploidization when overexpressedl. The second-highest ranked,
PRC1, encodes a regulator of cytokinesis2 2 and a putative substrate of the product of another top-
ranking gene, CDC2 (ref. 23). FOXM1 encodes a transcriptional regulator of genes involved in
chromosomal segregation and cytokinesis24 , such as KIF20A (ref. 25), which also has one of the
highest CIN scores. In fact, the list of 70 top-ranking genes contain an array of key regulators
that maintain faithful replication and segregation of chromosomes, including A URKB, NEK2,
H2AFX, CDC20, ZWINT, CCNBJ, CCNB2 and AURKA (Supplementary Table 1 online).
Therefore, these genes may represent members of one or more functional modules, the
overexpression of which causes or is associated with CIN.
We examined the ability of the top-ranked genes to predict clinical outcome in the 18
aforementioned cancer data sets. We stratified patients into two groups, based on whether the top
25 or 70 genes with the highest CIN score (designated the CIN25 and CIN70 signatures,
respectively) in each individual were above or below mean expression of the CIN25 or CIN70
signature in the cohort (Fig. ld,e). This simple classifier (CIN25) was a significant predictor of
clinical outcome in 12 of the 18 data sets representing breast cancer 5, lung cancer6 ,
medulloblastomal, glioma7,9, 12 , mesothelioma8 and lymphoma"' (Fig. 2). (Nonsignificant
predictions are shown in Supplementary Fig. 4 online.) We obtained similar results using the
CIN70 signature (13 of 18 data sets were stratified according to clinical outcome; data not
shown).
We next evaluated the CIN25 and CIN70 signatures in data from a study that examined
primary tumors and metastatic foci from several solid tumor types26. The metastasis samples
expressed a higher level of the CIN25 signature than did the primary tumors (P = 0.0067, Fig. 3
and Supplementary Methods online). The same analysis using the CIN70 signature gave a
similar result (P = 0.0035; data not shown). Furthermore, we observed a subset of primary
tumors with higher relative expression of the signatures, consistent with the hypothesis that the
metastatic expression profile originates in primary tumors and is maintained in the distant
metastases.
Clinically, the degree of malignancy is thought to be reflected by tumor grade, which is a
subjective histological assessment of cellular differentiation and proliferation. We examined the
relationship between the CIN25 signature and tumor grade in three breast cancer data sets 3 for
which tumor grade data were available. We stratified grade 1 and grade 2 tumors according to
their CIN25 signature expression and found that high-CIN25 tumors within each of these grade
categories were associated with a worse clinical outcome (Fig. 4). However, grade 3 tumors
were uniformly associated with high CIN25 signature expression and could not be separated
using this measure. This result supports the recent suggestion that histopathological grading
might be refined or replaced by gene expression signatures, which more accurately reflect patient
outcome'.
Because many of the genes we identified as associated with CIN are periodically
expressed during the mitotic cell cycle, it was formally possible that the prognostic ability of the
CIN signature was due to its detection of proliferation rate rather than to its detection of CIN
itself. Previous work has examined genome-wide patterns of gene expression over time in
synchronized HeLa cells 27. Each gene was assigned a score proportional to the periodicity of its
expression over the time points after synchronization27 . We considered 888 unique genes
(represented by 1,133 clones on the cDNA microarrays used) to be cell cycle regulated; these
had cell cycle scores exceeding an empirically determined false discovery rate (FDR)
threshold27 . The total expression level of these genes in a tissue sample is thought to be a
surrogate measure of cell proliferation rate, which is associated with poor prognosis in human
cancer27
The CIN score and cell cycle scores were modestly correlated over 10,795 matched
measurements representing 5,484 unique genes (r = 0.186), although the genes with the highest
CIN scores were more likely to have high cell cycle scores (Fig. 5a). To compare the utility of
the CIN score and the cell cycle score for choosing predictive genes, we systematically dissected
the two signatures.
First, we divided the 70 genes with the highest CIN scores (CIN70) into a set that was
considered cell cycle regulated (CIN70_CC), and one that was not (CIN70_noCC) (Fig. 5a). We
found that the CIN70_noCC group generated significant outcome predictions in 10 of the 18
tested cohorts, whereas the CIN70_CC group did so in 11. Therefore, the predictive ability of the
CIN70 signature was not solely due to the inclusion of cell cycle-regulated genes. We then split
the set of cell cycle-regulated genes into two groups based on their mean CIN score (Fig. 5a).
Although the high-CIN cell cycle group generated significant predictions in 11 of 18 cohorts
tested, the low CIN-score group worked in only five (Fig. 5b and Supplementary Fig. 5 online).
We evaluated functional categories representing specific aspects of the cell cycle
implicated in CIN14 ,15 for CIN score enrichment relative to the set of cell cycle genes. Gene sets
representing the mitotic spindle assembly (P = 0.003), spindle checkpoint (P = 0.00078) and
DNA damage checkpoint (P = 0.048) had significantly greater CIN scores than the cell cycle
genes (Fig. 5c), consistent with the hypothesis that overexpression of these specific cell cycle
control genes is associated with CIN and is not simply due to an increased proportion of mitotic
cells. Gene sets representing DNA repair, centrosome duplication and chromosome segregation
were not significantly enriched in CIN score relative to cell cycle-regulated genes (P = 0.52,
0.64, 0.99, respectively).
We also evaluated the gene sets with CIN score enrichment for enrichment in cell cycle
score27 (Fig. 5d). While the mitotic spindle assembly and spindle checkpoint gene sets showed
strong enrichment for cell cycle score, the DNA damage checkpoint gene set showed only
modest enrichment. The fact that DNA damage checkpoint genes are not cell cycle regulated but
tend to be overexpressed in aneuploid tumors suggests that transcriptional induction of the DNA
damage checkpoint is specifically associated with CIN. This result was in agreement with a
previous finding that activation of the DNA damage checkpoint in preneoplastic and neoplastic
lesions is not directly related to the proliferative status of tumor cells 28.
There was also an overlap of four genes between our CIN25 signature and a previously
described 44-gene 'proliferation cluster 29 that is overexpressed in high-grade tumors29.
Multivariate analysis confirmed that the CIN signature had greater prognostic relevance
(Supplementary Fig. 6 online), and systematic dissection of the proliferation signature
demonstrated that its prognostic utility was due to its inclusion of CIN-associated genes
(Supplementary Fig. 7 online).
The overexpression of the CIN signature in cells with high levels of aneuploidy may be
due to at least three distinct mechanisms. It is possible that cells with aberrant DNA content
produce more of the machinery required for chromosomal duplication and segregation.
Alternatively, the expression level of the CIN signature may reflect a compensatory mechanism
for impaired functioning of the machinery responsible for maintaining the integrity of genetic
information at the chromosomal level. This possibility would provide potential targeting
strategies for cancer treatment. A third possibility is that the overexpression of the CIN genes
allows cells to complete mitosis unimpeded by the usual checkpoints, thus conferring both direct
proliferative advantage and increased cellular heterogeneity.
Our results focus attention on a specific set of genes involved in cellular processes critical
for maintenance of genome integrity that are relevant both biologically and clinically. The CIN
signature stratifies multiple tumor types according to clinical outcome across tumor grade and
shows elevated expression in metastatic foci, suggesting the importance of these genes in
defining a more aggressive cancer phenotype. Dissecting the mechanisms by which CIN arises
and contributes to the malignant phenotype remains a major challenge in cancer research. By
identifying specific genes associated with CIN, we hope to elucidate a key process underlying
malignant transformation. In addition, these results support the more widespread application of
chromosomal instability measures in clinical diagnostics, which have been rarely used owing to
technical difficulty and unclear significance 16. Finally, this work identifies important cellular
targets that may yield broadly applicable therapies.
METHODS
Integration of gene expression data sets. The methods used to integrate and normalize the
microarray data sets are given in Supplementary Methods.
Functional aneuploidy measure. For a given data set, all of the normalized gene expression
measurements present on the microarray and mapping to a given chromosomal cytoband region
were grouped into a set designated 'B' (short for band). The rest of the genes, localized elsewhere
on the genome, were grouped into a set 'G' (short for genome). The functional aneuploidy
measure for the given cytoband is the value of Student's t statistic comparing sets B and G:
t = JUB - G
a2I|NB) + (C2 ING)
where m is the mean, s2 is the variance and N is the number of genes within a set. This process
was iterated for each gene expression profile in a given data set such that we obtained a matrix of
t statistics for each of 300 cytobands per array. If fewer than ten genes were present in a given
cytoband, then we considered the statistical measure unreliable, and that cytoband was
eliminated from further analysis. This left 200-250 features per sample in a given data set,
depending on the coverage of the microarray platform used.
'Total functional aneuploidy' (tFA) is the sum of all functional aneuploidy magnitudes
(the absolute t statistics) in a given tumor sample, giving a single measure of spatially
coordinated transcriptional activity.
Derivation of the CIN25 signature. First, we calculated, for each data set, the tFA for each
sample. We then computed for all genes the correlation coefficient across all samples between
each gene's expression vector and the tFA vector. We considered only the 10,151 genes
measured on each of the Affymetrix U133A, U133+2 and Rosetta 25k microarray platforms. We
then ranked the genes in each data set by their correlation with tFA. Ranks were normalized
within each data set such that the gene with the highest (positive) correlation had rank 1.0 and
the gene with lowest (negative) correlation had rank 0. We then selected three of the data sets
representing diverse tumor types (breastio, ovarian 13 and small-cell lung carcinoma 3), with the
highest coverage of the transcriptome (for which we had greater confidence in our computations
of functional aneuploidy and tFA), and we summed the ranks of each gene to derive the final
integrated ranking (Supplementary Fig. 3). The top 25 genes from this ranking formed the
CIN25 signature. The CIN70 signature was derived in a similar manner using the 70 top-ranked
genes.
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Figure 1 Schematic overview of the process used to derive and apply a gene expression
signature of chromosomal instability. (a) Published microarray data sets from various microarray
48
+
platforms were integrated for the analysis. (b) Profiles of functional aneuploidy were computed
for each tumor as described in the text. Shown are two examples with low (left) and high (right)
levels of total functional aneuploidy (tFA). The color and intensity of the individual cytobands
indicate the direction and magnitude of the differential expression of the genes contained in the
given chromosomal region. (c) Heat map showing expression of the 500 genes most correlated
with tFA, the top 25 of which define the CIN25 signature. (d) Heat map showing normalized
expression levels of the CIN25 signature for a cancer-associated data set. Tumors with an above-
average level of CIN25 signature net expression are predicted to have a poor clinical outcome
(bar at the bottom indicates clinical outcome). (e) Censored survival (Kaplan-Meier) curves for
each predicted category.
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Figure 2 The CIN25 signature predicts survival in 12 independent cohorts representing six
cancer types. Data sets are identified by the first author of the published manuscript and the type
of cancer profiled. P values correspond to the log-rank test comparing the survival curves
generated from the CIN25 signature as a categorical predictor.
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Figure 3 Metastatic foci expressed higher levels of the net CIN25 signature than primary tumors
of diverse origin. Shown are cumulative density plots of CIN25 expression for the primary
tumors (green) and metastases (red). The vertical dashed line indicates the average level of the
CIN25 signature's net expression for all samples. P values assessing the significance of
increased CIN25 signature expression in metastases were calculated from one-sided t tests, as
decreased expression would contradict our previous results that the CIN signature is associated
with a more advanced tumor phenotype. A subset of the primary tumors showed elevated levels
of CIN25 signature expression, possibly indicating higher malignant potential in these tumors.
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Figure 4 The CIN25 signature stratifies three independent cohorts of grade 2 breast tumors
according to clinical outcome, and one cohort of grade 1 breast tumors. The CIN25 signature did
not stratify any of the grade 3 cohorts according to clinical outcome, despite the presence of
heterogeneity in clinical outcome among these tumors. P values correspond to the log-rank test
comparing each pair of survival curves.
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Figure 5 The ability of CIN genes to predict clinical outcome is independent of their cell cycle
score. (a) A plot of cell cycle score versus CIN score shows modest overall correlation. Gene
sets were formed by imposing combined thresholds on CIN score and cell cycle score:
CIN70_noCC (red, the CIN70 genes with the 41 cell cycle-regulated genes removed). The 764
unique cell cycle-regulated genes were divided into two groups, based on whether their CIN
score was above or below average relative to the cell cycle group (blue and turquoise, termed
CChighCIN and CClow CIN, respectively). (b) Comparison of prediction performance of
r=w0.186
various gene sets. Each bar indicates the log-rank test statistic comparing the survival curves
corresponding to the two prognosis classes generated using the indicated gene set for outcome
prediction. The CIN70-CC signature generated significant predictions for 11 data sets, and the
CIN70-noCC was effective in 10, confirming that the general prognostic power of the CIN genes
is not due to a direct association with proliferation. The CClowCIN signature classified only
five data sets significantly. (c) Gene categories implicated in the faithful propagation of genomic
information, such as mitotic spindle assembly, spindle checkpoint and DNA damage checkpoint,
are enriched for high CIN scores, relative to all cell cycle-regulated genes (one-sided Wilcoxon
test, P = 0.003, P = 0.00078, P = 0.048, respectively). (Gene category membership is based on
NCBI Entrez Gene as of 25 April 2006.) The cumulative density of CIN scores is plotted for the
genes in the indicated categories. (d) Although the mitotic spindle assembly and spindle
checkpoint gene sets show high enrichment for cell cycle score, the DNA damage checkpoint
gene set showed only modest enrichment. Shown are cumulative density plots of cell cycle score
for the clones mapping to genes in the indicated categories.
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Abstract
Interpretation of allelic copy measurements at polymorphic markers in cancer samples
presents distinctive challenges and opportunities. Due to frequent gross chromoso-
mal alterations occurring in cancer (aneuploidy), many genomic regions are present
at homologus-allele imbalance. Within such regions, the unequal contribution of al-
leles at heterozygous markers allows for direct phasing of the haplotype derived from
each individual parent. In addition, genome-wide estimates of homologue specific copy-
ratios (HSCRs) are important for interpretation of the cancer genome in terms of fixed
integral copy-numbers. We describe HAPSEG, a probabilistic method to interpret bi-
allelic marker data in cancer samples. HAPSEG operates by partitioning the genome
into segments of distinct copy number and modeling the four distinct genotypes in each
segment. We describe general methods for fitting these models to data which are suit-
able for both SNP microarrays and massively parallel sequencing data. In addition, we
demonstrate a specially tailored error-model for interpretation of systematic variations
arising in microarray platforms. The ability to directly determine haplotypes from
cancer samples represents an opportunity to expand reference panels of phased chro-
mosomes, which may have general interest in various population genetic applications.
In addition, this property may be exploited to interrogate the relationship between
germline risk and cancer phenotype with greater sensitivity than is possible using un-
phased genotype. Finally, we exploit the statistical dependency of phased genotypes
to enable the fitting of more elaborate sample-level error-model parameters, allowing
more accurate estimation of HSCRs in cancer samples.
Author Summary
The human genome typically exists in two copies of each chromosome, with one copy, or homologue
derived from either parent. One of the most fundamental hallmarks of human cancers is their
tendency to have aneuploid genomes, that is, unbalanced copy-number alterations in the genetic
material at various blocks of the normal human genome. This often results in unequal contributions
of the homologues derived from either parent to the genomes of cancer cells. Estimation of the
precise contribution of each homologue in a DNA sample obtained from cancer tissue is crucial
to understand the genetic alterations occurring specifically in the cancer cells. Such estimation
requires the identification and interpretation of alterations in the genetic sequence of each homologue,
such as they appear in the cancer sample, which contains a mixture of DNA derived from both
cancerous and normal cells. We have developed a statistical method to accurately model the resulting
data, producing summarizations of the information from hundreds of thousands of data points into
hundreds of segments, describing the concentration of both homologues for large genomic regions
of equal copy-number. In addition, we show that the tendency of cancer samples to be aneuploid
may be exploited to attribute contiguous chromosomal blocks of genetic variation to one or the
other homologue, representing the contribution of a single parent. Because they can help reduce the
dimensionality of the data, such summarizations will be useful to further understand the interaction
between inherited genetic variation and cancer development.
Introduction
The genomes of human cancer cells frequently harbor copy-number alterations, ranging from focal
gain and loss of small regions to widespread chromosomal aneuploidy [1], [2], in many cases exacer-
bated by DNA ploidy increases followed by predominant attrition of the fixed DNA in the evolving
somatic clone [3]. Allelic analysis of cancer genomes offers several advantages in analysis of cancer
genomes [4], [5]. Detection of genomic regions with fixed somatic loss of heterozygosity - (LOH)
helps identify recessively inactivated tumor suppressors, carrying mutations on the retained allele
[6]. In particular, allelic measurements are required for detection of copy-neutral LOH, which may
occur either due to compensatory gain of the retained alleles, or by homologous recombination. Fi-
nally, genome-wide HSCR estimates provide the foundation for inference of tumor-nuclei percentage,
cancer-genome ploidy, and integral allelic copy-numbers [7], [8], [9], [3].
Human genomes are normally diploid, with one haploid genome inherited from each parent
(although tetraploid cells are also involved in physiological processes [10].) As a result of widespread
chromosomal aneuploidy, many genomic regions are in homologos-allele imbalance, with the two
homologues fixed at unequal copy-numbers within the somatic clone [3]. Methods for genotyping
diploid samples are unsuitable for analysis of aneuploid cancer samples. For example, discovery of
both germline and somatic point-mutations in cancer samples using massively paralell sequencing
typically requires analysis of paired cancer-normal DNAs [11], [12]. For SNP microarrays, probes for
each SNP allele are calibrated using diploid control samples [13], making genotype calls unreliable
in aneuploid samples [14].
Accurate estimation of homologue-specific DNA concentrations in tumor samples is challenging
due to substantial marker-level noise occurring on a background of complex biases related to the
genotypes, sequence context, allelic copy-numbers at which loci are observed. The particular mani-
festation of these factors in the resulting data depends on physical properties of the technology used.
Development of explicit generative models describing these effects in particular samples can provide
greater sensitivity to detect true alterations in the underlying cancer genome. We extend previous
physically grounded error models for gene expression microarrays [15], [16] for use with Affymetrix
SNP arrays, facilitating our ability to estimate HSCRs in multiple cancer-derived datasets.
Early work with SNP microarrays demonstrated the feasibility of allelic cancer-genome analysis
[17, 18, 4], setting the stage for development of methods to detect allele-specific amplification [19],
and LOH in unpaired samples [20]. Development of high-resolution Affymetrix SNP6.0 microarrays
was enabled by the development of a method to accurately calibrate allelic probes, allowing for
highly accurate genotyping without the need for mismatch probes [13]. These calibrations became
the basis for modern cancer total copy-ratio analysis using these arrays [21], [22], [23].
The development of methods for allelic analysis in cancer samples has been further pursued to
identify genomic regions of LOH [24], and as part of solutions to the tumor purity/ploidy problem
using Illumina bead-arrays [7], [8], and in Affymetrix SNP6.0 microarrays [25], [14], [9]. Our view
is that this problem is best treated separately, allowing for detailed treatment of the HSCR problem
and facilitating comparison of various methods specifically addressing this problem [26], [27], [28].
We present a novel computational method, HAPSEG, for accurate estimation of haplotype-
specific DNA copy-ratios (HSCRs), offering several specific advantages over existing methods: (i)
implementation of an advanced error model tailored to the basic physics of Affymetrix SNP microar-
ray measurements; (ii) Internal recomputation of genomic segmentation using error-model fit; (iii)
utilization of LD information from phased haplotype panels [29], improving inference of genotypes
by exploiting statistical dependencies between the genotypes of adjacent markers, and improving
HSCR estimation.
We present a novel demonstration of direct haplotype phasing using allelic imbalances in cancer-
tissue samples. These are of interest to further characterize the influence of germline risk in cancer
development. In addition, this capability may be used to generate densley typed reference panels of
phased chromosomes for use with imputation of rare alleles in whole exome sequencing
Results
Method overview
Consider a defined set of polymorphic bi-allelic markers (SNPs), for which data proportional to the
concentration of each allele (channels a and b) has been generated. For microarray data, the set
of SNPs is fixed by the array design. We define the copy-ratio as the ratio of allelic concentration
in a cancer-derived DNA sample to that of the haploid locus concentration in an equivalent DNA
aliquot derived from diploid cells. The copy-ratio of a given allele depends on both the (germline)
genotype and on the concentration in the cancer-derived DNA of the homologue on which it resides
(the location).
Calibration is the process by which SNP measurements are standardized to copy-ratios. The
specific manner in which calibration is performed depends upon the measurement technology being
considered (e.g. microarray or sequencing). After calibration, the expected a and b values for a SNP
in a diploid sample (at a region of 2 copies) are (0,2), (1,1), or (2,0), corresponding to genotypes BB,
AB/BA, and AA, respectively. These values are observed with substantial noise, the distribution of
which depends upon the measurement platform being used.
Because DNA copy-number is expected to be locally constant along the genome, superior HSCR
estimates can be obtained by pooling datapoints within segments of constant total copy-ratio. For
the purpose of initializing such a segmentation, calibrated signal from the a and b channels is added
together genome-wide to produce copy-ratio estimates independently of marker genotypes. These
values are input to the a segmentation algorithm, (e.g. CBS [30]), which fits a piecewise constant
regression function to these values with respect to their location along the reference genome.
Figure 1 shows an example of HAPSEG on a cancer sample with pervasive allelic imbalance.
Calibrated allelic copy-ratio estimates for each marker (fig. la) were modeled using HAPSEG,
which performed haploid genotyping and segmentation (fig. 1b). The resulting HSCR estimates
are summarized at segmental level (fig 1c), revealing discrete levels occurring at regular copy-ratio
intervals, consistent with fixed SCNAs in the cancer clone (fig 1d). These estimates formed the basis
of a large-scale inference of absolute copy-numbers in cancer [3].
We assume that, within such a segment, the copy-ratios of both haplotypes will nearly always
remain constant. Violations from this assumption would correspond to coincident breakpoints,
with compensatory changes in the homologous copy numbers such that the total is unchanged.
We note that such cases are theoretically possible (homologous recombination), and have been
previously reported using related methods [28]; we leave the treatment of such alterations to future
development.
A maximum of two distinct homologous copy-ratios can exist in a given segment, and the sum
of A and B alleles at (germline) heterozygous sites must equal the number of A and B alleles at
homozygous AA and BB sites, respectively. The allelic concentration ratios therefore generally corre-
spond to four clusters the possible phased genotype of each SNP. The locations of these components,
denoted pAAj> /1 ABi, IBAj, /BBj, are specified by two free parameters: the total copy-ratio ri, and
the difference of homologous copy-ratios, denoted 5j. The locations of the homozygous components
are then:
AA (0, i I 1 BBi (Ti, 0) (1)
The locations of the heterozygous components are:
AAB I BAi -(2)
As segments approach allelic-balance (6 -+ 0), the two heterozygous clusters become superimposed,
with the natural corollary that no information is provided regarding the phase of SNPs in that
segment (as when genotyping diploid samples). To model observed allelic data, we represent the
four possible phased genotypes using a mixture model with components for each genotype {AA, AB,
BA, BB}. Figure 2 demonstrates HSCR estimation on 3 example segments (from a single sample,)
at differing homologous copy-numbers (fig 2a,b). The relationship between homologous imbalance
and phased genotyping is demonstrated (fig 2c-h).
The calibrated data for M measured markers, X, are a 2 x M matrix of bi-allelic (haploid)
copy-ratio point estimates. Segmentations of X are denoted by S, which specify partitions of X
into N successive matrices X1...N. For each segment i, Xi has dimension 2 x Mi, where Mi refers
to the number of SNPs in the segment. The model parameter C represents the 4 phased genotypes
of SNPs X. Denote by Xjj the a and b channels for SNP j in segment i, and by Ciy the genotype
of SNP j. Prior information about the genotype of each SNP may be available from population
allele-frequencies, from the analysis of a paired-normal sample, or from phased haplotype panels,
and is represented as g.
The conditional distribution of X, representing the mapping from segment locations si to proba-
bility densities over observed X1 , is denoted P (X Isi, 0), where E represents the set of sample-level
parameters representing specific sources of experimental fluctuation. Estimation of 9 at the sample-
level increases our power to fit realistically complex error-models without the risk of over-fitting small
segments. The function P and parameters 9 are specific to the measurement platform in use. We
developed a novel error-model for Affymetrix SNP microarrays (Methods) and applied it throughout.
We specify the probability density of an observed point, conditional on g as:
P (Xij |Ciy = g, o6, "r, 8) P (Xii IPig, 0) .(3)
The complete likelihood of segment i is therefore:
Mi
'i (xilo6, ri, 0, g)= fl Zi, (4)
j=1
where Ziy denotes the complete likelihood of SNP j:
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Zij= P (Xi|Cij =g, ir, 9) P (Ci3 = gg). (5)
9=1
The full sample-likelihood is:
Lf (X16, r, , S,) = ) f Li (Xi loi, 0, S, g). (6)
iES
We implemented model-fitting using general numerical optimizations which are independent of the
specific likelihood; support for alternate measurement platforms may be added by implementing
an appropriate density for P (Xi Pi, 0). We describe an general algorithm for joint estimation of
sample-level error-model parameters E and segmental allelic copy-ratios 6, r, denoted C*, allowing
updates of these parameters based on {X, S, g}: {6, , +} = C* ((n) X, $, g) .
We use the C*algorithm to iteratively update the genomic segmentation S, genotype probabilities
g, sample error-model parameters E , and HSCR locations 6, r.
Method HAPSEG:
1. Initialize: Compute $(1) from X. Set E(0), 6(0), r(O), g(0).
2. Fit error-model / segment-locations: {0(1),(1)-(1)} = C*(00)X, $1), g(o)
3. Refine segmentation: Compute $(2) from {(1), (1)(1)} Estimation of (1) allows for
more sensitive and specific evaluation of proposed segmental breakpoints. Consider a pair of
adjacent segments in the reference genome. Because the initial segmentation $(1) may have
introduced a spurious breakpoint, we develop a probabilistic criterion for their merger using
Bayesian model comparison (Methods).
4. Update: {(2), ,(2) ,(2)} = C* ((1)|X,$2), g()
5. Haploid genotype estimation: compute '(1) from P(CIX, 0, , +, g(0)). For a segment i,
posterior distributions Ci are computed for each SNP j as follows:
ai = 1 P (Xij|Ci = g, &, hi, $) P (gig(o)) , (7)
where Zij is computed as in (5). a(1) contains the probability distribution of the haploid
genotypes, with the phase information provided by homologous copy-imbalance in the somatic
clone.
6. Reconciliation of phased genotype estimates with reference panels: compute #(1)
from C1), D, m.
This procedure examines the evidence for the phased genotypes in a given segment in a panel
of phased reference chromosomes characterizing population diversity of haplotypes Consor-
tium:2010en. This is accomplished using the statistical program BEAGLE [31] to phase diploid
genotypes estimates computed from C 1). This procedure utilizes phased panels D, and an
estimate of the genetic recombination rate m to compute a maximum-likelihood estimate of
phase. HAPSEG then identifies and corrects 'switch-errors' in this phasing by reconciling the
estimates with those based on homologous imbalance (C)). The phasing ability of HAPSEG
was validated by examining the local concordance with maximum likelihood phase estimates
produced via BEAGLE [31], a statistical method based on a population reference-panel of
phased chromosomes (fig 3). We demonstrate that phase estimates produced by BEAGLE are
locally concordant with those implied by HAPSEG, but that switch-errors tend to occur at
regions of high recombination rate (fig 3a,b).
7. Final estimates:
{$, 6, } = C*($& |X,$ 2 , ) (8)
a2) = p (Cigk |Xij, Si, -?;, 7, G(1)) (9)
8. Standard error of location estimates. With the Hessian Ai as in eq.(14), standard errors
on the segment locations are:
This approximation is valid given that the posterior distribution of 6 and r is multivariate
normal.
Affymetrix error model. Following a classic microarray error-model [15] we consider the
observed calibrated signal X to be distributed according to:
X = pe 7 + E, (10)
Ar~ (0, o), c ~ Nr(0, o,),
where I represents the true copy-ratio, y and e represent multiplicative and additive errors, respec-
tively. Importantly, this allows for specifying cluster variance as a function of the mean, without
the need to fit additional segment-level variance parameters, as in [28].
We generalized this error model to the two-dimensional case appropriate for fitting two-channel
microarray data (Methods, eq. (17)). Because an explicit formula for likelihood calculations could
not be obtained, we used an approximation whereby a transformation is applied to the data, after
which its distribution becomes approximately bi-variate Gaussian. Specifically, we extended the
variance stabilization technique described for the one-dimensional case [32] to the 2D error model,
accounting for additional observed correlations in heterozygous SNP clusters, which were presumed
to arise from the PCR amplification. Additional parameters are included in 0 taking into account
attenuation and background fluctuation (Methods). The quality of the model-fit to the marker-
level data is shown in figure 4, demonstrating that much of the variation in the data is accurately
captured.
Discussion
We have demonstrated the ability of HAPSEG to accurately estimate haplotype-specific DNA con-
centrations in tumor samples, including those for which no patient-matched normal sample exists.
We demonstrated the utility of HSCR estimates from HAPSEG to estimate tumor purity, ploidy,
and absolute copy-numbers using ABSOLUTE [3]. By factorizing general inference methods from
platform-specific error models, greater generality was achieved, allowing us to easily adapt HAPSEG
to the analysis of massively parallel sequencing data. Although promising results have been obtained
from whole-exome hybrid capture sequencing (WES) [33] data (not shown), further development is
needed to derive calibrated copy-estimates from multiplexed WES using bar-coded reads.
In addition to providing accurate estimates of haplotype-specific copy-ratios, HAPSEG can pro-
duce partially phased haplotypes by exploiting the widespread allelic-imbalance common in aneuploid
cancer genomes, without the need for methods based on phased reference panels. This will have
several applications in cancer genetics, such as establishing compound heterozygosity of germline
alleles. In addition, when used with sequencing data, long-range haplotyping using HAPSEG will
aid reconstruction of complete somatic karyotype and history of aberrations transforming from the
diploid state[34]. Furthermore, these methods may aid detection of specific SCNAs subject to allelic
bias in cancer [35, 36, 8].
The availability of partially phased genotypes will allow improvements in panel-based imputa-
tion methods, which attempt to model observed diploid genotypes as a mosaic of phased reference
haplotypes [37], [38], [39], [40], [31], (reviewed[41]). Optimal exploitation of will require extension
of these methods to handle partially phased genotype data containing variable gaps (due to somatic
allele-balance.)
Similar considerations apply to admixture mapping, whereby long-range phasing may be inferred
by differences in parental allele-frequency along the genome, due to recent mixing of outbred pop-
ulations [42], [43]. The phased homologues provided by HAPSEG, each of which is derived from
a single parent, will allow for more sensitive detection of recent admixture, possibly supporting
mapping with less divergent populations than permitted in the purely diploid case. Since admixture
inferences allow for inter-chromosomal phasing of homologues, they may be of interest in the analysis
of germline risk loci.
Long-range haplotyping has utility to uncover interactions between germline and somatic genetics
in cancer. Examples include variants at the 8q24 locus, affecting inherited risk of development of
multiple cancer types [42], and later shown to interact with MYC [44]. Furthermore, these methods
may facilitate identification of additional germline alleles mechanistically predisposed to somatic
alteration in cancer, such as JAK2 in myeloproliferative neoplasms [45]. In contrast, to the above
examples, the genetic basis by which EGFR mutations in lung adenocarcinoma occur predominately
in female non-smoking patients of East Asian ethnicity [46] remains unclear.
As whole-genome sequencing of aneuploid cancer samples becomes increasingly routine, directed
long-range haplotyping using HAPSEG will increase the available panels of densely genotyped chro-
mosomes, without the need for genotyping parent-child trios. This resembles the precedent of geno-
typing uniparental-disomic samples derived from complete hydatidiform moles [47], which formed
an important component of the phased Japanese HAPMAP panel [48]. HAPSEG generalizes this
requirement to allow direct phasing from homologous imbalance, extending the samples on which it
may be applied to tens of thousands of cancer samples [49].
Long-range haplotyping is an important technique for human population genetics, with wide
ranging applications including understanding haplotype diversity and genetic recombination rates
[29], illuminating recent positive selection in the human lineage [50] and human history [51].
Partially phased genotyping by analysis of cancer-derived DNA using HAPSEG represents a novel
technique to obtain such data. This may be particularly useful in the study of poorly characterized
populations, for which phased reference panels do not exist, and for which parent-child trio data
may be impossible to obtain. In such cases, this strategy may present a cost-effective alternative to
recently described molecular methods for long-range haplotyping [52], [53].
Methods
Algorithm C*
C* uses the data, segmentation S, and genotype priors 9 to update estimates of the sample error-
model 9 and segment locations {6, r}. This is accomplished by iterating two conditional updates
until convergence of Lf:
1. Conditional update of locations {, 1r}:
Vi, l (o ,rf argmax log Li (Xjjl,, rj,E8(t), , g(ii
2. Conditional update of sample error-model 9. E is a vector of platform-specific param-
eters upon which conditional updates are performed serially. We found that the results are
insensitive to ordering, and suppress indexing:
9 (t+) = argmax logf (XIP), -r(t), 8, $, ) P(q). (12)
Note the superscripts (t) above denote the internal iterations of the C*algorithm.
3. Stop if the full likelihood Lf does not change significantly.
Probabilistic segment merging
Let Wo and ?i1 denote the seperate and merged segment hypotheses. In order to compare the
evidence supporting each model, we compute an approximation to the Bayesian evidence (Laplace)
by approximating the normalizing constant of the posterior distribution P(i, riIXj, 9). If the
posterior is multivariate Gaussian, the normalization constant may be calculated from the likelihood
and curvature at the mode:
Ev(Xi) = j i(Xilji, r, (, g(0)) (13)
det Ai -1/ 
-
~i x der x (5/2)2, (14)
where ei denotes the maximum likelihood (at oi, fj), and Ai = -VV log Li (Xi 6i, r, 8) denote the
Hessian matrix around the mode of a segment location: {64, h}. We verified the accuracy of the
approximation using quadrature on a subset of segments (not shown).
The constant third term gives the volume of the domain: 6 x ri. Note that the first and
second-two terms correspond to the 'Best fit likelihood' x 'Occam factor' formulation of Evidence,
as described in [54].
Following Bayes' rule: P(WIXi) oc P(Xi1L)P(W), we compute the Bayes factor BF('Uo):
P(LoIX1, 2) _ Ev(X1)Ev(X 2)
P(-1X12) Ev(X 12 )
Our experience suggests that the cancer genome is often heavily over-segmented using the initial
segmentation $(1 ) described above. Adjacent segments are therefore merged if BF(Lo) < 1 x 10- 10 .
BF(Wo) is computed for all breakpoints in M(1) and segments are merged greedily by joining the
adjactent pair with the lowest BF(Wo) value. The merge-probability for any breakpoints adjacent
to the resulting combined segment are computed at each step. The procedure is finished when no
pairs exist with BF(Wo) below the threshold, resulting in a refined segmentation (2). We note
that the Bayes factor defined above could equivalently be applied to accept or reject novel proposed
breakpoints in S. We leave the development of an efficient method to identify valid breakpoints to
the future.
Reconciliation of phased genotype estimates with reference panels
1. Compute diploid genotype estimates d from haploid estimates a( 1) by collapsing (marginaliz-
ing) the two heterozygous clusters.
2. Compute the maximum likelihood statsitical phasing of d using BEAGLE [31]:
a(B) = BEAGLE(d, D, m)
If evidence exists for the haploytype configurations a(1) as a mosaic of phased chromosomes
in D with recombination rate m, then these configurations will be present in a(B), Up to
occasional spurious phase reversals (switch-errors), which are expected to occur at frequency
related to m.
3. Reconcile haploid estimates from allelic-imbalance al) with a(B) by allowing for occasional
switch-errors:
- Viterbi(aC(), a(B), ]M)
This is accomplished using the Viterbi algorithm, which finds the best path through adjacent-
marker phased-genotype probabilities a,') such that they are concordant with a(B), with
occasional switches to the phase-reversed a(-B) (obtained by swapping of the AB and BA
genotype probabilities). Switching dynamics are governed by the transition-probability matrix
0.9 0.1
0.1 0.9
Thus, switches between a(B) and (-B) are expected to occur with marginal probability 0.1. We
note the adjusting the switch-error probability according to the recombination rate m would likely
be more sensitive, however these values appear to work well on our data (fig. 3). Upon termination,
0(1) contains updated knowledge about haploid genotypes C. If no phase information is implied in
a(1) (due to allelic balance), 0(1) = a(B), since the phase of either configuration in a(1) will be
equally probable. Likewise, if a(1 ) reflects a spurious phasing from over-fitting the locations of a
given segment, then the switch probability 0.1 is not adequate to form a path with expected switches
at every other marker. In such cases, the locations will be corrected by recomputing the segment
HSCRs using O(1) = aJ(B).
Calibration
(Note: The remaining sections describe methods specific to SNP microarrays)
Calibration of Affymetrix SNP-array measurements was accomplished using the Birdseed algo-
rithm [13], which combines population allele-frequency estimates with location estimates on training
samples with known genotypes. These prior estimates are adjusted by Birdseed to fit data from
batches of samples. These adjusted location estimates are then used to define the three diploid
genotype hybridization-intensity clusters, with locations denoted IAA, IAB, IBB. A large amount
of measurement error is thought to arise from variability in the conditions under which the PCR
reaction is run. We therefore define batches of PCR (eg., 96-well plates for which the reactions
were run in parallel.) Calibrations are performed independently for each of such batches. Genotype
locations are estimated using only the normal (non-cancer) samples in the batch, which need not
be paired to the cancer samples. Because Birdseed jointly determines the genotypes of the normal
samples along with the locations of the genotype clusters for the batch, it is not necessary to use
controls with known genotypes. Because normal samples are essential for calibration, we generally
recommend that at least 10 such samples be included in each batch.
With the intensity of the 3 genotype-clusters determined by Birdseed, background and scale
parameters for the a and b channels of each probe-set can be obtained. The background for each
channel is estimated as the observed intensity corresponding to zero copies of that allele:
O = IBBa ,Ob = IAAb-
The scale for each channel is estimated as the difference in observed intensities corresponding to one
and zero copies of that allele:
di. = IABa - IBBa. d1, = TABb - IAAb-
Calibrations of observed intensities in cancer samples are then computed as:
Xa = Ia - TO" , Xb = Ib - O. (16)dia dib
The calibrated signals may therefore be interpreted as ratios of the locus-concentration in the tumor-
sample to the concentration corresponding to 1 copy in a sample derived from diploid cells.
The above calibration procedure is strictly valid given linear responses throughout the domain
of locus-concentration. In fact, attenuation effects are observed for many probe-responses at locus-
concentrations corresponding to 2-copies / diploid cell, and become more pronounced with increasing
concentration. By performing calibration using only locus concentrations corresponding to 0 and 1
copy, we have sought to base our estimates on values from the linear response range in karyotypically
normal samples. Attenuation effects occurring in tumor samples are dealt with in a subsequent
section.
Following the procedure described above, we perform an additional probe-set level calibration
step designed to remove spurious correlation between the a and b channels arising due to cross-
hybridization. This procedure is described in a subsequent section.
Error model
Modern SNP microarrays measure on the order of 100-1000K polymorphic sites present in an input
DNA aliquot. Specifically, these arrays allow for the measurement of hybridization occurring be-
tween input DNA and substrate-bound oligonucleotides corresponding to each of two forms for each
polymorphic locus interrogated (an a and a b channel for each SNP). In ideal cases, the experimental
conditions under which the array is run result in hybridization proportional to the concentration
of the specific locus being interrogated, plus some unknown background (presumed to arise from
non-specific hybridization.)
The motivation for the model in eq. (10) stems from the consideration of two major noise sources
inherent in the measurement procedure. A molecule with concentration proportional to p is subjected
to n rounds of PCR amplification, to yield 2n molecules. Assume n ~ Af(m, om), then log(p) ~ N.
Hybridization of species to the microarray then results in measured signal X - N(pe, o). The
distribution of X is therefore the convolution of a normal and a log-normal distribution, representing
the measurement of a process subject to multiplicative noise using a process (hybridization) subject
to additive noise.
Although the error-model of eq. 10 fits the observed data reasonably well, consistent positive
correlation is observed between the a and b channels of the heterozygous clusters AB and BA.
Furthermore, the magnitude of this correlation is directly proportional to &, (not shown). Noting
that the two alleles of any given SNP lie on restriction fragments that typically differ by a single
base, we surmise that any variations in PCR efficiency arising due to sequence composition are likely
to be shared. This phenomenon affects only the heterozygous clusters because, by definition, one
allele is absent for any homozygous SNP, and is not subject to PCR amplification. We therefore
generalize the error-model of equation 10 to the 2-dimensional case as follows:
Xa 1a aea 1 [ E
Xb J Ibe 7b J [EbJ
a N(0, E,71 ); 77 = [ 0r77 pa, 7  (17)[ Tb I pr 7  0'??[ea ] a 01
~aNr(0, E0); E, = r IEb 10 o
Note that the assumption of diagonal additive covariance (E,) in the above equation is reasonable
only because of the calibration procedure which removes cross-hybridization signal prior to fitting
the model. This procedure is described in a subsequent section.
Attenuation
The heterozygous segment locations are overdetermined with respect to 6 and r (2). For each seg-
ment, 8 genotype-cluster coordinates are determined by two free parameters. Observed discrepancies
from these dependencies can be exploited for improved estimates of microarray attenuation.
As in [55], we adopt the Langmuir isothermal adsorption model [56] to deal with attenuation
effects observed as the concentration of a given hybridized species increases:
#$C0 = C
1+#C'
where 0 indicates the proportion of bound species (presumed to be equivalent to the observed
hybridization signal), C indicates the concentration of a particular species, and 4 is a constant
related to the binding affinity of the species to the oligonucleotide probes targeting it. This model
has been previously shown to accurately model the attenuation characteristics of microarray probes
[16].
Due to the calibration procedure described in eq (16), the observed copy-ratio X is actually the
ratio of two isotherms:
OCT pCN
1 + OCT 1 + 4CN'
where CT and CN are proportional to concentration in the tumor and normal sample, respectively.
Let CR = CT/CN. Because CN is defined to be the hybridization intensity corresponding to 1 copy
for a given probe-set, we can rewrite the above equation as:
_ CR(1+0)
(1+CRO)
We can then define a transformation of genotype-cluster coordinates:
g(p) = +1q) (18)(1 + pO)
This transformation is applied to the locations of the 4 genotype-clusters defined in equations 1, 2.
This ensures that the physical constraints defined by the model are compatible with the observed
data.
Noting that
lim CR( =±+ 1 0
cR-+oo (1 + CRq) #
corresponds to the asymptotic saturation copy-ratio, m, gives a direct physical interpretation for
the value of 4; 0 = mo -i
Variance-stabilizing transformation
Following [32], we make use of a variance-stabilizing transformation h, such that
h(x) h(i) + E1; e- ~A(0, Oh), (19)
where a is constant over the domain of X. Writing the variance of X as a function of the mean p:
var(X) = v(p), a general form for h can be expressed as [57]:
h(x) = du.
The specific form of h(x) for use with the error-model defined by eq. (10) is derived in [32]:
h(x) = log (bx + /1+ bx2) (20)
= sinh-1(bx).
The transformation has a parameter b that is calculated from o', and o, as follows:
o2
b= e 1 (21)
The transformed data, denoted X', will have variance, denoted Os, approximately independent of
X, with
9~h = Te d h(x)Ix=o (22)x
Using simulated data, we verified that the approximation in eq. 19 is accurate for values of 0, and
a, within the range of typical estimates (data not shown).
Likelihood calculation
We construct an approximation to the model defined in eq. (17) based on application of the variance-
stabilizing transformation (eq. 20) applied to both data channels. We use the scaled bivariate t-
distribution on the transformed data X', which has an additional parameter v E E allowing excess
density in the tails.
'P (Xiihr, = eXi IPik, - E)
1 / X T -X (v/2+1) (3
=27r|Eili/2 1+v( Ay-pik) E I(X 'k)) j 1i y, (3
where
X'; = (Xij),
and
p1 ik = h(g(p)),
with g and h given by eqns. 18 and 20, respectively. Define
X'
The Jacobian of the transformation h is:
ah(X ) ah(X )
ax' aX;
1jij 1 = hX~' 0 h(Xb)
ax, ax'b
-~h(X,) ah(Xb)
oxa1 aX
b b
V1l + (bX' )2 V1 + (bXb')2'
where b and ch may be calculated from o and a, via equations (21) and (22), respectively.
Introducing a sample-level parameter 0 < Ph < a c 0, we approximate the covariance-matrix
of the transformed data in a given segment i as:
U sPh . [ikj Likb if Ilik.Mikb < 1
E I 2', with s=SPh Ch 1 otherwise.
Thus, the covariance is spherical for the homozygous clusters. The scaling of ph by s provides a
consistent approximation to the covariance implied by eq. (17) for heterozygous clusters.
Substitution of eq. (23) into the generic form for P (Xpi ik, 0) in eq. (3) completes the
specification of our HSCR estimation based on SNP microarray data. The sample-level error model
parameters which must be estimated from the data are: 9 = {u,, h, ,  .
Calibration of cross-hybridization effects
We develop a calibration step to remove allelic-crosstalk from copy-ratio data X in a SNP-specific
manner as follows. Starting with large collection of normal samples, genotyped using Birdseed
[13], we compute the cluster-centers for each genotype for each SNP. We attempt to estimate the
covariance matrix for each SNP, denoted Ii. We make use of the factorization E = SRS, where
1 rA S 2 0
rAB 1 0 g0
with rAB denoting the correlation between the A and B allele. go and U2 denote the standard-
deviation of genotype-cluster axes corresponding to 0 and 2 copies, respectively.
Because we are attempting to estimate a large number of parameters from data which may
be limited, we make use of a Bayesian regularization technique. Population priors describing the
distribution of scales and correlations are estimated from all SNPs, and these are then used to
compute the most probable (MP) estimates for each SNP. This follows standard use of a hierarchical
model, as in [58].
We use scaled-inverse-X2 prior distributions for ao and 02, defined as follows:
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Let X ~ x2 (v) and Y = , then Y ~ Scale-inv-X2 (V, 0 2 )
X
We use a normal distribution for the Fisher-transform of rAB, ZAB = log (}t . We denote the
standard error of z as z, = . We define population-level distributions on the SNP covariance
parameters as:
ZAB ~ (7rpz, 7raz)
CO ~ Scaled-Inverse-x 2 (7r,, ir)
U2 ~ Scaled-Inverse- 2 (rS 2 , r 2 )
irj, and r, are estimated via maximum likelihood from the calculated SNP correlation-coefficients.
The MP estimate of z is the mode of the posterior (Gaussian) distribution:
imp = 1~ - Z
The MP estimate of r is the inverse of the Fisher transform on imp:
e ip- 1
rmp = e 2 1mP + 1
The posterior distribution for the scales ao and 02 is:
a2 1X - Scaled-Inverse-X2 (06, 6v),
with
o2 -7tvors0 +N NbOM
or - i-7 0 rvo + N 61V - ir, 0 ± N
The posterior mode is therefore
v02
oMp -
&2MP is computed in a similar fashion.
We then construct the MP covariance matrix for each SNP:
&w,2 MP 0 ( 1 MP' ( 2 MP 0
0 &Om rMP 1 )\ 0 &OMP
Denote the slope of the 1st eigen-vector of Eb, as MBB. We construct an affine transformation
as follows:
(1I -kBB 1 00 1 
-MBB 1
The corrected data is then:
X' = TX.
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Figure 1. Overview of analysis with HAPSEG a., Input data from an Affymetrix SNP
microarray hybridization. The calibrated allelic copy-ratios of A and B channels is shown for each
SNP vs. its genomic location. b., The data in (a), after processing with HAPSEG. SNPs axe
colored according to their phased genotype: grey homozygous, red/blue heterozygous (phased),
purple heterozygous (unphased). The HSCR segmentation is indicated by green horizontal lines. c.,
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Summary of the data in (b), where the individual SNPs have been removed and each HSCR segment
is colored by the average phasability of the heterozygous SNPs from which it was estimated. d.,
A histogram summarizing the data in (c), by marginalizing over the genome. Although the HSCR
locations are independent between segments, only four discrete levels are apparent in the histogram.
These corresponding to fixed SCNAs fixed in the tumor sample, and are the basis for analysis with
ABSOLUTE [3].
Tumor copy-ratio profile by parental haplotype
Ar-
-e,
0.0- .* -. . *. . ..e.. *** . . * . *.*.*.*.*..
1 3 5
2 4 6
9 11 13 15 17 19 21
10 12 14 is 1 20 22
Chromosome
-0.5 0.0 0.5 1.0 1.5 2.0 2.5
A alle copy-ratio
0 50 100 150
Chr 7 position (Mb)
2.5
2.0
1.5 -1
1.0
0.0 - -
-0.5
-0.5 0.0 0.5 1.0 1.5 2.0 2.5
A allele copy-ratio
9
2.05
2.0-
1.5-
1.0-
0:5
-0.5 -
I. i i i I
-0.5 0.0 0.5 1.0 1.5 2.0 2.5
h
2.5
2.0
1.5
1.0
0.5
0.0
-0.5
0 50 100 150 200 250
Chr 2 position (Mb)
A allele copy-ratio
110 120 130 140 150 160 170
Chr 6 position (Mb)
Figure 2
Figure 2. Examples of segmental HSCR inference by HAPSEG a., A tumor sample
with genome-wide HSCRs as inferred by HAPSEG, as in fig. 1c. b., Summary histogram of estimated
HSCR values, as in fig. 1d. c., e., g., Plots of calibrated A vs. B-allele copy-ratios for SNPs in three
genomic locations indicated in (a) (arrows). SNPs are colored by inferred (haploid) genotype, as in
fig. 1b. Contours denote the error-model fit for each genotype cluster: black - homozygous, green -
heterozygous. d.,f.,h., Plots of A and B-allele copy-ratios vs. genomic position for the segments in
(c,e,g). SNPs are colored as in (c,e,g). Horizontal lines denote genotype cluster locations, colored
as in (c,e,g) The heterozygous locations (HSCRs) correspond to the allelic copy-ratios in (a). c.,d.,
A segment (chr 7) at allelic balance, with equal copy-numbers of both homologues. No phase
information is available for heterozygous SNPs in this segment. e.,f., A segment (chr 2) at allelic
imbalance, with unequal homologous copy-numbers. Note that the SCNA affecting this segment
0-
0.0 0.1 0.2 0.3
Genomic fraction
Summary histogram
was predicted to be subclonal by ABSOLUTE [3]. g.,h., A segment (chr 6) at more extreme allelic
imbalance. Note that the lower HSCR here corresponds to LOH in this tumor sample [3]; the DNA
contributing to the heterozygous alleles is derived from normal contaminating cells.
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Figure 3. Demonstration of direct haplotyping by homologous imbalance a.,b., Com-
parison of HAPSEG and BEAGLE phase in example segments. Top - Allelic copy-ratios of heterozy-
gous SNPs are shown at their genomic coordinates. Color indicates phase as estimated by HAPSEG
((2)), eq. (9). Grey horizontal lines indicate the HSCR estimates for the segment, estimated by
HAPSEG, eq. (8). Middle - The genetic recombination rate is plotted vs. the genome. Bottom - As
in (a), but replacing the HAPSEG phase estimates by those obtained using the statistical phasing
program BEAGLE [31]. Switch errors in the BEAGLE phasing, detected by HAPSEG, are indicated
by dotted vertical lines.
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Figure 4. Demonstration of error-model for Affymetrix SNP microarrays. a-d., The
fit of the error-model to marker-level data is shown in a single example segment. a., The histogram
summarizes the A and B channels for assayed markers within the genomic segment. The marginal
fit of the A/B marker copy-ratios is denoted by the green (het) and coral (het+hom) curves. b.,
Marker copy-ratios in (a) are shown separately for the A vs. B channel. Contours denote fit of
the error model to the 4 modeled genotype clusters, eq. (1), (2) (green - het, black - hom). c,d.,
as in a,b., but using the variance stabilizing transformation, eq. (20). Likelyhood calculations are
performed in this space using a bi-variate t distribution, eq. (23). Positive covariance of the A/B
channels is modeled in the heterozygous clusters (green), this aspect of the fit cannot be dispalyed
in one dimension, as in (a,c). Contours show the fit of this density to the data, as in (b), which were
derived by inverting the variance stabalizing transformation. We note that the covariance matrix
E; in the density used here is fully determined by the segment HSCR locations, conditional on error
model parameters 9, which are fit at the sample level, eq. (12). Only two degrees of freedom are
fit to the data specifically shown here, eq. (2). e-h., an additional example segment is shown, as in
a-d.
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ABSTRACT
Defining chromosome copy number and allele ratios is fundamental to
understanding the biological consequences of the mutations and the evolution of
cancer. Current genomic characterization techniques measure somatic alterations
in a cancer sample in units of genomes (DNA mass). The meaning of such
measurements is highly dependent on the tumor's purity and its overall ploidy; they
are hence complicated to interpret and compare across samples. Ideally, copy-
number should be measured in copies-per-cancer-cell. Such measurements are
straightforward to interpret and, for alterations that are fixed in the cancer cell
population, are simple integer values. Here, we describe a novel computational
method (ABSOLUTE) that infers tumor purity and malignant cell ploidy directly
from allelic analysis of DNA. Using these values, ABSOLUTE can detect subclonal
heterogeneity, somatic homozygosity, and calculate statistical sensitivity to detect
specific aberrations. We used ABSOLUTE to analyze ovarian cancer data and
discovered that 54% of somatic point mutations were, in fact, subclonal. In contrast,
mutations occurring in key tumor suppressor genes, TPS3 and NF1 were
predominantly clonal and homozygous, as were mutations in a candidate tumor
suppressor gene, CDK12. Analysis of absolute allelic copy-number profiles from
3,155 cancer specimens revealed that genome-doubling events are common in
human cancer, and likely occur in already aneuploid cells in many cancer types. By
correlating genome-doubling status with mutation data, we found that homozygous
mutations in NF1 occurred predominantly in non-doubled samples. This finding
suggests that genome doubling influences the pathways of tumor progression, with
recessive inactivation being less common after genome doubling.
Introduction
Interpreting the mutational drivers of cancer requires the ability to accurately infer the
absolute copy number of somatic copy-number alterations (SCNAs) across the human
genome, corresponding to integral copy-numbers per cell in a cancer clone. This is
considerably more challenging than measure relative copy-number in units of diploid
DNA mass in a tumor-derived sample.
Measuring copy number alterations on a relative basis is straightforward using
microarrays 1, 2 ,3 4 , or massively parallel sequencing technology 6,7; it has been the
standard approach for copy-number analysis since the development of comparative
genomic hybridization (CGH) 8.
Inferring absolute copy-number is more difficult because: (i) cancer cells are nearly
always intermixed with an unknown fraction of normal cells (tumor purity); (ii) the actual
DNA content of the cancer cells (ploidy), resulting from gross numerical and structural
chromosomal abnormalities, is unknown 9 10, 11 12, 13 and (iii) the cancer cell population
may be heterogeneous, perhaps due to ongoing subclonal evolution 14 1. In principle,
one could infer absolute copy-numbers by rescaling relative data based on cytological
measurements of DNA mass per cancer cell 16, 17 18 , or by single-cell sequencing
approaches 1. However, such approaches do not scale well for high-throughput
characterization of cancer genomes 19
We began focusing on this issue several years ago, initially developing ad hoc techniques
2 . We subsequently developed a fully quantitative method (ABSOLUTE) and applied
it to several cancer genome analysis projects, including The Cancer Genome Atlas
(TCGA) consortium. We used these methods to correlate purity and ploidy estimates with
expression subtypes {Verhaak, et al., submitted} and to develop statistical power
calculations and use them to select well-powered samples for whole-genome sequencing
in several published 2, 3, {Bass, A., et al. (accepted)}, and numerous ongoing projects,
including breast, prostate, and skin cancer genome characterization. Recently, we
extended ABSOLUTE to infer the multiplicity of somatic point-mutations in integral
allelic units per cancer-cell.
Our purpose here is to: (i) to present the mathematical inference framework of the
ABSOLUTE method, as well as experimental validation of its predictions; (ii) to apply it
to analyze a large cancer dataset, enabling novel characterization of the incidence and
timing of whole-genome doublings during tumor evolution; and (iii) to describe a novel
integrated analysis of point-mutation and copy-number estimates and its application to
ovarian carcinoma.
We describe two key mathematical features of ABSOLUTE. First, it jointly estimates
tumor purity and ploidy directly from observed relative copy profiles. Second, because
joint estimation may not be fully determined on a single sample, it uses a large and
diverse sample collection to help resolve ambiguous cases.
We then report the first large-scale 'pan-cancer' analysis of copy-number alterations on
an absolute basis, across 3,155 cancer samples, representing 25 diseases with at least 20
samples. The analysis reveals that whole-genome doubling events occur frequently
during tumorigenesis, ultimately resulting in mature cancers descended from doubled
cells, bearing complex karyotypes. Despite evidence that genome doublings can result in
genetic instability and accelerate oncogenesis 24,13,25 the incidence and timing of such
events had not been characterized in human cancer.
We then describe how estimates of tumor purity and absolute copy-number allow us to
analyze sequencing data to distinguish clonal and subclonal point-mutations. Clonal
events may be classified as homozygous or heterozygous in the cancer cells, guiding
interpretation of their function. In addition, the ability to quantify integral multiplicity of
point mutations distinguishes events occurring prior to DNA amplification involving the
mutated locus from those occurring later.
Finally, our data allows characterization of somatic cancer evolution with respect to
genome doubling, which we demonstrate in ovarian carcinoma and associate with
clinicopathological parameters.
ABSOLUTE provides a foundation for integrative genomic analysis of cancer genome
alterations on an absolute (cellular) basis.
Results
Inference of sample purity and ploidy in cancer copy-profiles
We begin by describing the inference framework used in the ABSOLUTE method.
Suppose a cancer-tissue sample consists of a mixture of a proportion a of cancer cells
(assumed to be monogenomic - that is, with homogenous SCNAs in the cancer cells) and
a proportion (1-a) of contaminating normal (diploid) cells. For each locus x in the
genome, let q(x) denote the integral copy-number of the locus in the cancer cells. Let r
denote the mean ploidy of the cancer-cell fraction, defined as the average value of q(x)
across the genome. In the mixed cancer sample, the average absolute copy number of
locus x is a q(x) + 2(1 - a) and the average ploidy is D = ar + 2(1 - a), measured in units
of haploid genomes.
The relative copy number of locus x is therefore:
R(x) = [a q(x)+ 2(1 - a)]/D = [a/D] q(x) + [2(1 - a)/D] (1)
Because q(x) takes integral values, R(x) takes discrete values. The smallest possible value
is [2(1 - a)/D], which occurs at homozygously deleted loci and corresponds to the
fraction of DNA from normal cells. The spacing between values is [a/D] corresponds to
the concentration ratio of alleles present at one copy per cancer cell and 0 copies per
normal cell (e.g. somatic point-mutations). Importantly, if a cancer cell is not
monogenomic, copy-number alterations occurring in substantial subclonal fractions will
appear as outliers from this pattern (Fig. la-c, arrows).
The ABSOLUTE algorithm examines possible mappings from relative to integral copy
numbers by jointly optimizing the two parameters a and r (Fig. I c-d,h-i; Methods eq. 4).
In many cases, several such mappings are possible, corresponding to multiple optima. In
such cases, we use recurrent cancer karyotype models based on large data sets of samples
(Supplementary figure 1; Methods eq. 6) to identify the simplest (that is, most common)
karyotype that can adequately explain the data. The method selects the simplest solution,
while preserving the flexibility to identify unexpected karyotypes given sufficient
evidence from fitting the copy-profile (Fig. le,j). Indeed, several unusual karyotypes,
including near-haploid (<1.2n) and hyper-aneuploid (>6n) genomes, were identified
using ABSOLUTE (Supplemental Figure 2).
Validation
We validated the purity and ploidy predictions made by ABSOLUTE by several
approaches: (i) mixing experiments, in which cancer cell lines were mixed with paired
normal B-lymphocyte-derived DNAs in varying mass proportions (mean absolute
differences of 6%, Fig. 2c, Methods); (ii) ploidy analysis of 37 TCGA ovarian carcinoma
samples by fluorescence-activated cell sorting 26 (Methods) (mean absolute difference =
0.32, and 87% of samples concordant within one unit, Fig. 2a); and (iii) ploidy analysis
of the NC160 cell lines by spectral karyotyping (SKY) 27 (mean absolute difference =
0.36, and 91% of samples concordant within one unit, Fig. 2b);
Notably, the purity estimates produced by ABSOLUTE appeared to be more accurate for
the bulk tumor than those derived from histological examination of frozen tumor sections
(Methods). Estimates of the proportion of contaminating normal cells for 458 ovarian
carcinoma samples 26 produced by ABSOLUTE were strongly correlated with a molecular
signature of genomic methylation (Methods) seen in leukocytes (r = 0.59, P < 2.2x 10-16,
Fig. 2d), but only weakly correlated with estimates of contamination from histological
examination (r =0.1, P = 2.4x 1012; Methods; Fig. 2d x-axis scale, Supplemental figure
3). These results suggest that leukocyte infiltration may not be reliably detected by
histological examination.
Estimation of tumor purity and ploidy across cancer types
We used ABSOLUTE to analyze copy-ratio profiles derived from SNP arrays from 3,155
cancer samples, comprising 2,791 tissue specimens and 364 cancer cell lines. The
samples came from two TCGA pilot studies describing glioblastoma (GBM; 192
samples) 21 and ovarian carcinoma (488 samples) 26, as well as 2,445 profiles
incorporated from a previous pan-cancer copy-number analysis 2 8 (Methods). A minority
of these samples (519 or 16.4%) could not be analyzed because they lacked clearly
identifiable SCNAs, either because they were nearly euploid ("non-aberrant"), or were
excessively contaminated with normal cells ("insufficient purity"), (fig 2e).
For the 2,636 samples with detectable SCNAs, ABSOLUTE provided purity and ploidy
calls for 92% of cases, and designated the remaining samples as "polygenomic"
(genomically heterogeneous) (Fig. 2e), (Methods; Supplemental figure 5). The fraction
of called samples varied by disease type, from 34.6% (myeloproliferative disease; mostly
non-aberrant genomes) to 96.7% (ovarian carcinoma, 100% aberrant genomes), with a
median call-rate of 79.2% (Fig. 2e).
The distributions of estimated purity varied among cancer types, with the tested lung,
esophageal, and breast cancer samples being the least pure on average in our dataset. The
effect of contamination was readily visible in the copy ratios of impure tumor types
(Supplemental figure 6). Distributions of estimated ploidy (Supplemental figure 7a) were
qualitatively consistent with those derived from previously obtained cytological data for
13each tumor type 1 .
Coverage requirements for detection of somatic point-mutations by sequencing
We used ABSOLUTE to determine the depth of sequencing necessary to detect point
mutations. For example, suppose that a region is amplified to 6 copies with only 1 copy
carrying a mutation, in a sample that has 50% contamination with normal cells. In this
case, only 1 of 8 alleles at this locus (6 from the cancer cells and 2 from the normal cells)
carry the mutation (fig 3a). We therefore expect that the mutation will be observed in
only 12.5% of reads. Given this allelic fraction, sequence coverage of 33-fold is required
to detect the mutation with 80% sensitivity, assuming a sequencing error rate of 10-3 per
base and a false positive rate controlled at <5x10-7, (Methods, eq. 7, Fig. 3b).
Using ABSOLUTE's estimates of purity and genome-wide integral copy-numbers, we
can calculate the required coverage to confidently detect mutations present at specified
allelic multiplicity per cancer cell. Similar considerations apply to detecting subclonal
mutations, present in a fraction of cancer cells, by using fractional multiplicities (Fig. 3c).
We note that consideration of tumor purity in units of cells, rather than DNA mass, is
preferred for devising power calculations for sequencing experiments, since many
somatic alterations of interest are expected to occur at a single copy per cancer cell.
We analyzed the distribution of purity and ploidy values in cancer samples analyzed for
allelic copy number 28 21 26 to determine an appropriate depth of sequencing coverage
needed to detect clonal mutations with power 0.8 in each sample. For this purpose, we
calculated the number of reads needed to detect a mutation present in one copy at a locus
present at the average ploidy level given the sample's purity. (One could alternatively
choose a particular percentile on the ploidy distribution.) For such a locus, we found that
30X coverage sufficed for most samples (Fig. 3d). By contrast, such locus carried in a
subclone at 20% frequency would require coverage of - 00-fold to allow detection in
about half of the samples (fig 3e).
We then examined whole-exome sequencing (WES) data (~150X coverage) from 214
TCGA ovarian carcinoma samples 26 to determine whether detection power was related to
the number of mutations actually observed. For each sample, we calculated the
proportion of loci for which the sequence data provided at least 80% power to detect
mutations present at single copy in a subclone present at 5%. Those samples with the
lowest proportion of such well-powered loci tended to be those in which the least
mutations were detected (r2 = 0.24, P = 2.7x10-13 ; Fig. 3f), suggesting that the failure to
find such mutations was due to the lack of power. This result also demonstrates the
importance of power calculations for characterization of the subclonal frequency
spectrum.
Cellular multiplicity analysis of somatic point mutations from sequencing data
We next used ABSOLUTE to infer the absolute copy-number not simply of loci, but of
specific mutations. For this purpose, we examined 29,268 somatic mutations identified
in whole-exome hybrid capture Illumina sequencing (WES) 29 data from 214 ovarian
carcinoma tumor-normal pairs 26 (Methods, Fig. 4a). Tumor purity, ploidy, and absolute
copy-number values were obtained from Affymetrix SNP6.0 hybridization data on the
same DNA aliquot that was sequenced, allowing the rescaling of allelic-fractions to units
of multiplicity (average cancer-cell units) (Fig. 4a,b; Methods, eq. 10).
This procedure identified pervasive subclonal point-mutations in ovarian carcinoma
samples. While many of the mutations were clustered around integer multiplicities, the
majority of variants (54%) occurred at multiplicities substantially less than 1 copy per
average cancer cell, implying the variants were subclonal (Fig. 4b).
As a control, we applied multiplicity analysis to known germline polymorphisms; as
expected, these polymorphisms showed no indication of subclonal multiplicity (not
shown). The mutation spectrum seen for clonal and subclonal mutations was similar
(RMSE = 0.02, Fig. 4c), consistent with a common mechanism of origin. (The power
calculations show that the percentage of subclonal mutations that can be detected with
80% power in these sample ranges from 10% to 53%, with a median of 19%, Fig. 3e.)
We next used ABSOLUTE to analyze the multiplicity of both the reference and alternate
alleles, to classify point-mutations as either heterozygous or homozygous in the affected
cell fraction. We considered 15 genes with mutations recently indentified in these data 26
including 5 known tumor suppressor genes (TSGs) and 5 oncogenes (Fig. 4g). The
frequency of homozygous mutations in known TSGs and oncogenes were significantly
different, with a significantly elevated fraction of homozygous mutations in the TSGs (P
= 0.006, Fig. 4g) and no homozygous mutations in the oncogenes: (P = 0.012, Fig. 4g).
This result provides additional evidence that CDK12 is a putative TSG in ovarian
carcinoma 26, since 7 of 12 carrying mutations were homozygous (P= 6.5x10 5 ; Fig. 4g).
Overall, TP53 had among the greatest fraction of clonal, homozygous, and amplified
mutations of any gene in the coding exome (Fig. 4h), demonstrating the clear
identification of a key initiating event in HGS-OvCa carcinogenesis 30 directly from
genomic data and independently of statistical recurrence analysis.
Whole genome doubling occurs frequently in human cancer
For many cancer types, the distribution of total copy number (ploidy) was markedly bi-
modal (Supplemental figure 7a), consistent with chromosome-count profiles derived from
SKY 0, 13. Although these results are consistent with whole-genome doubling during
their somatic evolution, it has been difficult to rule out the alternative hypothesis that
evolution of high-ploidy karyotypes result from a process of successive partial
amplifications 12
To study genome doublings, we used the fact that ABSOLUTE provides not just total
copy-number information, but allelic copy-number information - that is, the copy
numbers, b, and ci, of the two homologous chromosome segments at each locus. By
looking at the distribution of bi, ci across the genome, we can draw inferences regarding
genome doubling. Immediately following genome doubling, both, bi and ci would be
even numbers. Following the loss of single copy, the larger of the two numbers will
remain even, but the smaller would be odd. In fact, when we looked at high-ploidy
samples, we discerned a clear bias for the higher of the two numbers to be even. This
bias was coincident with the transition from low to high-ploidy samples (Supplemental
figure 7) being due to genome doubling. Using simulations, we found that the observed
profiles were unlikely to arise due to SCNAs occurring in serial fashion at multiple
independent chromosomes (P < le-3; Methods).
Using such information, we could classify samples into three groups, which we
interpreted as corresponding to 0, 1 and > 1 genome doubling events in the clonal
evolution of the cancer. These three groups had modal ploidy values of 1.75, 2.75, and
4.0, respectively (Fig. 5a), and also segregated into three clusters by ploidy and mean
allelic copy-number imbalance (Fig. 5b). We interpreted this as evidence of SNCAs
occurring with net losses, interspersed with the genome doublings. This process resulted
in intermediate ploidy values for the doubled clones (2.2 - 3.4N), with pervasive
imbalance of homologous chromosomes (Fig. 5b).
The frequency of genome doubling varied across tumor types (Fig. 5c), reflecting
differences in disease specific biology and clinical progression status. Hematopoietic
neoplasms (MPD, ALL) had nearly no doubling events, whereas GBM, RCC, prostate
cancer, various sarcomas, HCC, and medulloblastoma all had -25% incidence of
doubling. Genome doubling was more common in epithelial cancers, with colorectal,
breast, lung, ovarian, and esophageal cancers all having > 50% incidence of doubling
(Fig. 5c). Esophageal adenocarcinoma had the greatest incidence of genome doublings,
consistent with previous reports of frequent "4N" populations at various stages of
Barrett's esophagus progression 31, 32.
Specific aneuploidies precede genome doubling
We then used ABSOLUTE to infer the temporal order of genome doubling in
tumorigenesis, relative to SNCAs involving specific chromosome arms. In many cancer
types, the fixation of arm-level SCNAs was inferred to occur prior to genome doubling,
since both doubled and non-doubled samples had similar frequencies of specific arm-
level SNCAs (Fig. 5d, Supplementary figure 8).
In GBM samples, LOH involving chromosomes 9 and 10, and gains of chromosome 7
occurred at equivalent frequencies (Fig. 5d), demonstrating that the most common broad
SCNAs in GBM occur prior to genome doubling. Gain of chromosomes 19 and 20 was
nearly exclusive to non-doubled samples, and several arms had greater LOH frequency in
doubled samples (Fig. 5d), suggesting that additional biological differences underlie these
samples.
Because ABSOLUTE could not distinguish between ploidy 2N and 4N in cases with no
observed SCNAs, we discarded such non-aberrant samples from our analysis (Fig. 2e).
For many tumor types, such cases were rare, due to the tendency for chromosomal losses
following doubling (Fig. 2e, Fig. 5a,b, Supplemental figure 7). The representation of
specific cancer subtypes may be biased by differences in ascertainment, however.
In contrast to broad chromosomal alterations, focal SCNA events occurred at greater
frequency in doubled genomes (Fig. 5e). The frequency of focal SCNAs as a function of
their length (L) appeared to follow power-law scaling: P(L) c L-, for L between 0.5 and
20 Mb (Fig. 5e). The observation of power-law scaling was consistent with previous
reports 28 33. Although samples with genome doubling showed a higher number of
SCNAs, we obtained equivalent estimates of a ~ 0.71 for each group (Fig. 5e),
suggesting that the mechanism(s) by which they were generated did not depend on
ploidy.
Genome doubling interactions with somatic genetics in ovarian carcinoma
We next sought to correlate whole-genome doubling occurrence in ovarian carcinoma
with other genetic and clinical features. Genome-doubled samples showed a higher
incidence of heterozygous mutations, but correcting for sample ploidy removed this
effect (Fig. 6a), suggesting that the per-base mutation rates are equivalent. Clonal
amplified mutations were approximately ten-fold more prevalent in doubled samples;
many of these events likely occurred prior to the doubling event. Genome-doubled
samples had a lower frequency of homozygous deletions (Fig. 6b) and a two-fold lower
rate of clonal homozygous mutations (P = 1.55x10-8 , Fig. 6c). We expect that many of
the observed homozygous alterations in the doubled samples were fixed prior to genome
doubling.
The lower incidence of homozygous mutations in genome-doubled samples may reflect
the fact that more events are required to render a mutation homozygous in a genome-
doubled sample (although the effect may be partially offset, however, by a possible
increase in genetic instability following doubling, e.g., by centrosome duplication 34).
These considerations suggest that genome-doubled samples evolve via distinct
trajectories, because inactivation of tumor suppressors may occur less frequently
following doubling.
We note that 13 of the 15 detected point mutations in the tumor suppressor NF1 occurred
in the 93 samples that had not undergone genome doubling (P = 0.002), and these
mutations were uniformly homozygous (not shown). This is consistent with selection for
recessive inactivation of NF1, a typical pattern for a tumor suppressor gene. It also
suggests that non-genome-doubled ovarian carcinoma samples evolved via a distinct
trajectory, rather than being precursors to doubled samples. If not, many NF1 mutations
would be homozygous and amplified in doubled samples, as is seen for TP53.
Although the genome doubled and non-doubled samples showed significant overall
differences in the frequency of subclonal mutations, this number did not provide a useful
way to characterize individual samples, because it was too strongly dependent on the
sequence coverage, and therefore on the sensitivity to detect mutations (Fig. 3c,e,f).
Finally, we noted that genome-doubled samples were associated with a significant
increase in the age at pathological diagnosis (Fig. 6d) and with a significantly greater
incidence of cancer recurrence (Fig. 6e).
Discussion
The development of a reliable high-throughput method to infer absolute allelic copy-
number from DNA derived from tumor samples represents an important advance in
cancer genome analysis. ABSOLUTE is currently the most technically complete
approach to analyzing cancer genomic data in cellular units, both for point mutations and
SCNAs, and has become an established step in ongoing integrative genomic analysis
projects. It may be possible to extend ABSOLUTE to other types of genomic alterations,
such as structural rearrangements and small insertions/deletions, although this may
require longer sequence reads in order to ensure accurate sequence alignment.
We have demonstrated that the classification of point-mutations based on their
multiplicities, as estimated by ABSOLUTE, can help distinguish tumor suppressors and
oncogenes beyond traditional evidence based on mutation types (nonsense, frame-shift
indels and splice site mutations are more common in tumor suppressors) and their
distribution along the gene (clustered mutations are more common in oncogenes) (Fig. 4).
Further development of techniques utilizing these classifications may contribute clues to
the function of novel recurrent somatic alterations in the cancer genome.
ABSOLUTE provides a framework for the design of genomic sequencing efforts, based
on calculation of sensitivity to detect mutations as a function of a sample's purity, local
copy-number and sequencing depth (Fig. 3). The high accuracy of tumor purity and
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ploidy estimates produced by ABSOLUTE based on SNP microarray data (Fig. 2) make
it possible to determine the sequencing depth required for a given sample or to select
suitable samples given a fixed sequencing depth. Furthermore, these considerations are
important for interpretation of apparent differences in mutation rates across samples of
differing purity, such as primary tumors and cell lines, metastases, or xenografts 35,36.
Finally, such considerations are vital to the interpretation of subclonal point-mutations
(Fig. 3f, Supplementary figure 9).
The detection of subclonal mutations in primary tumors will further enable the study of
tumor heterogeneity, as in 37, 38. Further analysis of the subclonal multiplicities, provided
by ABSOLUTE, may expose discrete structure in the tumor subclonal populations
reflecting distinct fractions of clonal sub-populations in polyclonal tumors. Such analysis
will require adequate sequence coverage, as suggested by our sensitivity-calculations
(figure 3, Supplementary figure 9).
ABSOLUTE analysis of SCNAs demonstrated that many of the copy-number profiles
analyzed in this study could be explained as derived from approximately monogenomic
tumor samples. In many other cases, however, ABSOLUTE predicts that some SCNAs
are, in fact, present in different number of copies in minor subclones. These predictions
present opportunities to study tumor subclonal evolution.
Analysis of the predicted absolute allelic copy-number profiles across human cancers
produced by ABSOLUTE shed new light on our understanding of cancer genome
evolution. The profiles (Supplemental figure 7) were consistent with a common
trajectory consisting of an early period of chromosomal instability followed by the
emergence of a stable aneuploid clone, as previously described ". Our data further
indicate that genome doublings occur in a subset of cancer cells already harboring arm-
level SCNAs characteristic of the corresponding tumor type. The genomes of these
cancers were therefore shaped by selection at chromosomal arm-level resolution prior to
doubling and further clonal outgrowth (Fig. 5g).
These findings are broadly consistent with an earlier interpretation of primary breast
cancer FACS/SKY profiles 39, and has recently been recapitulated in studies of macro-
dissected and ploidy-sorted cell populations 14, and single cell sequencing 15 of primary
breast tumors. A notable exception occurred in prostate cancer samples, a subset of
which were predicted as near-tetraploid, with few broad SCNAs (Supplemental figure 7a,
8); further validation is required to confirm these predictions. We note that this model
represents a departure from the idea that tetraploidization is an initiating event 4,13 25 41
42. In addition, the association of genome doubling with epithelial lineage (Fig. 5c), and
with age at diagnosis in ovarian carcinoma (Fig. 6d) is consistent with a recently
described mechanism linking telomere crisis, DNA damage response, and genome
doubling in cultured mouse embryonic fibroblasts (MEFs) 41.
Further analysis of absolute allelic copy-number profiles and the classification of samples
based on the number of genome doubling events they have undergone may help improve
methods for implicating specific SCNAs as driver events in cancer 2 8 , 33 For example,
background alteration rates could be adjusted to account for differing alterations
frequencies during various phases of cancer genome evolution (eg. pre/post doubling).
Because genome doubled cancers had a greater incidence of focal SCNAs (Fig. 5e) and
point mutations (Fig. 6a), it may be valuable to use different background mutation rates
corresponding to different phases of cancer genome evolution (e.g., pre- vs. post-
doubling).
Synthetic lethality screens have identified genetic dependencies with yeast polyploidy 43
44and aneuploidy 45. In addition, chemical compounds have been identified with pro-
apoptotic function specifically in primary MEFs bearing specific aneuploidies 46.
Analysis of aneuploidy and genome doubling status in large collections of human cancer
cell-lines using ABSOLUTE will inform further chemical and genetic screening of these
cells 47.
Finally, knowledge of discrete tumor copy-states and genome doubling status provides an
important foundation for reconstruction of the temporal sequence of alterations by which
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the cancer genome arose. The idea of using the fraction of homozygous mutations in
regions of copy-neutral LOH to time duplication events has been previously proposed 48,
and applied to ovarian cancer {Durnick 2011, in press}, where it confirmed the known
early occurrence of TP53 mutations3 0 . The use of ABSOLUTE will extend these
techniques by providing information about the timing of events that do not occur in
regions of copy-neutral LOH, thereby extending the applicability of these and related
methods 49,50, 51 and enabling the development of novel strategies for temporal inference.
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Figure 1 I Example of ABSOLUTE analysis on two tumor samples.
a-e, A lung adenocarcinoma tumor sample processed using ABSOLUTE.
a, Genome-wide view of allelic copy ratios. The copy ratios for both homologues are shown
for each genomic segment with locally constant copy number. Color-axis indicates distance
between low (blue) and high (red) homologue concentration; segments where these are similar
(homologous-allele balance) are purple.
b, Allelic copy-ratio histogram. Allelic copy-ratios shown in (a) were binned at 0.04 resolution
(y-axis); the length of each block corresponds to the (haploid) genomic fraction (x-axis) of each
corresponding segment in (a). Several discrete peaks are visible, each corresponding to either
an (unknown) integral copy state in the somatic clone, or to a subclonal alteration.
c, Three potential interpretations of the allelic copy-ratio histogram (b) in terms of absolute copy
numbers. Horizontal dotted lines indicate the copy ratios corresponding to the indicated absolute
somatic copy-numbers.
d, Purity (fraction of tumor nuclei) and cancer-genome ploidy values corresponding to each
interpretation in (c). Dotted lines denote potential solutions that share either b, the copy-ratio
associated with zero somatic copies (from upper-left to lower-right), or 8,, the spacing between
consecutive integral copy-levels (from lower-left to upper-right). Candidate solutions lie on the
indicated grid of b = 2(1-a)/D and 8, = a/D (eq. 1).
e, The log-likelihood (score) of each solution in terms of the peak-fit of the observed copy-ratios
to integer absolute copy-numbers and plausibility of the proposed karyotype. The highest-scoring
solution (green) is identified by the combination of peak-fit and karyotype log-likelihood values.
This interpretation implies subclonal gain of chromosome 2 (arrows). The peak-fit score alone
cannot distinguish between this and an additional solution (blue), in which the arrowed region is
closer to an integral copy-state, but the overall peak-fit score is equivalent to that of the first
solution.
f-j, An HGS-OvCa sample processed using ABSOLUTE, as in a-e. In this sample, the excellent
peak-fit score is strongly opposed to a karyotype score indicating a simpler solution, and
dominates the final ranking.
108
37 primary tumor samples: concordance = 66.5%
6-
5.
4.
3-
2-
1-
X 0,
5 -
4 -
3
g2-
1 2 3 4 5 6
Estimated ploldy (FACS)
HCC38 HCC1143
1 - : ,e - 1 .0 -
0.681
0.6 --
E 0. - - 0.8-
0 2__ _0_.01
- wj - _ __ e_ _ 
_ 
_0.4
2 -.
04 06 0. 1. 04 06 0.6 0.2-
0.4 0.6 0.6 1.0 0.4 0.6 0.6 1.0
Cancer mixing fraction Cancer mixing fraction
5 6
'S
I I I I I I
1 2 3 4 5 6
Estimated plody (SKY)
Leukocyte methylation signature
0.1 0.2 01A 04iIIF-
%-
:it:
ace
0.7 - 0.8 0.8 - 0.9 0.9 - 0.95 0.95 - 1
Histological purity estimate
Scaed (76.7%
Snrsib-eerrat (9.1%)
E Isufient purty (7.3%)
a polygenomIc (6.9%)
TCGA - HGS-OvCa (485)
RCC (7)
Glioms (27)
TCGA - GBM (192)
Neuroblatma (25)
Cell is (364)
HCC (108)
Coorectal Cancer (125)
Medulabsitma (96)
ALL (235)
MFH (36)
Ovafln Cancer (0)
Prostale Cancer (61)
Esophagel adeo (60)
Olh1r Swooma (66)
UPoe-moma (93)
Brsas Cancer (134)
Lung squaimu (46)
Esophagel amous (32)
Lung adeno (543)
GIST (36)
MPD (205)
0.0 0.2 0.4 0.6 0.5 1.0
FracWon ofsamples
109
33 NCI-80 cell lines: concordance = 90.9%
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Figure 2 1 ABSOLUTE method validation and call rate.
a, FACS-based ploidy estimates vs. ABSOLUTE predictions for 37 primary tumor samples.
Dashed line indicates y=x. The dotted lines indicate a margin for correct prediction of ploidy of -
1. Five tumor samples were predicted to have ploidy values that differed by more than one unit
from the FACS result (x's).
b, SKY-based ploidy estimates vs. ABSOLUTE predictions for 34 cancer cell-lines. Data are
displayed as in a.
c, Cancer-normal DNA mixing experiment results for two cell lines. DNA from each cancer
cell line was mixed with DNA from the matched B-lymphocyte in varying proportions (x-axis).
(top) predicted vs. true DNA mixing fractions compared to the y=x line (dashed). (bottom)
predicted cancer cell-line ploidy vs. mixture purity. Dashed line indicates the median prediction.
Ploidy estimates are consistent with previous SKY analysis of these cell lines:
http://www.path.cam.ac.uk/-pawefish/cell%201ine%20catalogues/breast-cell-lines.htm.
d, Leukocyte methylation signature enrichment In tumors of histologicaly underestimated
purity. HGS-OvCa samples are shown grouped according to the indicated histological purity
estimates (x-axis){Network:201 1 bq}. Black horizontal lines indicate the median purity of each
group, as estimated by ABSOLUTE (y-axis). The color of each point corresponds to the degree
to which that sample's methylation profile resembled that of purified leukocytes (Methods).
e, ABSOLUTE result types: (i) 'called' -- unique purity / ploidy solution; (ii) 'non-aberrant' --
sample has no detectable somatic copy-number alterations; (iii) 'insufficient purity' - insufficient
fraction of cancer cells; (iv) 'polygenomic' discrete copy-ratio levels could not be determined.
See Supplemental figure 5 for examples of each result type.
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Figure 3 1 Effect of tumor purity and ploidy on power for detection of somatic point-
mutations by sequencing
a, Combinations of tumor purity and ploidy which imply equal values of 8 (eq. 8), the
concentration-ratio of molecules present at a single copy per cancer cell (multiplicity 1) in the
tumor population. Dotted lines indicate equal values of b (eqn 2).
b, Theoretical power to detect clonal somatic point mutations present at multiplicity 1, as a
function of sequence coverage, for various values of 8 (shown in a). Power was calculated for
FPR <= 5x10~ , assuming a uniformly random sequencing error-rate of 10. (methods, eqn. 7).
a,b, Green dots correspond to an example case of a region amplified to 6 copies, with I copy
mutated, and purity 50%. Only 1 of 8 alleles at this locus carry the mutation (a), and 33 reads are
required to detect the mutation with 80% power (b).
c, Theoretical power (as in b) to detect subclonal somatic point mutations present at multiplicity 1
in 0.2 of cancer cells.
d,e, Values were calculated for each tumor using the purity and ploidy estimates obtained from
ABSOLUTE. Samples were considered powered if their detection power (as in b, c) exceeded
0.8.
f, Tumor purity and local absolute copy-number estimates were used to calculate the number of
bases powered for the detection of subclonal mutations present at fraction 0.05 (x-axis, Methods,
eq. 7), and to compute the number of subclonal mutations at cancer-cell fraction <= 0.05 in each
sample (y-axis). The dashed line, r2, and P values refer to a linear regression fit of the data
points.
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Figure 4 1 Multiplicity analysis of somatic point-mutations detected by whole-exome
sequencing of 214 primary HGS-OvCa tumor samples.
a, Histogram of allelic fraction (alternate / total read-count) values for 29,628 somatic point-
26mutations detected in 214 primary HGS-OvCa samples
b, Allelic fractions for the mutations shown in (a) were converted to point estimates of integral
allele-counts per cancer cell (cellular multiplicity; x-axis) by correcting for sample purity and local
copy-numbers (Methods eq. 11). Subclonal mutations were identified using the model defined in
equation 10.
c, The fraction of each of the 6 distinguishable nucleotide substitutions for clonal vs. subclonal
point-mutations. The solid grey line indicates y=x. RMSE: root mean squared error.
d, Empirical density estimate of allelic concentration-ratios, which are obtained by multiplication of
the allelic fraction by the copy-ratio at that locus.
e, Density estimate of allelic multiplicity estimates, as in (b), for reference vs. mutant allele.
Mutations were classified into the four indicated categories according to their mutant and
reference allele multiplicity.
f, The density estimates of allelic concentration-ratios are shown for each of the four mutation
classes in b are shown superimposed.
g, Mutation classification profiles of genes identified as significantly recurrent in HGS-OvCa, as
26well as several COSMIC genes with previously observed mutations in these data . Note that
only individual point mutations were considered here; the possibility of recessive inactivation via
multiple events (compound heterozygosity) was not considered. Color code as in e.
h, Histograms of gene classification fractions for 1412 genes having at least 5 mutations.
Dashed vertical lines denote the 5t (top) and 95th (other) percentiles of each distribution. No
mutations occurring at multiplicity > 1 were observed in NF1 (not shown).
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Figure 5 | Incidence and timing of whole genome doubling events in primary cancers.
a, b, Ploidy estimates were obtained from ABSOLUTE. Mean allelic imbalance was calculated as
the average difference in absolute allelic copy numbers at every position in the genome.
Genome doubling status was inferred from absolute allelic copy-numbers (Methods,
Supplemental figure 7).
c, MPD - myeloproliferative disease, ALL - acute lymphoblastic leukemia, GBM - Glioblastoma
multiforme, RCC - renal cell carcinoma, HCC - hepatocellular carcinoma, HGS-OvCa - high-grade
serous ovarian carcinoma.
d, LOH (loss of heterozygosity) was defined as 0 allelic copies. Amplification was defined as > 1
allelic copy for samples with 0 genome doublings, and as > 2 allelic copies for those with 1
genome doubling. Calls were made based on the modal allelic copy numbers of each
chromosome arm. Dashed lines indicate y=x.
e, SCNAs, defined as regions differing from the modal absolute copy number of each sample,
were binned at adaptive resolution to maintain 250 SCNAs per bin, and renormalized by bin
length. The value in each bin was further divided by the number of tumor samples in each
genome doubling class, indicated by color as in a. Linear regression models were fit
independently for each class; solid lines indicate the resulting fits. Only SCNAs 0.5 < x < 20 Mb
were used in the regression (dotted vertical lines)
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Figure 6 1 Genetic and clinical associations with genome doubling in primary HGS-OvCa
samples.
a-e, Colors correspond to putative genome doubling status, as indicated.
a-c, Number of mutations in indicated classes as a function of genome doublings. P-values were
calculated with the two-sided Wilcoxin rank-sum test comparing samples with 0 and I genome
doublings. Error bars indicate standard errors of the means.
d, P-values were calculated with the two-sided Wilcoxin rank-sum test.
e, P-values were calculated using the log-rank test.
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Methods
Inference of purity, ploidy, and absolute somatic copy-numbers
ABSOLUTE is based on the assumption that in many specimens, the cancer cell-fraction is grossly monogenomic
in terms of copy-number alterations, i.e. most of the cancer cells share a similar copy-number profile. Al-
though clearly, heterogeneity of cancer-cell populations presents a challenge to such analysis, both cytological
Mitelman, 2000 #749 and genomic data Albertson, 2003 #821 have supported this assumption, as have re-
ports of similar SCNA profiles obtained from paired primary and metastatic lesions Kuukasjarvi, 1997 #916,
Liu, 2009 #812, Campbell, 2010 #867, Navin, 2011 #863. Recent sequencing of single cancer cells has di-
rectly demonstrated the presence of cancer-cell populations with nearly identical copy-profiles Navin, 2011
#863.
Additional statistical methods have been reported for integral copy-number interpretation from SNP-
array data without experimental ploidy determination Attiyeh, 2009 #767, Greenman, 2010 #759. These
methods did not attempt to model tumor purity, however, making them best suited for analysis of cell lines.
In addition, several methods have appeared for joint estimation of tumor purity and ploidy without using
prior karyotype data, which forced them to either limit the range of possible tumor ploidy values (1.8 -
4.6)N Van Loo, 2010 #818, or else leave the data up to multiple interpretations Popova, 2009 #913, Yau,
2010 #912. As a comparison, the concordance of ploidy estimates from a related method Van Loo, 2010
#818 with the FACS results was 69% compared to 87% for ABSOLUTE; purity of the cell-line mixtures was
systematically underestimated, (mean difference of 15%, Supplemental figure 4).
Homologue-specific copy ratios (HSCRs) derived from analysis of microarray or sequencing data are
the required input for ABSOLUTE. HSCR values are obtained by analysis of allele-specific copy ratios at
polymorphic loci in order to infer germline genotypes, phase of imbalanced heterozygous markers, and copy
ratio of both homologues in the cancer clone. The use of HSCRs reduces the ambiguity of observed copy-
profiles. For example, the total copy ratio profile of a sample without SCNAs would be equivalent for ploidy
values of 1,2,3, etc., however the HSCR profile would rule out odd ploidy values, since these would not be
consistent with equal allelic copy-numbers. In order to accurately perform these inferences without a paired-
normal sample, we employed a novel method, HAPSEG (S.L.C. et al., manuscript submitted). HAPSEG
currently uses an error model tailored to Affymetrix SNP arrays, developed using thousands of array samples,
to perform accurate and robust HSCR estimation.
The likelihood of a proposed purity/ploidy solution is obtained by modeling the HSCRs with a Gaussian
mixture model, with components centered at the discrete concentration-ratios implied by eq. 1 (eq. (3)
below). The model also supports a small fraction of subclonal events which are not restricted to the discrete
levels. Candidate solutions are identified by searching for local optima of this likelihood over a large range
of purity and ploidy values. This results in a discrete set of candidate solutions with corresponding peak-fit
likelihoods (eq. 1, Fig. ld,h).
Additional information is generally required in order to reliably select the correct tumor purity and ploidy
solution from this set of candidates. In a given tumor sample, several combinations of theoretically possible
purity, ploidy, and copy number values may map to equivalent copy ratios (fig 1c,h). Furthermore, the
presence of subclonal SCNAs may result in a spuriously high ploidy solution with an implausible karyotype
receiving a greater peak-fit likelihood by over-discretizing the copy profile, allowing their assignment to
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integral copy-levels (fig lh,ij).
Previous techniques have dealt with this issue by presenting multiple interpretations of the sample for
manual inspection Popova, 2009 #913,Yau, 2010 #912, or by restricting the range of malignant ploidy values
Van Loo, 2010 #818. ABSOLUTE models common cancer karyotypes by grouping tumor sets according to
similarities in their absolute allelic copy-number profiles (Supplemental figure 1; methods). These models
are constructed directly from the tumor data in a boot-strapping fashion, whereby a subset of tumors with
relatively unambiguous profiles (eg., e.g. due to high purity values and lack of subclonal SCNAs) is used ini-
tialize the models, iteratively allowing more tumors to be called, etc. Previous cytogenetic characterizations
of human cancer were used to guide this process Storchova, 2008 #763. These models enable calculation
of a karyotype likelihood, for each candidate purity / ploidy solution, reflecting the similarity of the corre-
sponding karyotype to models associated with the specified disease of the input tumor sample (methods, eq.
7).
Integration of the peak-fit and karyotype likelihoods allows for robust and unambiguous identification of
the correct purity and ploidy values in many tumor samples (fig ld,h). The selection of a solution implying a
less common karyotype requires greater evidence from the peak-fit of the copy profile. This ensures that the
simplest (most common) karyotype adequately explaining the data is preferred over more complex solutions,
while preserving the flexibility to identify unexpected karyotypes given sufficient evidence from the peak-fit.
Indeed, several unusual karyotypes, including near-haploid (< 1.2N) and hyperaneuploid (> 6N) genomes,
were identified using ABSOLUTE (Supplemental figure 2).
Identification and evaluation of candidate tumor purity and ploidy values
We describe identification of candidate tumor purity and ploidy values and calculation of their peak-fit log-
likelihood scores using a probabilistic model. These scores quantify the evidence for each solution contributed
by explanation of the observed allelic copy-ratios as integral SCNAs. These computations are independent
for each sample. The input data consist of N segmented allelic copy-ratios xi, i E {,..., N}. Each of
these is observed with standard error a-, and corresponds to a genomic fraction denoted wi. Each of the
xi is assumed to have arisen from either one of Q integral copy-number states: Q = {0, 1,. . . , Q - 1}, or
an additional state Z corresponding to sub-clonal copy-number. We refer to the collection of possible copy-
states as S = Q U Z. We define Q +1 indicators s for the copy-state of each segment, with p(si) representing
the probability of segment i having been generated from state s E S. The integral copy-states of S are
indexed by q E Q; the non-integral state is denoted by z.
The expected copy-ratio corresponding to each integral allelic copy-number q(x) in a tumor sample is
given by:
pg = 2[a/D]q(x) + [2(1 - a)/D] (2)
where D is related to tumor purity and ploidy (a and r) (Figure 1; the factor of 2 arises because allelic
copy-ratios are relative to haploid control concentrations, as opposed to the diploid values assumed by eqn.
1.)
The observed x are modeled with a mixture of Q Gaussian components located at t = {pqEg} repre-
senting integral copy-states Q and an additional uniform component Z. The mixture Z allows segments to
be assigned non-integral copy values so that occasional subclonal alterations or artifacts do not dramatically
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impact the likelihood.
si ~ Multinom (p (si Iwi, 0))
pi-Lq + Ci if si E Q (3)
u if si =Z
e, ~ Nr (0,Oi +U ),
u ~ U(d)
N and U denote the normal and uniform densities, respectively. The free parameter IH represents sample-
level noise in excess of the HSCR standard-erorr ci, which might represent a moderate number of related
clones in the malignant cell population, ongoing genomic instability, or excessive noise due to faulty experi-
mental conditions. The mixture weights 6 = {8Es} specify the expected genomic fraction allocated to each
copy-state. The parameter d represents the domain of the uniform density, corresponding to the range of
plausible copy-ratio values (we used d = 7).
Some complication arises due to the fact that the data consist of copy-ratios calculated from a segmen-
tation of the genome. For consistent interpretation, the mixture weights P(sil wi, 0) must be calculated for
each segment separately, taking into account the variable genomic fraction wi. This is accomplished by
constraining the canonical averages of genomic mass allocated to each copy-state to match those specified
by 0:
VI ES, ( i Z 0
i1 C
where (-)c denotes the average over all configurations {si}, weighted by the function C = P(silwi, A). This
density corresponds to the maximum entropy distribution over s subject to these constraints:
P (Slwi, A) = e' SW
Lagrngemultplirs aredetrmind va ZkES e-,kk#wi 7
where s# indicates the order of state s in a sequence of copy-states, beginning with 0. Values of the Q
Lagrange multipliers A are determined via Nelder-Mead optimization of L 2 loss:
N 2-
A = argmin [WiP (si wi, A)] -  )
(SES i=1
This approximation allows for robustness of the peak-fit score to over-segmentation of the data.
The likelihood of a given segment i can then be calculated as:
(X~i, Oi, 0H, 0 , wi) = [P (q I w, A) K i H + P (z Iwi, A)U(d),
qEQ
and the full log-likelihood of the data is then:
N
log 4 (zily , 19i, OH, 7, OWi) . (4)
i=1
We define the parameterization b = 2(1 - a), 6, = 2(a/D), which determines y via eq. (2). Candidate
purity and ploidy solutions for a tumor sample are identified by optimization of eq. (4) with respect to b
and 6,. Calculation of eq. (4) requires estimates of 6 and OH, which are not known a priori. We make an
approximation (scale-separation) assuming that locations of the modes of eq. (4) are invariant to moderate
fluctuations in these parameters. A provisional likelihood for each xi may then be calculated by
Lp~x~Ip~r~,o) + Ui [Kx~i~~o 2 ]±(d).
qEQ
Candidate purity and ploidy solutions are then identified by optimization of
N
log L (Xily, o p),
i=1
initiated from all points in a regular lattice spanning the domain of b and 6,. The parameter op was set to
0.01 for this study. We verified that the above approximation identified modes equivalent to those obtained
through a full Metropolis-Hastings Markov chain Monte Carlo (MCMC) simulation (data not shown). The
approximation allows for much simpler computations to be used.
The peak-fit score for each solution is calculated after optimization of UH [0, 0.04]:
N
16H = argmax log L (XiI i, i, H 0, wi),
i=1
with the elements of 0 calculated for each value of CH by:
N (xiI Aq,o +2 )- N U(d)
O, =i + wOH ; 0Z = E wi.
EZrp (zi ly[, ui, LTH) Lp (xi 1#, uj, oH)
The final calculation of the peak-fit log-likelihood for each mode is obtained by inserting t, 6, and &H into
eq. (4). Estimates of the copy-state indicators for each segment are calculated as:
.A( (zX, of + &2)q4i = P (qil1wi, A) (X,
1A OziA7o &H 107mi)
ii = P (zilwiA) U(d)
L (XiI#, Ui, &H, Wi)
Note that each 4i is a vector representing the posterior probability of each Q E Q integral copy-states,
corresponding to the copy-ratios (locations) p.
Genome-wide absolute copy-profiles are over-determined with respect to DNA ploidy estimates. An
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alternate estimate of ploidy may be calculated as twice the expected absolute allelic copy-number over the
genome:
N Q-1
=2 wi Z q'igq. (5)
i=1 q=O
Validation of absolute copy-number predictions was performed by consideration of the expected absolute
copy-number, genome-wide. By definition, this quantity (fg) is an alternate estimate of cancer ploidy.
Because -ig is a weighted average over discrete states identified in the data, it is robust to experimental
fluctuations that shift and scale the copy-profile slightly. Validation of this ploidy estimate using FACS data
(fig. 2a), demonstrates that the average absolute copy-numbers are correct genome-wide. We adopted this
measure of cancer-genome ploidy throughout.
Estimation of ploidy by 5- relies on accurate calibration of the input copy-ratios. In contrast, ploidy
estimates derived the above expectation over discretized states are more robust to systematic fluctuations
(e.g. microarray background, input DNA quantity). For this reason, ABSOLUTE uses rg as the final
ploidy estimate for each mode. We note that these estimates are generally close to the values of 5 obtained
by optimization of the peak-fit likelihood (data not shown). Note that, for this computation, the 4i5 are
calculated with Oz = 0, so that the above expectation is over integral states only.
Two additional transformations of the copy-state locations yA are used when copy-ratios are measured
using microarrays. The first of these accounts for the effect of attenuation with an isothermal adsorbtion
model [Chiang 2009]:
(1 + 4 )
= (1+qx$)
where the value 4 parameterizes the attenuation response in a given sample, and is estimated via HAPSEG.
The second transformation is a variance stabilization for microarray data adapted from REF Huber:
xed -1h(x) = sinh- 1  I,
where or. and o-, represent multiplicative and additive noise scales for each microarray, estimated by HAPSEG.
This transformation is applied to the marker-level data during estimation of the xi values, after which
their distribution is approximately normal. The normal mixture component specified in (3) then becomes
h(xi) = h(g(Aq)) + ej, and the corresponding likelihood calculations are performed under these transforma-
tions.
Karyotype models
In a given tumor sample, several combinations of theoretically possible purity, ploidy, and copy number values
may map to equivalent copy ratios (fig 1c,h). Furthermore, the presence of subclonal SCNAs may result in
a spuriously high ploidy solution with an implausible karyotype receiving a greater peak-fit likelihood by
over-discretizing the copy profile, allowing their assignment to integral copy-levels (fig 1h,ij).
Previous techniques have dealt with this issue by presenting multiple interpretations of the sample for
manual inspection Popova, 2009 #913,Yau, 2010 #912, or by restricting the range of malignant ploidy values
Van Loo, 2010 #818. ABSOLUTE models common cancer karyotypes by grouping tumor sets according
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to similarities in their absolute allelic copy-number profiles (Supplemental figure 1). These models are
constructed directly from the tumor data in a boot-strapping fashion, whereby a subset of tumors with
relatively unambiguous profiles (eg., due to high purity values) is used initialize the models, iteratively
allowing more tumors to be called, etc. Previous cytogenetic characterizations of human cancer were used
to guide this process Storchova, 2008 #763. These models enable calculation of a karyotype likelihood, for
each candidate purity / ploidy solution, reflecting the similarity of the corresponding karyotype to models
associated with the specified disease of the input tumor sample (methods, eq. 7). Integration of the peak-fit
and karyotype likelihoods allows for robust and unambiguous identification of the correct purity and ploidy
values in many tumor samples (fig 1d,h). The selection of a solution implying a less common karyotype
requires greater evidence from the peak-fit of the copy profile.
Prior knowledge of karyotypes characteristic of a particular disease is summarized as a mixture of K
multivariate multinomial distributions over the integral allelic copy-states Q = [0,7] of each chromosome
arm. For a given candidate purity and ploidy solution, the corresponding segmental copy-state indicators
for each segment i, 4ij, are summarized into estimates of the J arm-level allelic copy-numbers, denoted C.
The karyotype log-likelihood score is calculated as:
K J
LK a|K) = log E wi f Ko , (6)
i=1 j=1 qEQ
where wi denotes the weight of each mixture component. The karyotype models Ki are J x Q SCNA
probability matrices obtained by clustering arm-level allelic copy-states of modeled copy-profiles using the
standard expectation-maximization (EM) algorithm {Dempseter, Laird} for multinomial mixtures. This
calculation identifies groups of disease subtypes with similar genomic copy profiles (Supplementary figure
1). Note that copy-states for both homologues of each arm are modeled (J = 78). The number of clusters
K for each disease was chosen by minimizing the Bayesian information criterion (BIC) complexity penalty:
-2Lk + KJlog(N), where Lk indicates the sum of LK values over the N input samples, computed using K
clusters. In order to avoid local minima, the EM algorithm was run 25 times for each value of K E [2,8]
with randomized starting points and the best model was retained.
The models were constructed in a semi-automated fashion by seeding with relatively unambiguous copy-
profiles. As tumors were added, the use of recurrent karyotypes clearly identified the correct solutions of
additional samples, etc. For example, LOH of chr17 occurs in nearly 100% of ovarian carcinoma samples
[TCGA OV], allowing the model to learn that solutions implying LOH of chr17 are likely to be correct.
The qualitative similarity of the resulting ploidy distributions with those obtained from cytogenetic data
[Storchova 2008] (Supplemental figure 7a) bolsters the veracity of the models created in this exercise. In
total, models for 14 disease types were created. Diseases with fewer than 40 samples called by ABSOLUTE
were omitted from this procedure.
Limitations of joint purity/ploidy inference from copy-profile data
Accurate calibration of both the peak-fit and karyotype models to the true level of certainty implied by
the data would allow for assignment of probabilities to each candidate solution; we do not believe that
the models we have presented here sufficiently capture the complexity of cancer genomes to allow for such
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interpretations. We therefore expect that manual review is currently an important part of joint purity/ploidy
inference using copy-number data, as was concluded in related studies {Popova, 2009 913} ,{Yau, 2010 912}.
Even with skilled manual review, analysis with ABSOLUTE may occasionally result in incorrect inter-
pretations, for example genome-doubling without subsequent detectable gains or losses would result in a
solution implying half the true ploidy value, which in many cases will correspond to a plausible karyotype
model (fig 5d). Alternately, when multiple subclonal SCNAs appear close to the midpoints between adjacent
clonal peaks, a solution implying twice the true ploidy may be chosen. We note that samples with no reliably
detected SCNAs could not be called in our framework (ploidy 2N or 4N; purity cannot be determined). Such
samples were therefore excluded from downstream analysis (see below). Estimation of inference error-rate
requires external measurement of sample ploidy. Further validation experiments in diverse tumor types will
help to clarify any disease specific caveats.
Fortunately, many cancer samples demonstrated marked SCNAs before and after genome doubling, en-
abling unambiguous inference for many samples. This aspect of cancer genome evolution was noted previously
in breast cancer cytogenetic data {Dutrillaux, 1991 905}. We note that manual review of ABSOLUTE re-
sults was performed prior to generation of the FACS validation data or analysis of the NCI60 cell-line ploidy
estimates (fig 2a,b).
Identification of samples refractory to purity/ploidy inference
In order to facilitate rapid analysis of many cancer samples, ABSOLUTE attempts to automatically identify
copy profiles that cannot be reliably called and to classify them into informative failure categories (fig 2e),
which in this study were defined by the following criteria. Define rhn as the sorted vector of posterior genome-
wide copy-state allocations (0), so that ?^in represents the greatest element of 0 (the modal copy-state). This
vector is constructed with 00 replaced by 0 if 0 < 0.01 and b < 0.15, so that germline copy-number variants
(CNVs) or regions of inherited homozygosity are not confused with small SCNAs implying very pure samples.
The categories are then:
1. non-aberrant: fn3 < 0.001, in2 < 0.005, &H < 0.02
2. insufficient purity: 7 n3 < 0.001, 7 n2 < 0.005, &H > 0.02
3. polygenomic: 0, > 0.2.
These criteria are applied to the top-ranked mode for each sample (combined peak-fit and karyotype scores).
Several examples of each outcome are shown in Supplemental figure 5. The above designations led to
reasonably good concordance of automated calls with those obtained after manual review. This is an area
for potential methodological improvement, likely to be aided by additional validation data.
Cancer cell-line DNA mixing experiment
DNA extracted from two cancer cell lines (HCC38, HCC1143) was mixed with DNA from matched B-
lymphocyte cell lines (HCC38BL, HCC1143BL) in various proportions, and hybridized to Affymetrix 250 K
Sty SNP arrays. Stock DNA aliquots were created for each cell-line by normalization of DNA concentration
to 50ng/pl. Mixing of cancer and matched B-lymphocyte DNA to each required mixing fraction was done
by volume.
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FACS analysis of primary tumor samples
Formalin-fixed and paraffin-embedded blocks from ovarian serous carcinoma cases were available from tumor-
sections corresponding to the frozen blocks from which DNA-aliquots were obtained for SNP-array hybridiza-
tion. Multiple curls containing at least 70% tumor cell nuclei were cut to an aggregate thickness of 150
microns. Sections were disaggregated and labeled with propidium iodide (DNA stain). FACS was performed
to determine ploidy.
Determination of tumor purity via pathology review
Frozen ovarian serous cystadenocarcinoma specimens were collected from multiple hospital tissue banks and
maintained frozen in liquid nitrogen vapors. A tissue portion was created with two flanking H&E slides
(arbitrarily named top and bottom) as follows: tissues were mounted in optimal cutting temperature media
(OCT) and brought to -20 C. A 4pm frozen section (top slide) was cut with a cryostat (Leica Microsystems,
Wetzlar, Germany). A specimen for molecular extraction was created by shaving 100 mg of tumor tissue
from the tissue face with a scalpel, then a second 4pim frozen section was cut (bottom slide). An H&E
stain was conducted on both slide tissue sections using an Autostainer XL with integrated coverslipper
(Leica). Digital images of slides were created at 20x resolution using a Scanscope XT (Aperio, Vista,
CA, USA). Board-certified pathologists conducted the pathology review remotely via ImageScope software
(Aperio). Pathologists initially reviewed each slide at low magnification to determine low power microscopic
morphology, then increased magnification to 20x and reviewed 10 representative high power fields on each
slide. Diagnosis of ovarian serous cystadenocarcinoma was verified, and tumor purity was determined as the
proportion of tumor nuclei present compared to the total nuclei present on the slide. The tumor purity of
the extracted specimen was calculated as the average purity score of the top and bottom slides. Quality
control included a random review of 10% of slides by a second pathologist to verify consistency of reads.
Leukocyte methylation signature
DNA methylation data for 489 high stage, high grade serous ovarian tumors and eight normal fallopian tube
samples was obtained from http://tcga.cancer.gov/dataportal/. In addition, buffy coat samples from two
female individuals were obtained. All data were generated with Illumina Infinium HumanMethylation27
arrays, which interrogate 27,578 CpG sites located in proximity to the transcription start sites of 14,475
consensus coding sequencing in the NCBI Database (Genome Build 36). The level of DNA methylation at
each probe was summarized with beta values ranging from 0 (unmethylated) to 1 (methylated) Noushmehr
et al [PMID: 20399149].
The leukocyte methylation signature was derived as follows. Each probe was ranked by the difference in
mean beta value in buffy coat and fallopian tube samples. We retained the 100 top-ranking probes in each
direction, designated BC and FT, (buffy coat and fallopian tube enriched, respectively). Let Tik denote the
beta value for probe k in tumor sample i. Let B1 denote the average beta value of buffy coat samples for
each probe. Let #Tk denote the minimum observed beta value across all tumor samples for the BC probes
and the maximum for the FT probes. Denote by fB the fraction of buffy coat components in the sample,
then we have the following equation for each probe: #Ti = 3BkfB +#ITk(1 - fB). Solving this equation for
fB gives: fB = 3Tik - 3Tk/3Bk - 3Tk. The values of fB for each of the 200 probes in the signature were
calculated and a kernel density estimate was obtained. The leukocyte signature was then calculated as the
mode of this density estimate.
Selection of datasets
We analyzed 2445 Affymetrix 250 K Sty SNP samples from a previous pan cancer survey {Beroukhim 2010}
containing 3131 cancer samples. Because our processing of the data required use of the Birdseed algorithm
{Korn 2008}, external datasets with no diploid PCR controls could not be used. In addition, cancer types
with fewer than 20 samples were excluded. In addition, 680 Affymetrix SNP6.0 samples were taken from the
TCGA GBM {} and HGS-OvCa {} studies, as well as 30 cell-line samples, bringing to total sample count
to 3155. The complete table of cancer samples analyzed is available as Supplementary file 1. The complete
table of ABSOLUTE results is available as Supplementary file 2.
Power calculation for somatic mutation detection in cancer tissue samples
We develop a framework for calculation of statistical power for the detection of mutations. Power to detect
a variant depends on the allelic fraction f and local depth of coverage n. To calculate power, we model the
idealized scenario in which random sequencing errors occur uniformly with rate c. We calculate a minimum
number of supporting reads k such that the probability of observing k or more identical non-reference reads
due to sequencing error is less than a defined false-positive rate (FPR):
k = min IP(m) < FPR,M
where
P(m) = 1 - Binom (iln, E/3).
i=O
Variants with > k supporting reads are then considered to be detected. We specified the sequencing error
rate E = 1 x 10- 3 and FPR = 5 x 10- for all computations in this study. Power is then calculated as:
k-i
Pow(n, f) = 1 - Binom (iln, f) + d Binom (k~n, f), (7)
i=O
where
FPR - P(k)
P(k - 1) - P(k)'
We consider the case of detecting clonal somatic variants present at a single copy per cancer cell in
cancer-tissue derived DNA samples. Given estimates of purity (a) and local absolute copy-number (qt), the
allelic fraction of such variants is:
a (8)2(1 - a) + aqt
Power is calculated in such cases as Pow(n, 6).
In order to simplify the relationship between power and tumor purity/ploidy for presentation in fig. 3,
we considered the detection power of the expected locus, over the genome-wide copy average. Power as such
is determined by the sample allelic index 6, = a/D, which is solely a function of tumor purity/ploidy (eqn.
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1). Expected power is obtained by using allelic fraction f = 6, in eq. (7). This calculation differs only in
the substitution of expected genomic copy-number, i.e. ploidy (r), for the local copy-number qt in eq: (8).
Power for expected subclonal variants present in fraction sf of cancer cells is given by Pow(n, sf6, ). This
calculation was used for Figure 3c,e. Local copy calculations using Pow(n, sf 6) were used for Figure 3f and
Supplemental figure 9.
Detection of somatic point mutations in ovarian carcinoma
We analyzed whole-exome hybrid capture Illumina sequencing (WES)Gnirke, 2009 #848 data from 214
ovarian carcinoma tumor-normal pairs previously analyzed by the TCGA consortium Bell, 2011 #944. We
used the program muTect K. Cibulskis, et al., in preparation We have used a newer version of the program
muTect than used in previous analysis of this data Bell, 2011 #944. The primary improvement in the new
version is a reduction in the prior that somatic mutations be at an allelic fraction of 0.5, allowing greater
sensitive at low allelic-fraction mutations, such as clonal events in impure samples, or to subclonal mutations.
This procedure resulted in 29,268 somatic mutations.
Inference of point mutation multiplicity
We develop a probabilistic model for inference of the integral multiplicities for both germline and somatic
variants, based on knowledge of tumor purity and genome-wide absolute allelic copy-number. Denote the
absolute allelic copy-numbers at a mutant locus as qi and q2, with qi 5 q2. The possible multiplicities of
germline variants are then:
gq = {qi, q2, qt},
where qt = qi + q2. Under the assumption that all somatic point-mutations arise uniquely on a single
haplotype, the possible multiplicities are:
sq{1,...,q2}.
Germline mutations are potentially present in both the cancer and normal cell populations, with so-
matic copy-number alterations affecting the allelic fraction. A heterozygous variant in the germline, with
multiplicity gq in the cancer genome, has allelic fraction:
S(1 - a) + agq
f 2(1 - a) + aqt'
whereas the allelic fraction of homozygous germline variants is 1 regardless of a. For somatic point
mutations, the expected allelic fraction at multiplicity sq is fsq = s 6 , with 6 as in eq. (8).
Consider an observed somatic point-mutation of unknown copy sq E sq, observed allelic fraction f, and
with n total reads covering the locus. The complete likelihood of f may represented as a mixture of beta
distributions corresponding to each element of sq, plus an additional component S corresponding to subclonal
states:
Em (in, sq, wq, = "" Beta (jnf, n (1 - fsq) + w,S(fIn, A), (10)
,Esq Iq2
where wS, E Wq specify mixture weights for each state in sq, and w8, specifies the subclonal component
weight. The subclonal component S is specified by composing a Beta distribution modeling sampling noise
with an exponential distribution over subclonal cancer-cell fractions, having a single parameter A:
S(f In, A) = Beta (flnf, n (1 - f)) Exp(f/6|A)61df
0
Note the change of coordinates in the exponential component using 6; this allows modeling in consistent
units of cancer-cell fractions, regardless of tumor purity and local copy-number (note this distribution is
renormalized on the unit interval). The probability of a given integral copy-state sq may then be calculated
as:
w q Beta (flnfs,, n (1 - fs)
sq=
q2 Lm(fn,sqwqws)
Similarly, the probability that a given mutation is subclonal is calculated as:
S(f In, A)
E m (fIn, sq, wq, wse
For the computations in this study, we fixed A = 25, w,q to 0.25, and w,, to 0.75, which produced a fit to
the combined-sample mutation-fraction distribution (fig. 4b). The results presented in fig. 4 were robust to
various settings.
We describe a rescaling of somatic variant allele-fractions into point estimates of multiplicity. These
estimates may be used to visualize the distribution of somatic variant multiplicities in the cancer genome,
along with sampling noise. Consider a mutation with Na and N, reads supporting the alternate and reference
alleles, respectively. Denote the observed mutant allele-fraction by:
Na
f = .Na + Nr
Under the assumption that no systematic bias exists favoring the observation of reads supporting either
allele, this quantity estimates the ratio of alternate-allele to the total concentration at this locus:
-Ca
f = a +e
Ca + Cr
where Ca and C, denote concentration-ratios of the alternate and reference alleles, respectively, and c
represents sampling noise, which is approximately normal for coverage values > 30. Let det denote the
absolute total copy-number at the mutant locus, then C = b + ort gives the total concentration-ratio.
Noting that C = Ca + Cr, we can obtain estimates of the variant and reference concentration-ratios as
Ca = fC, and C, = C - Ca. These estimates can then be rescaled to point estimates of multiplicities for
variant and reference alleles:
Ma = Oa/6, Mr = 6r -) /4 (11)
This rescaling projects the reference and variant allelic concentration-ratios onto the lines y = -x + qt. This
transformation was used to rescale the data in Figure 3b,e.
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Simulation of cancer-genome evolution to support genome-doubling inferences
A simple simulation was performed to obtain P-values for the probability that an observed configuration of
allelic copy-numbers could be produced from a serial process of independent gains and losses. Genome-wide
allelic copy-numbers are summarized at chromosome-arm resolution as integral allelic gains/losses (total of
78 states). We then fix the total number of gains / losses N for the sample, and calculate rates for each arm,
which are normalized to probabilities. Simulation of the sample is performed by independently sampling N
gains and losses from these probabilities. This was repeated 1000 times for each sample, keeping track of the
number of times M that the extent of even high parental-allele copy-number present in the observed sample
was attained or exceeded. The P-value is then: P = M/1000, if M > 0, otherwise P < 0.001.
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Supplemental Figure 1I Karyotype models for GBM, constructed by grouping tumor sets according to
similarities In their absolute allelic copy-number profiles
(top) multivariate multinomnial mixture model with 3 components, representing genomic subtypes.
(bottom) individual GBM samples are shown grouped according to their cluster membership in (top).
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Supplemental Figure 2 | Unusual karyotypes Identified using ABSOLUTE.
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a-d, Analysis of allelic copy-ratio profiles with ABSOLUTE, as in figure 1.
a,b, Near-haploid genomes
c,d, Hyperaneuploid genomes
a, Lung adenocarcinoma sample SM-11ZY. Purity = 0.36, ploidy = 1.12.
b, Glioma sample 'glioma 612'. Purity = 0.88, ploidy = 1.14.
c, HGS-OvCa sample TCGA-25-1320-01A-01 D-0452-01. Purity = 0.58, ploidy = 6.03.
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Supplemental Figure 4 | Evaluation of the ASCAT {Van Loo, 2010 #818} method
a, Cancer-normal cell-line mixing experiment, as in figure 2b. The estimated purity values for the cell-line
mixtures obtained by ASCAT were systematically lower than the true values, with a mean difference of 17% and
13% for HCC38 and HCC1 143, respectively, and three low-purity mixtures were misinterpreted.
b, Concordance of ASCAT ploidy predictions and FACS analysis, as in figure 2a. The concordance of the
ASCAT ploidy estimates with the FACS results was 68.6%, mean absolute difference 0.66. Ploidy of the NCI-60
cell lines could not be evaluated due to the requirement of a matched-normal sample for analysis with ASCAT.
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Haplotype-specifc copy ratio (HsCR)
Supplementary figure 5 | Haplotype-specific copy-ratio profiles of called and uncalled cancer samples
a-d, Haplotype-specific copy-ratio (HSCR) profiles for 12 cancer samples. Rows correspond to called samples
(a), and three distinct failure modes (b-d), as indicated (left-hand labels). HSCR profiles are colored according to
allelic imbalance, as in figure 1 (b,g). The distribution of each outcome is shown for each tumor type in figure 2e.
a, Called samples annotated with fit haplotype-specific copy numbers (HSCN; top-axis).
b, The most common failure-mode designation was "non-aberrant" (9.1% of samples), indicating that the copy
profile was indistinguishable from that of a normal (diploid) sample.
c, An additional 7.3% of samples failed due to insufficient purity. In these samples, copy aberrations were
apparent, but so attenuated as to obscure the pattern of integral copy states.
d, The remaining 6.9% of failed samples were designated as "polygenomic"; although clear SCNAs were
observed, they were not consistent with a single dominant copy profile (eqn. 1).
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Supplemental figure 6 1 Distribution of estimated purity in various tumor types, and effect on observed
copy-ratios
a, Distribution of estimated tumor purity for several datasets. The number of called tumor samples in each group
is shown in parentheses. We note that, because heavily contaminated tumors are difficult to call using
ABSOLUTE, several of these distributions are biased towards higher purity samples.
b, Data are shown for each indicated sample-type, with samples sorted by tumor purity.
c, Genome wide copy-ratio profiles are shown for several tumor cohorts. The effect of tumor contamination is
evident as the 'fading' of copy ratios towards 1 as tumor purity decreases.
d, The data from c are shown after 'in silico' removal of tumor contamination by dividing total absolute copy-
number by sample ploidy. This transformation enables more direct comparison between datasets, as samples
without copy alterations may be clearly distinguished from heavily contaminated tumors.
c,d, Copy ratios in were median-centered at 1 for plotting.
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Supplementary figure 7 || Distribution of estimated ploidy in various tumor types, and correspondence
with absolute allelic copy-numbers
a, The number of called tumor samples in each group is shown in parentheses. Because tumors without SCNAs
cannot be called using ABSOLUTE, these distributions do not incorporate the prevalence of such samples.
b, Data are shown for each indicated sample-type, with samples sorted by cancer-genome ploidy.
c,d, Absolute copy-numbers of genomic segments for each sample are partitioned into low (c) and high (d) allelic
copy values.
b,c,d, Genome doubling events are discernable as inflections in the ploidy distributions of each cancer (b),
corresponding with an increase in genome-wide allelic copy-numbers (c,d).
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Supplementary figure 8 | Incidence of chromosome arm-level SCNAs In non genome doubled (WGD=O)
vs. genome doubled (WGD=1) samples from 10 cancer types.
As in figure 3g. LOH (loss of heterozygosity) was defined as 0 allelic copies. Amplification was defined as > 1
allelic copy for samples with 0 genome doublings, and as > 2 allelic copies for those with 1 genome doubling.
Calls were made based on the modal allelic copy numbers of each chromosome arm. Dashed lines indicate y-x.
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Supplemental figure 9 1 Power for detection of subcIonal somatic mutations In 8 HGS-OvCa samples.
Histograms of cellular multiplicity point-estimates (as in supplemental figure 9b) are shown for individual tumor
samples, in order of decreasing A, which determines the expected detection power for each sample (figure 5).
Individual point mutations are colored according to their estimated detection power, calculated using their
observed allelic fraction, coverage, tumor purity, and local absolute copy-number (Methods, eqn. X).
Coverage values and absolute copy-numbers were used to calculate theoretical detection power at each base for
subcIonal fractions between 0.025 and 0.5 (Methods, eqn. X). The number of bases with power >= 0.8 are shown
for each fraction (blue curve, right axis).
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CIN signature (Chapter 2)
Subsequent studies have validated the prognostic ability of the CIN signature in
additional tumor types, including colon cancer [1] and several other cancers. A recent
report described the use of the CIN signature (chapter 2) [2] for the construction of a
"CINSARC" gene expression signature, conopensisting of 67 genes. This genelist was
obtained by intersecting three t tests for gene expression values in 183 sarcoma samples,
comparing expression in tumors with many vs. few CGH imbalances, grade 3 vs. grade 2,
and high vs. low expression of the CIN signature. High expression of the resulting
"CINSARC" genes was significantly predictive of poor clinical outcome in a validation
set of 127 sarcoma profiles [3].
In 2009, Julian Downward and colleaguesi examined the relationship between genes
described in the CIN-signature (Chapter 2) with those identified as being related to the
response of primary tumors and model systems to treatment with taxanes[4]. Although
microtubule-stabilizing (MTS) agents such as taxanes are important chemotherapeutics,
their mechanism of action is incompletely understood. The specific mechanisms by
which cell death is induced following MTS exposure may depend on a competent mitotic
spindle checkpoint[5]. However, the inactivation of this checkpoint is likely to be a
prerequisite for the development of CIN [6], [7], [5]. The karyotypic complexity of
cancer cell lines has been associated with altered cytotoxic response profiles in vitro [8],
suggesting that the poor success of treating CIN cancers with MTS agents may be
partially due to processes required for the generation and maintenance of the CIN
phenotype, rather than the ability of CIN cancers to rapidly evolve resistance mechanisms
to cytotoxic therapeutics.
Downward and colleagues derived a MTS expression signature by analysis from
expression profiling of 4 cancer cell lines and an ovarian cancer xenograft model treated
with taxanes or epothilone. Notably, 27 non cell-cycle regulated genes from the CIN70
signature[2] were significantly repressed following MTS treatment, but not by treatment
1 Including Dr. Zoltan Szallasi, the senior author of the CIN-signature paper.
with the cytotoxic agent 5-FU[4]. In addition, these genes were observed to have lower
expression across several data sets generated from tumors prior to and following
treatment via MTS exposure[4]. The authors identified 50 "MTS-repressed" genes by
intersecting genes down-regulated following MTS exposure in several datasets with the
CIN70 genes[4]. Silencing 22/50 of these genes by shRNAi caused significantly
impaired cell viability and/or promoted increases in sub-GI DNA content in the HCT-
116 cell line, and silencing all of them produced the same effect in two additional cell
lines. Taken together, these results suggest that DNA damage and spindle checkpoint
genes, as identified in the CIN signature[2] (Chapter 2), may play a causal role in
mediating cell-death following MTS exposure.
In addition to its utility in cancer prognosis, subsequent experimental investigation of
specific genes comprising the "CIN signature" has confirmed roles for several such genes
as functionally related to CIN. CIN scores were computed for 10,152 genes. Over-
expression of several of the top 70 scoring CIN genes had been previously reported to
cause aneuploidy (PTTG1), chromosomal instability (AURKB, CCNB1, CCNB2,
FLJ10036), or polyploidy (TPX2, AURKA) (references and the full list of the top 70
genes are given in Appendix A of this thesis).
Recently, high levels of the Mpsl protein, (formerly TTK, CIN-gene #23) were reported
to contribute to the ability of breast cancer cells to tolerate aneuploidy, although over-
expression of Mps 1 was insufficient to induce aneuploidy or transformation of
immortalized human cells [9]. Inhibition of this gene by shRNAi resulted in increased
apoptosis in the human cancer cell-line T47D, and reduced growth in breast cancer
xenografts [9]. These results provide functional validation for an additional CIN gene
and provide another demonstration of non-oncogene addiction in human cancer cells
[10], [11].
Another gene, FOXM1 (CIN-gene #3) has since been shown to be an important master
transcriptional regulator, disrupted in human cancer, and has been recently identified to
play a role in high-grade serous ovarian carcinoma[1 2]. Previous reports had described
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the chromatin modifying polycomb-group (PcG) gene EZH2 (CIN-gene #37) as over-
expressed in breast cancer. Interestingly, recurrent mutations in this gene have recently
been reported in myelodysplastic syndrome (MDS), showing patterns of homozygosity,
frame-shift, and truncation consistent with tumor suppressor function [13], [14].
In 2006, shortly after the CIN signature paper appeared, David Pellman and colleagues
reported results from a synthetic lethality screen for yeast genes essential to the viability
of polyploid strains [15]. Only 39 out of 3,740 mutations screened exhibited ploidy-
specific lethality. Almost all of these mutations affected genomic stability by impairing
homologous recombination, sister chromatid cohesion, or mitotic spindle function.
Several of these genes had high CIN-scores, such as RAD54L (#75), BUB1 (#42 1), and
RAD51 (#487), although a rigorous mapping to yeast/human gene-homologs was not
performed.
Although aneuploidy is found in approximately 90% of human cancers, it produces a
strongly deleterious phenotype in normal eukaryotic cells[1 6]. In 2007, Angelika Amon
and colleagues addressed this paradox by investigating haploid yeast strains for which
single chromosome gains of each individual autosome had been constructed[17]. The
authors used proliferation assays in various conditions and gene expression microarrays
to characterize the phenotypic consequences on these induced aneuploidies. They
showed that aneuploid strains shared a number of phenotypes, including defects in cell
cycle progression, increased glucose uptake, and increased sensitivity to conditions
interfering with protein synthesis and protein folding[1 7]. To investigate the general
effects of aneuploidy, the authors down-weighted genes on the disomic chromosome
present in each strain and clustered the profiles, revlealing that several disomic strains,
and all of the strains bearing multiple extra chromosomes exhibited a gene expression
signature characteristic of the yeast environmental stress response (ESR) [18].
Notably, the above growth and gene-expression phenotypes were observed only with gain
of yeast chromosomes bearing transcribed genes (and not with artificial chromosome
constructs); this indicates that the observed phenotypes were likely the result of protein
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imbalances, and not due to mitotic defects due to purely geometric differences in the
aneuploid strains relative to wild-type. However, the gene expression profile shared by
aneuploid strains grown under phosphate-limiting chemostat conditions was also
observed in strains with artificial chromosomes[1 7], indicating that replication and
maintenance of extra DNA has distinct phenotypic consequences.
The gene annotations most over-represented in the 397 aneuploidy genes co-regulated in
the aneuploid strains were ribosome biogenesis, and carbohydrate metabolism, which
bear no obvious resemblance to the annotations associated with the CIN signature [2].
This suggests that in human cancer, aneuploidy does not arise randomly, but rather is due
to positive selection, in which case it occurs with proliferative advantages. This is
supported by the patterns of chromosomal SCNAs in human cancer, where gain and loss
of particular arms are highly recurrent within particular diseases and cell-lineages [19].
Because virtually all oncogenic pathways are expected to result in a cellular phenotype
with greater proliferative capacity, it is difficult to disentangle gene expression
'signatures' related to specific oncogenic mechanisms from the downstream induction of
normal cell-cycle transcriptional programs [20]. This caveat applies to all such "gene
expression signatures" related to the cancer phenotype, whether they seek to describe the
induction of specific known oncogenes [21], [22], or cellular states related to cancer
development [23], [24], [25], [26], [2], [27].
In the case of the CIN signature, many genes were annotated in functional categories
related to replication and segregation of chromosomes. However, many such genes are
also by their nature cell-cycle regulated [28]. An important aspect of the CIN-signature
work involved dissecting out the prognostic ability of genes specifically associated with
aneuploidy (as ascertained by regionally coordinated expression deviation[2]), vs. those
with expression patterns driven by the cell-cycle (in the HeLa cancer cell-line [201)2.
2 One might wonder whether the use of a cancer cell-line to identify genes regulated by
the cell-cycle might result in the identification of genes with such expression patterns due
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This procedure revealed that many genes with high CIN-scores did not appear to be
regulated by the cell cycle (and that these genes were highly prognostic). To further
examine this relationship further, it might be informative to compare the genes correlated
with each of the core cell-cycle and CIN genes across large and diverse collections of
cancer gene expression profiles. Although these gene-sets will almost certainly overlap,
clustering or PCA analysis of each signature's expression "neighborhood" might reveal
evidence for finer correlation structure, given sufficient data.
The difficulty of de-coupling the downstream effectors of cellular oncogenes from the
normal functioning of physiological processes was further highlighted in a recent paper
describing the regulation of 13 such signatures by the MYC oncogene in human cancer
cell-lines [29]. The c-Myc oncoprotein was recently demonstrated to function as a post-
initiation regulatory mechanism, controlling pause-release by the RNA polymerase II
(Pol II) transcription initiation apparatus [30]. Furthermore the expression of this protein
was linked to the production of a large population of actively transcribed genes in
embryonic stem cells [30]. These results suggest that MYC over-expression may
orchestrate the unregulated proliferation characteristic of stem cells by directly regulating
the transcription of thousands of target genes. Notably, MYC is the most frequently
amplified gene in human cancer [19].
Further dissection of chromosomal instability as a cellular phenotype might be aided by
screening for genes with CIN-associated phenotypes, such as progression of the cell-
cycle through the mitotic-spindle checkpoint in the presence of nocodazole, a
microtubule poison, as previously described [6]. Such efforts could be integrated with
other high-throughput screening efforts on cell-lines with partially defined karyotypes 3
to the cancer phenotype itself, rather than as a normal constituent of the cell cycle
program.
The use of ABSOLUTE to further resolve these karyotypes and annotate them with
respect to genome doubling status may be used to interpret screening data in these cell
lines.
150
In 2011, Zoltan Szallasi and colleagues demonstrated excellent correlation between the
CIN score and a structural chromosomal complexity score based on SNP array data, as
well as a measure of nuclear DNA mass (ploidy)[31]. In addition, they showed that
breast cancers with CIN signature values greater than the 7 5 th percentile showed
improved prognosis relative to the 50-75% percentile, suggesting that extreme excess
transcription of the CIN-genes was associated with decreased fitness, possibly due to the
difficulty of maintaining an extreme mutator phenotype[31].
HAPSEG (Chapter 3)
In addition to its utility for HSCR estimation, we exploit unequal copy-numbers in
parental homologues to achieve direct haplotype phasing, which is of general interest
beyond cancer genome analysis. We demonstrate the validity of our phasing estimates by
comparison with phasing methods based on reference chromosome panels.
We believe that HAPSEG has potential application to areas other than cancer biology.
Specifically, the capacity of HAPSEG to produce definitive long-range haplotype
phasing from bi-allelic measurements will be of immediate interest. For example, we are
currently using HAPSEG on whole-genome sequencing data in order to generate densely-
typed reference panels for imputation of rare variants using whole-exome sequencing.
Specifically, because the reference panel can be genotyped at greater density than the
input genotypes, information about untyped SNPs can be filled in using the reference
panels, a technique termed imputation in the genetics literature. Several statistical
algorithms have been described implementing imputation within this framework
[32], [33], [34], [35], [36], (reviewed in[37]). Importantly, all of these techniques assume
that the phase of the heterozygous genotypes is unknown, requiring them to average over
statistical configurations of the haploid genotypes.
Long-range haplotyping provided by HAPSEG in aneuploid cancer samples provides a
means of obtaining segmental regions of definitive phase. This information has the
potential to increase the sensitivity of imputation in these regions, and in adjacent
unphased regions, allowing for inference of lower minor allele frequency (MAF)
variants. This may present an attractive strategy by which to undertake a pan-cancer
analysis of preferential somatic alteration of specific alleles in cancer development.
Identification of recurrent alterations of specific variants would be of interest because
they would be contribute evidence of positive selection at these loci during cancer
evolution, possibly identifying novel mechanisms of interaction with germline risk and
evolution of the cancer phenotype.
The common risk locus at 8q24 was previously reported to show -1.5 fold preferential
amplification in colorectal cancer [38], and later to functionally interact with MYC by
affecting a binding site for the Wnt-regulated transcription factor TCF4, with the risk
allele showing stronger binding. Although genome-wide ChIP assay revealed this
element as the strongest TCF4 binding site within 1 Mb of MYC [39], "an unambiguous
correlation between rs6983267 genotype and MYC expression was not detected" [39].
At the same time, Matthew Freedman and colleagues reported that this locus displayed
enhancer activity and long-range interaction with MYC in colorectal cancer [40].
Unfortunately, the unbiased genome-wide detection of novel selected variants at effect
sizes of -20-fold or less will likely require the analysis of several thousand cancer
samples [41 ]4. Early studies using smaller sample sizes have not yielded definitive
evidence for the moderate prevalence of allelic selection in cancer evolution [42], [43].
We hope to probe deeper into lower effect-size variants by using HAPSEG, as described
above, on several thousand cancer samples produced in collaboration with The Cancer
Genome Atlas.
ABSOLUTE (Chapter 4)
As of 2011, characterization of tumor copy-profiles and point-mutations using
ABSOLUTE has become an essential methodological component of our cancer genome
analysis pipeline at the Broad institute, and provides a key foundation for virtually every
aspect of our continued analytical developments. This will impact future efforts in The
4 Identification of such variants requires large sample-sizes because only heterozygous
SNPs with somatic copy alteration are informative.
Cancer Genome Atlas (TCGA) project, in which we are characterizing 500 tumor/normal
pairs in >20 tumor-types, as well as all of our other cancer genome projects. In addition,
several insights into the evolution of aneuploidy and genome doubling in human cancer
are discussed below.
Aneuploidy precedes genome doubling in many human cancers
Analysis of modeled absolute allelic copy-number profiles across human cancers
produced by ABSOLUTE allowed for refinement in the understanding of cancer genome
evolution. The profiles were consistent with a period of chromosomal instability early in
the development of many tumors, followed by the emergence of a stable aneuploid clone,
as previously described [44]. Our data further indicate that genome doublings occur in a
subset of cancer cells harboring the characteristic arm-level SCNAs of the corresponding
tumor type. The genomes of these cancers were therefore shaped by selection at broad
resolution prior to doubling and clonal outgrowth.
Our model whereby aneuploidy precedes genome doubling is broadly consistent with an
earlier interpretation of primary breast cancer FACS/SKY profiles [45], and has recently
been recapitulated in studies of macro-dissected and ploidy-sorted cell-populations [46],
and single cell sequencing [47], of primary breast tumors. However, most other
descriptions of genome doubling in cancer typically have referenced tetraploidization
itself as an initiating oncogenic event [48],[49],[50], [51], [52], [53], an interpretation
inconsistent with our data. A notable exception occurred in prostate cancer samples, a
subset of which were modeled as near-tetraploid, with few broad SCNAs; further
validation is required to confirm these predictions.
Annotation of cell-line collections using ABSOLUTE will inform future genetic
screening of cell-lines, allowing integration of shRNAi sensitivity profiles with specific
aneuploidies, genome-doubling status, and point-mutation multiplicities. Such
annotations may be further used to screen for mutations that are specific to aneuploidy or
genome-doubling status.
153
The relationship between aneuploidy and genome doubling
Polyploidy has previously been proposed to buffer the deleterious effects of aneuploidy
[54]. Deleterious phenotypes caused by gain of individual yeast chromosomes were
more severe in haploid yeast strains than in diploids, consistent with the doubled baseline
DNA content buffering proteomic imbalances due to aneuploidy [17], [54], [55]. This
may provide an explanation for the frequent genome doublings observed in human
cancers, especially in those of epithelial lineage (Chapter 4).
Buffering of aneuploidy may also partly explain the rarity of near-haploid karyotypes in
human cancer. These genomes virtually always display absence of focal alterations and
loss of all autosomes except for those with the greatest amplification frequency (eg.
Chromosomes 7 and 8 in lung adenocarcinoma and GBM; Chapter 4). Such
configurations may represent islands of selective advantage, since the paths leading to
them by concerted loss of individual chromosomes likely involve intermediates with
severe relative imbalances in the genome; virtually no karyotypes were observed with
ploidy values between 1.25 and 1.6 (Chapter 4). In addition, the random loss of any
chromosome from this configuration would likely be lethal; a state which we expect
would be incompatible with ongoing chromosomal instability.
Buffering of genomic imbalances by genome doubling would not explain why only some
cancers pass through genome doubling during their evolution. High-grade serous ovarian
carcinoma (HGSOC) may be an especially instructive disease in which to consider this
question[56],[12], because the rates of specific chromosome-arm deletions and
amplifications are nearly identical in the genome-doubled cases (-55%) vs. non-doubled
cases (45%) (Chapter 4). Thus, aneuploidy itself is unlikely to influence somatic
evolution with regard to genome doubling in these cancers.
In 2009, David Pellman and colleagues demonstrated a mechanistic link between
abnormal centrosome content and chromosomal instability in human cells [57]. Human
cells normally contain two centrosomes, which localize to either end of the nascent
mitotic spindle during mitosis where they are critical in the nucleation of microtubule
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polymerization forming the spindle scaffold. The authors showed that cells with doubled
centrosome content could sometimes cluster their four centrosomes into a bipolar
orientation, resulting in a reasonably normal mitosis, although with a greater rate of
chromosome mis-segregation[57]. However, when this clustering did not occur, a multi-
polar mitosis ensued, resulting in catastrophic errors and total lethality. Because genome
doubling by cytokinesis failure [48], [58], [49], [59], or mitotic bypass [52] doubles the
centrosome number, these results predict that the rate of chromosomal instability would
be greater in the resulting cells.
In 2010, Titia de Lange and colleagues demonstrated that critical erosion of telomeric
DNA provokes a persistent DNA damage response in mouse embryonic fibroblasts
(MEFs), leading to cytokinesis failure, resulting in polyploidy. We observed a significant
association between genome doubling and increased age at diagnosis, consistent with a
role for telomeric erosion in HGSOC genome doubling. Alternately, this association
could be related to menopausal status and estrogen signaling.
Genome doubled cancers have greater incidences of focal SCNAs than non-doubled
cases (Chapter 4), and this increase did not appear to be explainable solely by the
increased DNA content subjected to equivalent mutation rates in the two sample classes.
This raises the possibility that the same mechanism which produced the excess focal
SCNAs in the doubled genomes caused bypass of cytokinesis in these cells, leading to the
genome doubling as previously described[52], but independent of telomere status.
Deeper analysis of the absolute allelic copy-numbers of focal alterations in genome-
doubled cancers may shed light on whether they occurred pre- or post- doubling, at least.
In the final days before the defense of this thesis on 08/29/2011, additional insights into
the relationship between aneuploidy and cancer evolution were published. Angelika
Amon and colleagues reported that multiple budding yeast strains bearing additional
copies of single yeast chromosomes showed an increase in various forms of genetic
instability, thus demonstrating that aneuploidy itself drives a mutator phenotype [60]. By
showing that aneuploidy enhances genetic recombination and defective DNA damage
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repair, the authors provide a mechanistic link between aneuploidy itself and further
genomic instability [61]. Notably, they found that loss of yeast artificial chromosomes
(YACs) 5 was increased in 9/13 of aneuploid strains tested, relative to wild type[60], an
observation which is consistent with our results in primary human cancers, where
individual chromosomal losses were predicted to exceed gains (Chapter 4).
In the same issue of Science, a separate group demonstrated that the STAG2 gene is
homozygously deleted in a small number of glioblastoma, Ewing's sarcoma, and
melanoma cell lines [62]. Because the STAG2 gene is located on the human X
chromosome, only a single genetic hit is required to recessively inactivate the gene in
either male patients or female patients in which the remaining allele is silenced by the X-
inactivation. The STAG2 gene encodes a subunit of the cohesin complex, which
regulates the separation of sister chromatids during cell division. The authors showed
that targeted correction of the endogenous mutant allele of STAG2 in human glioblastoma
cells restored sister chromatid cohesion [62].
Additional future applications of ABSOLUTE
Clustering of absolute allelic copy-profiles at chromosome arm resolution produced 3
clusters of GBM samples (Supplemental figure 1, chapter 4) 6. Integration with
additional genomic features resolved from sequencing data will allow further
characterization of genomic heterogeneity in diverse cancer types. In addition, see the
discussion section of Chapter 4.
5 Because these do not contain transcribed genes, they are not subject to selection for
beneficial protein products, and allow for measurement of the rates of chromosomal gain
and loss.
6 The models used for clustering may not have been sensitive enough to resolve small
clusters of rare sample types, given the available data. For example several near-haploid
samples are observed as outliers in the first cluster (Supplemental figure 1, chapter 4).
Analysis with ABSOLUTE provides information that helps distinguish somatic from
germline mutations in unpaired DNA samples7. Differences in the effect of tumor purity
on the allelic-fractions of somatic vs. germline mutations can be exploited to distinguish
the two classes of events in unpaired tumor DNAs.
Promising results were obtained in preliminary analyses using ABSOLUTE to
probabilistically classify variants as somatic or germline by modeling the observed allelic
fraction of each variant compared to the expected fraction given by each possible
germline and somatic multiplicity. Receiver operating curve AUC values of -0.85 for
somatic classification recall as verified by analysis of paired-normal DNA (not shown).
Note that this refers exclusively to the clonal variants. Subclonal somatic alterations
rarely occur with plausible germline allelic fractions, making them much easier to
distinguish in the data8.
Further integration of this information with computational prediction of functional
consequences [63],[64] and statistical analysis of recurrence patterns would likely result
in adequate power to distinguish recurrent somatic alterations in particular genes. We
note that heavily contaminated tumor samples sequenced at high coverage would be ideal
for such analysis. The sensitivity of this approach can be increased by joint analysis of
multiple tumor samples of differing purity, perhaps from different sectors of a tumor
specimen, although it will be important to account for subclonal variation.
7 This might be the case when considering analysis of DNA derived from paraffin
embedded tumor specimens; such samples are available from many clinical trials, and are
thus richly annotated with valuable retrospective data.
8 Although an important exception occurs in the case of very pure tumor samples or
cancer cell-lines.
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Figure S1. Total functional aneuploidy (tFA) is correlated with the total number of
chromosomal aberrations in the NCI60 cell line panel as measured by SKY analysis. The
number of structural aberrations (NSA) is equal to the total number of insertions,
deletions, translocations and homologously staining regions, present in at least two
metaphases'. A) The tFA of each cell line is correlated with its NSA (r = 0.43). Each
point represents a cell line. The significance of this correlation was verified by
permutation testing (10,000 random permutations of cell-line labels, p = 0.0009). B) The
Pearson correlations of individual genes to tFA and to NSA are correlated (r = 0.61). For
each gene, the correlation between tFA and the expression level of the gene is plotted on
the horizontal axis, and the correlation between NSA and the expression level of the gene
is plotted on the vertical axis. Each point represents a gene.
While the trend in these plots is clear, a perfect correlation between tFA and NSA
cannot be expected. Structural chromosomal aberrations are directly observed by SKY
analysis in only a few cells, and those results are averaged and extrapolated for the entire
cell population. Furthermore, the tFA metric was conceived to take both copy-number
aberrations and structural aberrations into account. In accordance with these
considerations the above outlined results confirm that tFA and NSA are correlated,
though not equivalent.
Figure S2. SNPchip aCGH data from the NCI60 cell line panel confirms that FA is an
estimate of regional chromosomal aberrations and that tFA is an estimate of the total
level of chromosomal aberrations. Mean copy number (MCN) was determined for each
sub-band using SNPchips (see supplementary methods). A) MCN and FA are correlated
across cell lines for most sub-bands. The cumulative distribution of the MCN/FA
correlations is plotted with each point representing a sub-band. B) MCN and FA are
correlated across sub-bands for most cell lines. The cumulative distribution of
correlations is plotted with each point representing a cell line. C) tFA is correlated with
the sum of the magnitudes of MCN deviations (r=0.52). The significance of this
correlation was verified by permutation testing (10,000 random permutations of cell-line
labels, p = 0.0004). D) The Pearson correlations of individual genes to total MCN-based
aneuploidy and to tFA are correlated (r = 0.66). For each gene, the correlation between
tFA and the expression level of the gene is plotted on the horizontal axis, and the
correlation between total MCN-based aneuploidy and the expression level of the gene is
plotted on the vertical axis. Each point represents a gene.
Although the observed correlation is significant, a perfect correlation between
expression-based tFA and SNPchip-based total aneuploidy is unlikely for several reasons.
First, while there is a significant ploidy regulation of gene expression in aneuploid
tumors2A, the mean correlation between DNA copy number and gene expression levels is
around 0.2-0.34. Second, the distribution of cell-line based correlation (panel B) appears
to be bi-modal, perhaps indicating that failed hybridizations for a subset of the cell-lines
might be contaminating the analysis.
Figure S3. Total functional aneuploidy (tFA) is a significant predictor of clinical
outcome in four breast, lung, and brain cancer datasets5-8 of 18 datasets evaluated.
Samples are categorized as having poor (good) prognosis if the level of tFA is above
(below) the mean tFA across all samples in that cohort. Data sets are identified by the
first author of the publication listed in the references of the main text. Significance was
assessed using the log-rank test comparing survival curves corresponding to the two
prognosis classes.
Figure S4. Correlation between gene expression profiles and tFA is conserved in diverse
human cancer datasets. The heat map shows normalized ranks of correlations for 10,151
genes (columns), ordered according to the final integrated ranking (see methods).
Datasets (rows) are ordered by the mean difference between the normalized correlation
ranks and the ranks of the integrated ranking. For each gene (vertical bar) the color
indicates the ranking of the Pearson correlation coefficient between the gene and tFA
across the data set. Yellow indicates highest level of correlation to tFA in a given dataset;
blue indicates lowest (negative) correlation. The three datasets used to derive the
integrated ranking are marked with asterisks. This figure is also available as an image file
for better viewing.
Figure S5. Visualization of the CIN25 signature in eight datasets. Heat maps showing
normalized expression profiles of the 25-gene CIN signature. Samples are ordered by
total expression of genes in the CIN25 signature. Categorical prediction of outcome is
determined by above average (bad) or below average (good) total CIN expression (the
two categories are divided by the black line). Red and blue indicate over and under-
expression of a gene, respectively.
Figure S6. The prognostic ability of cell-cycle regulated genes is dependent on CIN
score.
A, The 764 genes with cell-cycle scores exceeding the false discovery rate (FDR)
threshold (vertical blue line) were divided into four groups based on combined thresholds
of CIN score and cell-cycle score. A high cell-cycle score threshold (vertical black
dashed line) was determined by removing genes having the highest cell-cycle score from
the CC highCIN group until the average cell-cycle score in this group was equal to that
of the CClowCIN group.
B, The prognostic ability of the four groups was compared across 18 independent
cohorts. Each bar represents the. log-rank test statistic comparing the survival curves .
corresponding to the two prognosis classes generated using the indicated gene group for
outcome prediction. While the highCIN midCC group (yellow) significantly risk-
stratified nine of the eighteen cohorts, the lowCIN_CC group (turquoise, F5A) only did
so for five (F5B). Because these gene-sets were constructed to have equal average cell-
cycle scores, we conclude that the difference in performance was due to the difference in
CIN-score between the groups.
Although the highCIN highCC group (orange) significantly risk-stratified eleven
of the eighteen cohorts, we noted that this group contained higher CIN-score genes than
the highCIN_midCC group. Furthermore, we noted that the CIN70_lowCC group was
able to risk-stratify ten of the eighteen cohorts (Figure 5B), suggesting that cell-cycle
score is relevant for prediction primarily due to the fact that many of the genes with the
highest cell-cycle scores also had very high CIN-scores.
The seven genes in the lowCIN_highCC group (green) significantly risk-stratified
five of the eighteen cohorts, whereas the the lowCIN midCC group (salmon) only did so
for two. This might indicate that the predictive ability of the lowCINhighCC group is
indeed due to detection of increased proliferation, as the lowCIN midCC group is likely
to include a higher number of false-positive cell-cycle genes.
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Figure S7. Multivariate analysis of the CIN25 and proliferation signatures revealed that
CIN25 was generally more relevant for risk-stratification of cancer cohorts.
Multivariate analysis was performed using a Cox proportional hazards model built
from the CIN25 and proliferation signatures. Shown are bars representing the -log of P
values reflecting the significance of each signature's contribution to the model.
In five of eighteen cohorts evaluated, the CIN25 signature was significant in the
Cox model given the proliferation signature. The proliferation signature was not
significant given the CIN25 signature in any of the cohorts. The combined signatures
significantly risk-stratified eleven of the eighteen cohorts (data not shown).
Figure S8. Removal of proliferation-associated genes from the CIN signature does not
impair its predictive ability for clinical outcome. A) The correlation coefficient between
each gene and the population doubling time of NCI60 cell lines was calculated across the
cell line panel. The cumulative distribution of these correlations is shown for the entire
gene list, for the CIN25 signature and for the set of 8 genes of the CIN signature without
significant correlation with the population doubling time (CIN no dt). The cumulative
distribution of correlations after permuting the cell line labels is shown in pink. B)
Patients in each clinical data set were divided into two groups based on the average log
expression of the CIN25 signature or the CINno dt gene list. Each bar represents the
log-rank test statistic comparing the survival curves corresponding to the two prognosis
classes generated using the indicated gene group for outcome prediction. The CIN
signature and CIN no dt signatures show similar power to predict clinical outcome. C)
Cumulative distribution of the CIN score for the genes contained in the proliferation
signature9 . D) The proliferation signature genes were divided into two sets based on their
CIN scores. Patients in each clinical data set were divided into two groups based on the
average log expression of the proliferation signature genes with a high CIN score
(prolif highCIN) or the proliferation signature genes with a low CIN score
(prolif lowCIN). Each bar represents the log-rank test statistic comparing the survival
curves corresponding to the two prognosis classes generated using the indicated gene
group for outcome prediction. Proliferation signature genes with a low CIN score
produced successful classification of 5 data sets (at a significance level of p=0.05) as
opposed to the 10 data sets correctly classified by the full proliferation signature. These
results suggest that the ability of the proliferation signature genes to predict clinical
outcome is dependent in part on its inclusion of high CIN-score genes. Furthermore, the
ability of CIN genes to predict the clinical outcome of various solid tumors is mainly due
to the fact that they were derived to characterize the level of chromosomal aberrations
and not due to their association with the proliferation rate of the cells.
Figure S9. The CIN signature forms a coherent module such that its genes are more
correlated with each other than with tFA. For each cancer dataset, we show the
distribution of pair-wise correlations of genes in the CIN signature (red), as well as the
distribution of correlations between the CIN genes and the tFA measure (black). The
distributions of pair-wise correlations of those CIN genes without significant correlation
with the doubling time in the NCI60 panel are shown in green. In most of the datasets the
internal coherence of the CIN module exceeds the level of correlation to tFA.
Figure S10. The CIN signature does not generate significant predictions of clinical
outcome for six of eighteen datasets evaluated. See legend for Figure 2.
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Supplementary Table 1
The top 70 genes with the highest levels of consistent correlation with tFA in 3 cancer
associated data sets were determined as described in the supplementary methods. The
genes are listed in descending order in terms of their correlation coefficients with tFA.
The 28 genes with known functional association with CIN are underlined and the
appropriate references are listed.
1. TPX2 is required for normal spindle morphology and centrosome
integrity'
its overexpression provokes polyploidization 2
it is required for targeting Aurora-A kinase to the spindle
apparatus 3
2. PRCl critical to the formation of the central spindle4
contributes to the correct formation of the spindle during the
metaphase5
3. FOXM1 is a key transcriptional regulator of genes involved in
chromosomal segregation and cytokinesis6
4. CDC2 play important regulatory roles in cell cycle control.
plays an important role in the proper timing of mitotic spindle
formation7
5. C20orf24/TGIF2
6. MCM2 involved in the initiation of eukaryotic genome replication
7. H2AFZ this particular histone is required for embryonic development
8. TOP2A plays an essential catalytic role in chromosome segregation'
9. PCNA is involved in the RAD6-dependent DNA repair pathway
10. UBE2C is required for the destruction of mitotic cyclins
11. MELK is a potential regulator of the G2/M progression and may act
antagonistically to the CDC25B phosphatase
12. TRIP13
13. CNAP1
14. MCM7
15. RNASEH2A
16. RAD51AP1
17. KIF20A
18. CDC45L
19. MAD2L1
20. ESPL I
21. CCNB2
22. FEN I
23. TTK
is responsible for targeting CNAP1, and possibly condensin, to
mitotic chromosomes.9
involved in the initiation of eukaryotic genome replication
shows increased activity during DNA replication
is required for cytokinesis'
Relocation of the Aurora B/INCENP/survivin passenger protein
complex requires KIF20A"
required to the initiation of DNA replication
is a component of the mitotic spindle assembly checkpoint that
prevents the onset of anaphase until all chromosomes are properly
aligned at the metaphase plate
p31 (comet, formerly known as Cmt2) counteracts the function of
Mad2 and is required for the silencing of the spindle checkpoint"
reconstitution of Mad2 in Brcaldeficient cells partially restored the
spindle checkpoint"
binds directly to CDC2014
is required for sister chromatid separation during mitosis in human
cells "
is a member of the cyclin family and its overexpression results in
CIN'6
causes repeat instability and aberrant DNA repair
is required for centrosome duplication and for the normal
progression of mitosis17
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is a critical regulator of genetic stability, it is required for the
spindle assembly checkpoint18
Mutation in this replication factor leads to aberrant checkpoint
control in response to damage to chromosomes'9 or DNA damage.
26. ATAD2
27. ch-TOG
28. NUP205
29. CDC20
30 CKS2
31. RRM2
has roles during mitosis in focusing MT minus ends at spindle
poles, maintaining centrosome integrity, and contributing to
spindle bipolarity 20
plays a role in chromosome separation 2'
binds to the catalytic subunit of the cyclin dependent kinases
nzyme essential for the production of deoxyribonucleotides prior
to DNA synthesis in S phase
32. ELAVL1
33. CCNB1
34. RRM1
35. AURKB
36. MSH6
is a member of the cyclin family and its overexpression results in
CIN16
essential for the production of deoxyribonucleotides prior to DNA
synthesis in S phase
its aberrant expression leads to chromosomal instability.2 2
deregulated expression of EZH2 is associated with loss of
differentiation and development of poorly differentiated breast
cancer in humans
24. CCT5
25. RFC4
37. EZH2
38. CTPS
39. DKCl
40. 01P5
41. CDCA8
42. PTTG1
43. C10 or f3
44. H2AFX
45. CMAS
46. BRRN1
47. MCM10
48. LSM4
49. MTB
50. ASFIB
51. ZWINT
52. TOPK
53. FLJ10036
is important in the biosynthesis of phospholipids and nucleic acids,
and plays a key role in cell growth
The DKC 1 protein binds to the box H + ACA small nucleolar
RNAs and the RNA component of telomerase.
binds Survivin and INCENP in vitro, it is required for stability of
the bipolar mitotic spindle23 .
its overexpression causes aneuploidy2 4 .
its aberrant expression leads to chromosomal instability22
is required for the conversion of interphase chromatin into
condensed chromosomes25
is required .for proper chromosome condensation.
it is subunit of the condensin II complex implicated in
chromosome assembly and segregation 26
is essential for mitotic checkpoint signaling27 .
its aberrant expression leads to chromosomal instability22
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54. CDCA3
55. ECT2
56. CDC6
57. UNG
58. MTCH2
59. RAD21
cell cycle regulated gene
plays a critical role in cytokinesis2 s
a regulator at the early steps of DNA replication
Sccl is essential for the association of kinetochores with
microtubules."
60. ACTL6A
61.
62. SFRS2
63. HDGF
64. NXT1
65. NEK2
66. DHCR7
67. STK6
is a kinetochore-associated protein kinase essential for faithful
chromosome segregation 30
(Aurora-A) plays a role in the stabilization at the spindle pole
during chromosome segregation.
its overexpression leads to tetraploidization3'
68. NDUFAB1
69. KIAA0286
it is a kinesin playing essential roles in the organization of central70. KIF4A
spindles3 2
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Appendix B
Markov chain monte carlo simulations for tumor
purity/ploidy inference
Scott L. Carter and Gad Getz
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Genomic DNA extracted from primary solid tumor samples is derived from a mixture
of cancer cells having abnormal genomes, and various other genomically normal cells
associated with the tumor. The relative concentration of a given DNA locus in this
mixture is directly related to it's copy number in the cancer cell population, the total
amount of DNA present in each cancer cell (ploidy), and the percentage of normal cells
present. Because the fraction of tumor cells and the tumor ploidy in a given sample are
generally unknown, much of copy number analysis to date has been restricted to con-
sidering relative changes within a given sample. Substantial variation and bi-modality
exists in the ploidy of several common solid tumor types, making direct comparisons of
lesions across tumor-sets difficult. Here we consider the problem of jointly inferring the
sample purity, tumor ploidy, and absolute copy-number levels in DNA samples isolated
from primary solid tumors. We adopt a Bayesian approach throughout, which allows
consistent treatment of the many sources of inherent uncertainty, and which naturally
accommodates multiple possible solutions.
1 Basic considerations
We presume that the raw data have been normalized appropriately and fitted to a piecewise-constant
regression function (ie., a segmentation of the genome), which makes use of the assumption that
nearby loci in the (normal) genome are likely to have the same CN level. This is the only point in
our analysis in which genomic locations are used. A substantial amount of technical noise is typically
removed from the data by this procedure.
We express the relation between the observed log copy number ratio X and the absolute copy
number q as X = Aq + b. The quantities b and A are directly related to the unknown purity: a,
and ploidy: r of the tumor sample by:
2(1 - a) a
b = - A- (1)a- + 2(1 - a)' ar + 2(1 - a)
Where a E [0, 1], with a = 1 corresponding to a 'pure' sample, consisting only of cancer cells.
The cancer-cell ploidy -r is parameterized such that genomically normal (diploid) cells correspond
to r = 2. A description of this derivation can be found in Chapter 4 of this thesis (eqn. 1).
This derivation assumes that each cancer cell present in the sample is genomically identical.
While this is almost certainly not the case in a realistic tumor sample, we consider that the majority
of genomic loci will be present at the same absolute copy number level in each cancer cell. We
furthermore assume that each non-cancer cell present in the sample is genomically normal. While
this has been somewhat controversial, recent studies support the validity of this assertion [Ref Polyak
NatGen '08].
2 Graphical model
The observed data consists of N segments having relative CN log-ratio X and mass W, where
i= W = 1. The individual segments X are presumed to be generated from an unknown number
of cluster centers ,, corresponding to discrete genomic copy-number levels, with noise o- constant in
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a given sample (for now). The values of the pc are determined by the absolute cluster copy-number
Zc, the sample purity a, and the tumor ploidy r (eq. 1).
All of the information about the values of a and r is contained in the cluster-center positions pc.
Furthermore, the 'weight' of the evidence from a given cluster is independent of the cluster mass We.
For example, CN-level 0 (homozygous deletion) may be present at genomic locations corresponding
to only 25 probes (out of 2.5x 105, say). However, if this hypothetical genome has copy numbers 0-6
present, then these 25 probes ( 1  th of the raw data) represent jth of the evidence for a and r.
Accurate inference on a and -r therefore requires that the individual segments be grouped into
the correct number of CN-level clusters, and that the cluster positions pc are correctly determined.
Unfortunately, it is generally impossible to know these quantities in advance. It is therefore necessary
to integrate over uncertainty regarding groupings of observed segments into CN-level clusters. This
is accomplished by jointly sampling C, pc and We = E Wi 1{ci = C} from a Dirichlet process:
P (C, pe, We|IX, 8) = DP (X, W, y, 6)
Where -y is the concentration parameter of the DP. The fact that the data points X have differing
associated masses W renders the DP somewhat non-standard; the details are left to Section 3.
With a clustering of segments: {C, pe, We} in hand, our task is to fit them to Q unknown absolute
CN-levels Ze E 0, 1, . . . , Q - 1. It is crucial in this formulation to apply a complexity penalty over
the number of occupied levels (Q). Currently, we use a penalty: N * - log(span), where N is the
number of segments in a sample and span is the difference between the maximum and minimum
genome level indices. Also, assignment of total-copy values of 0 (i.e., homozygous deletion) is severely
penalized. Note that the model presented in Chapter 4 of this thesis is free from this defect, as it
optimizes the weights of each mixture component to fit the data. This procedure makes extra levels
irrelevant, since they receive mixing weights of 0.
P(Zc a, rIC,[pc, e) P(peIZc, a, , E)P(Zc, a, r|E)P(Zc, a r|C, cI8)
P(pe|Zc, a, r)P(ZcE|8)P(al-)P(-rl.)
P(pc|E)
P(al-)P(r|-) Hc P(peIZc, a, r)
P(pCE|))
We use the notation P(al-) to emphasize the dependence on a prior which we wish to avoid
specifying at this time. Assignment of the Ze to CN levels {0 : Q - 1} is complicated by the
requirement that the configuration must by definition satisfy: EC ZeWe = r (i.e., the ploidy of the
cancer genome must equal the sum of it's parts). Furthermore, we constrain the dispersion of mass
around r such that the standard deviation scales with rn. This constraint imposes a structural prior
reflecting our biological intuition that higher-ploidy genomes are likely to populate a greater number
of CN levels. The constraints Cz on a micro-configuration of segment-clusters {Zc}, conditional on
an unknown K,, are therefore:
Cz= zewc - ZcWC TKr, (2)
These constraints imply dependence between assignments of segment-clusters to absolute CN-
levels, making direct Gibbs sampling intractable. Re-parameterization to an alternate ensemble in
which the mass center and dispersion are distributionally constrained by r would simplify inference.
The maximum-entropy density over Ze subject to the moment-constraints given in (2) is:
P(ZIWe, A,) = _ We Z. A2 W. (Z. _)2
$ 20e -Awczc-A 2 Wc(Ze-r) 2
Values of the Lagrange multipliers AT = {A, A2} are readily determined via Nelder-Mead opti-
mization of L2 loss, such that:
K zcwc )Q
Where (-), denotes the
P(ZIWe, A,-).
We may then write:
P(a, r~pe, E)
C
=Y We (ZC) =
C
We ((Ze - r)2) =KT
average over all configurations {Ze}, weighted by the function Q =
= CzP(Zc, a, rlpe, E)
{zc}
:(P(a-)P(r-)
IZI P(AdE)) cz ]I(Aelze,-r, a))
P(al-)P(,r|-) C Q-1
~P #.cl() 2 P(zclwe, A,)P(pelze,7r, a)(Ze=0
Sa
C
N
(a) Microcannonical model (b) Variational approxima-
tion
Figure 1: Graphical models with plate notation summarizing the conditional dependencies in the
model. Blue circles denote observed data. Dashed lines denote deterministic relationships.
This approximation allows us to replace the sum of products with a product of sums in the
factorized likelihood, allowing independent summation over possible assignments of each segment-
cluster to a Ze level. The Ze may therefore be marginalized out of the likelihood:
Q-1
P(/ pc|ZeWe, @) ~ E P( pc|Zc,&,a, r )P(Ze|We,A,)
Ze=o
= P(pc|L)
For ease of notation, we define: T = {a, r, &c, AT}. Where &, is represents the standard error of
a given cluster-center:
The data-liklihood may then be written as:
N C
P(X|@) = f P (xi|C, p, a) fl P(pcI )
i=1
Where a two-dimensional grid over a and r allows easy calculation of:
C
P(a, rI/c) = P(a-)P(rl.) J7 P(pe lJ')
P(pc) is then readily obtained via:
P( Jc) ~ P(a|-)P(-) H PCu pc|)drda
Ugrid 
T
grid C
~ E P(a|.)P(r|-) 11 P( pc|xP)
We use metropolis moves to jump between modes of the posterior, based on the equations for a
and r. i.e., we propose jumps like: b' <-- b + 1, A' <- A, etc.
3 Dirichlet process
The standard Dirichlet process (described in [Antoniak 1974] and [West 1995]) is a method for
drawing a sample from an infinite-dimensional space consisting of probability distributions over
clusterings of a finite number N of data points.
Cluster assignments ci are sampled for each datum conditional on the assignments of all other
data-points c-i:
PE c')O i-h' F(xile)dHci(8) if c = c3 for some j i;P(ci = c~c_i) oc N1-
WN fF(xi18)dGo(9) otherwise.
Where Go is the base measure of 9, and Hc, (8) gives the posterior distribution of 6 given Go and
all observations for which j 4 i and cj = c. In general, draws of 9 from the DP are not distinct,
and the number of distinct values grows as O(log N).
In our case, the individual data points X correspond to genomic segments of various sizes W. We
wish to construct a DP in such a way as to be equivalent to the case where the data are observations
of the individual probes, but where probes in the same segment always fall in the same cluster. A
corollary of this requirement is that each sample genome should have the same expected number
of CN clusters under any genome segmentation (marginal on X and y). We therefore modify the
clustering probabilities:
Pr =j cI.c) f F(xij|)dHc, (9) if c = c3 for some j = i;P(ci = cIc-i) oc 1W+y_ (3)
1_+ f F(xIE)dGo(E) otherwise.
The concentration parameter -y plays an important role in determining the number of distinct
clusters k. We wish to specify the prior distribution on the expected number of clusters ko in a
given sample to be independent of the segment sizes W. Because we generally have strong biological
intuition for reasonable values of k, we can specify a relatively tight prior on ko. This will be
important for the development of a more flexible error model.
In order handle uncertainty in y, we must be able to calculate P(kJy, N, W), the probability
(marginal on X) that the N segments of mass W[i...N] form k distinct clusters, given concentration
parameter -y. This calculation differs from that of the standard DP in which the W all equal 1. Our
task is to enumerate the multiplicities of a given configuration: {k, N, W}. Normalization by the
total multiplicities over k E {1... N} then gives the sought probability. Following [Antoniak 1974],
we define a sequence of polynomials:
Mi(x) = (x + 0)
M2 (x) = (x+wi)Mi(x) = (x+0)(x-+ wi)
- N-1 -N-1-
Mn(x) = X + ( wi Mn-1(x) = x(x+w1) .. x + Wi
i=1i=
Mn(x) is therefore a polynomial of degree N in x:
Mn(x) = nmix + ,m2x2 + - + nmnx"
In the standard DP where all W[1...N] = 1, the coefficients nm[l...] are the unsigned Stirling
numbers of the first kind, and
P(k|'y,N) = nmk7Yk [Antoniak 1974]. (4)
Mn(,Y)
Unfortunately, our modification of the Mn(x) polynomials to take into account the different
segment masses has the problem that the values of the coefficients are clearly dependant on a given
ordering of the W[1...N]. Because the DP is infinitely exchangeable, all permutations of W lead
to the same equilibrium distribution. We therefore compute the average Mn(x) coefficients under
successive permutations of W, until approximate convergence is reached.
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Mn(x) coefficients
0.08+00 1.0e+30 2.09+30
Permutation limit
(a) Coefficients of Mn (x) generated
from a descending sort of W vs. the
permutation limit of W (dark blue),
and from uniform values of W 1 ... N =
1/N vs. the permutation limit of
W (purple). Arrows indicate the or-
dering of the points corresponding to
nmi ... nmn.
Predicted P(ky, N, W moments
IN
1 1 1 " 10
0.001 0.01 0.1 0.5 1 5 10
(b) Expectation and standard devia-
tion of P(k-r, N, W) obtained from eq.
4 using various coefficients, evaluated
under several values of y.
Predicted vs. Simulated P(kly, N, W) moments
0.001 0.01 0.05 0.1
(c) Expectation and standard devia-
tion of P(k|jy, N, W) obtained from eq.
4 with permutation limit coefficients
(blue), and from direct simulation of
the DP, marginal on X (black), with
boxplots showing values of k obtained
over 250 MCMC iterations, following a
bum-in of 250 iterations.
Figure 2: ,mk coefficients, predicted moments, and comparison with simulation results.
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This procedure allows us to calculate P(k|y, N, W) using eq.(4), by plugging in the coefficients
obtained from the permutation limit. The predicted moments of this distribution are in good
agreement with results obtained from simulation of the DP (marginal on X) (figure 2(c)). We may
then consider sampling y from P(ylk, N, W) oc P(-y)P(kly, N, W), which can be accomplished using
a one-dimensional grid over log y. However, we prefer to specify our prior information in units of k,
as this quantity has obvious biological meaning.
Specifically, we may construct a prior on the 1st moment of k, marginal on N and W as follows:
E[kly, N, W] = ko ~ Scaled-Inv-X2 (vkO, 7rko)
Where koo = {Vko, Ir } correspond to equivalent sample size and location parameters, respectively.
Posterior samples of ko, conditional on observing S values of k (in S samples, say) are obtained
by sampling:
k + SC2ko|Ic, S ~ FOX2(ko +S)
Values of the expectation E[k|I7, N, W] may be pre-computed for a given {N, W} over a grid on
log y to form a map f : -y -+ ko such that f-'(ko) gives the required value of -y for the DP (figure
2(c)).
3.1 Sampling considerations
We specify a prior distribution over pe,:
Go(pc) = P(a, r7ipc- ' 01 )Comb(pe,, a, r, Q)da, dr
Where pc '0 denotes the set of cluster means obtained from the previous MCMC iteration.
Integration over the conditional posterior of a and r is well worth the extra computational effort
required for a single MCMC iteration, as doing so allows rapid convergence of the simulation (on
the order of 100 iterations). Figure 3 illustrates the DP on an example sample.
1 -1
Comb(pc, a, -, Q) 1 6(pc - f(a, 7, q))Qq=o
Where f(a, r, q) is given in eq. 1.
He_ c)= (9) M(tc|Go(pc),o-)dGo (pc)
F(xi, 8) = K(xilyc, a)
pc =
x[c =c]
Where ax[e] is the [not yet defined] technical noise estimate of a given segment i.
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0.0 0.5 1.0 1.5 2.0 2.5
Observed copy-number ratio
(a) Clustering of observed segments
into CN-level clusters by the Dirichlet
process. Individual segments are drawn
as rectangles, with height proportional
to segment size W, and colored accord-
ing to ox. Five clusters are represented
as cyan log-gaussians.
6 -
O
P(a~tIpf^)
2.25 2.6 2.95 3.3 3.65 4 4.3 4.65 5 5.3
(b) Posterior distribution computed us-
ing the clusters sampled from the DP
(a). Contours are drawn at (0.99, 0.95,
0.9, 0.8, 0.7) times the log-density at
the mode.
Go(pe)
0.5 1.0 1.5 2.0
(c) Go(pe) computed from the poste-
rior density in (b). The color of each
stick indicates the position on the cor-
responding (a, -r) grid (b).
Figure 3: Example sample from the DP at equilibrium. A tri-modal posterior density on (a, r)
corresponding to unit shifts in ploidy (b) gives rise to a prior Go(ptc) (c) in which the 'comb teeth'
from the three modes overlap at unit shifts in absolute copy-number.
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4 Model extension and refinement
The full hierarchical graphical model is illustrated in figure 4.
4.1 Error model
Thus far our discussion has presumed that segments are present in equal copy numbers in each tumor
cell in a given sample. This assumption is not realistic, and many segments exist at non-clonal copy
numbers in most tumors, resulting in segments that appear much further from the predicted copy-
number levels than technical noise (o.,) can explain. Failure to account for this source of variation
can result in dramatic failure of the model, as extraneous copy-number levels are instantiated to fit
single non-clonal segments. This situation would often result in a value of A equal to twice the true
value, corresponding to lower purity a and higher ploidy r.
In order to deal with this situation, we allow segments to be fit by one of two mixture models,
indicated by Z,. Segments for which Z, = 1 are fit with variance o>, + S, where S is a scale of global
noise due to heterogeneity: oH. The scale S is proportional to A, and is therefore a function of a
and r.
We modify our DP clustering probabilities (eq. 3), taking into account that the only parameter
the cluster-members share is the mean (E) = {pc}):
-wi = ) c fz,, F(xilpe, Z , , )P( Zo|Xi dZ d He,( c) if c = c3 for some j %i;P(ci = cjc _i) 0c 1W+ Cf.{-+ fI f. F(xilpe, Zo , ao>)P(Z,| IXj)dZjdGo(pc) otherwise.
(5)
P( Za= O|X ) oc jN(Xi1Pc,7xi )dGo(c)P(Zj = O|Oz, )
P(Zi = 1 [Xi) C A(XIIpe, ox, + S)dGo(pc)P(Z,, = 1|Oz,)
Application of Bayes' rule, along with conditional independence of the {Z._,} gives:
Hc_ (pic) 0c {zsP({Xe|c,{ 7fZac_, }, o)P({Zov }{X_j})Go(pc)d{Za,}
-
! P(Xj pc, Zj, oj)P(Z,,| X3 )dZaj Go(pc)jEfc-i} z
This likelihood can be calculated over a 1-dimensional grid on p, and empirically normalized for
each Z, mixture. In the implementation described here, the DP location prior Go is a finite comb
of Q(= 9) delta functions corresponding to a single position on (a, r).
5 MCMC sampling
Given the graphical model of figure 4 and the observed data X, 0., W, our task is to generate samples
from the posterior distribution.
Figure 4: Graphical model for multiple samples, represented by the plate S. Beige ovals denote model
hyper-parameters. A and 6 account for small variability in attenuation and (log) offset, respectively,
in a given sample. The hyper-parameters for those nodes greatly reduces the effective number of
extra parameters for these effects. Adding these nodes was important to allow for realistic amounts
of uncertainty regarding a and r.
The algorithm proceeds as follows: For each sample
Choose a metropolis jump from 1 of 5 possible move types:
1. -r' - A(r,0.025), a' +-N(a,0.025) r'+- I
2. r' <-r + 1, a' +-'
3. 7-' < (r, 0.025),6' - 6 + log 2+a( r-2)T ~ 2+a(T' -2)
4. Stay still.
Sample parameters:
1. Sample O'z,
2. Compute S' = A' * 0 H * tooth2-1
3. Sample {C', p', W'} ~ DP(X, ox, C, W, y, Oz,), {Z,} are marginalized over.
4. Optimize A'I-r', W'
5. Marginalize over {Ze} to obtain P(p' a', r', W', A'.)
6. Compute E log P(Xi lx, C, ,t's, Z,,, S', 6', A')
7. The log-likelihoods of the remaining sample-level parameters are straight-forward to compute.
8. Accept the new configuration with probability given by the standard Metropolis-Hastings ratio.
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9. Repeat for all samples.
10. Gibbs sample the top level parameters from their conditional posteriors given all sample-level
parameter values and the model hyper-parameters. (straight-forward)
6 Validation results
HCC38 HCC1143
-K!q
0
I I I I I
0.4 0.5 0.6 0.7 0.8
Fraction tumor DNA
HCC38
I I
0.9 1.0
I I I I 1
0.5 0.6 0.7 0.8 0.9
Fraction tumor DNA
I- --
*1
J1
E-ip
I I I I I I I
0.4 0.5 0.6 0.7 0.8 0.9 1.0
Fraction tumor DNA
HCC1143
It
I I I I I 1 1
0.4 0.5 0.6 0.7 0.8 0.9 1.0
Fraction tumor DNA
Figure 5: Results of the sampling algorithm for purity/ploidy inference in two
experiments. These results are highly consistent with the results shown in Figure
further details of the experiment are available in Chapter 4.
cell-line mixing
2 of Chapter 4;
7 R source code
Hmodelmet-gibbs = function( sample. seg .dat, sample. HSCN_ params,
sample-GRID, Q, genome-coverage, gen-model, dataparams, init -model,
gibbs-params, metrop-params, sample_DP_coefs , samplek_0_-maps, PLOT
DEBUG=FALSE )
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S = length (sample. seg. dat)
combQ = Q
N-iter = gibbs-params$N-iter
# initialize
gen-point = list(S)
first _lambdaguess = list(S)
est = list ()
est$MEMC = list ()
est$MIVkN_accept = array( 0, dim=c(N_iter+1) )
est$assign _Z_CN = list (S)
est$assign = list (S)
est$assign-mu-c list (S)
est$assignW-c list (S)
est$assignZ-sigma = list (S)
est$Z-sigma = list (S)
est$seg-logliks = list ()
est$propseglogliks = list ()
est$cluster _Z_CN = list (S)
est$cluster W= list (S)
est$c-mu = list (S)
est$c-stderr = list (S)
for( s in 1:S )
{
alpha GRID= sampleGRID [ s]] $alpha _GRID
tauGRID = sample-GRID[[s]]$tauGRID
N-alpha = length(alpha_GRID)
N-tau = length(tau_GRID)
N-grid N-alpha * N-tau
if( !any(is.na(gen-model)) )
{
gen-point [[s]] c( which.min( abs( alphaGRIh genmodel$
alpha[s]) ),
which.min( abs( tauGRIiD - genmodel$tau[s])
)}
else{ gen-point[[s]] = NA }
est$cluster _Z_CN[[ s]] = list ()
est$cluster _W[s]] = list ()
est$Z-sigma[[s]] = list()
P-s = length( sample.seg.dat [[s]][ ,"copynum"] )
est$assign[[s]] = array( NA, dim=c(P_s, N iter+1) )
est$assign-mu-c[[s]] = array( NA, dim=c(P-s, N-iter+1) )
est$assignW-c[[s]] = array( NA, dim=c(P-s, N-iter+1) )
est$assign [[s]][,1] = c(1:Ps) ### converges fast!!!
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est$assignZCN[[s]] = array( NA, dim=c(P-s, Q, (Niter+1) ) )
est$assign-Z-sigma[[s]] = array( NA, dim=c( (N-iter+1), P-s, 2 ) )
est$seglogliks [[s]] = array( NA, dim=c(P-s, (Niter+1)) )
est $prop-seg _ logliks [[s]] = array ( NA, dim=c(P-s , (N_ iter+1)) )
first _lambda-guess [[ s]] c(0,0)
}
K-tau-hat = array( dim=S )
sample-sigma_H_hat = array( dim=c(S,2) )
est$alpha = array( dim=c(S,N_iter+1) )
est$tau = array( dim=c (S,Niter+1) )
est$alpha[,1] = 0.5
est$tau[,1] = 2.5
est$prop-type = array( NA, dim=c(S,Niter+1) )
est $MH correction = array( NA, dim=c(S,N iter+1) )
est$alpha-theta = array( dim=c( 2, Niter+1 ) )
est$tau-theta = array( dim=c( 2, N_iter+1 ) )
est$sigmaH = array( dim=c( N-iter+1) )
est$K-tau = array( dim=c (Niter+1) )
est$k_0= array( dim=c(N_iter+1) )
est$loglikD = array( -Inf , dim=c(S,Niter+1) )
est$prop-loglikD = array( NA, dim=c(S,N_ iter+1) )
est$DP_ oglik = array( NA, dim=c(S,Niter+1) )
est$Z-sigma-loglik = array( NA, dim=c(S,Niter+1) )
est $cluster _Z_CN_ loglik = array( NA, dim=c(S,Niter+1) )
est$prop-DP_ oglik = array( NA, dim=c(S,Niter+1) )
est$propZ-sigma-loglik = array( NA, dim=c(S,N_iter+1) )
est $prop_ cluster _ZCN_ loglik = array( NA, dim=c(S,Niter+1) )
est$k = array( dim=c(S,N-iter+1) )
est$thetaZ-sigma = array( dim=c(S,2,N-iter+1) )
est$ThetaZ-sigma = array( dim=c (2,N_iter+1) )
est$deltatheta = array( dim=c (2,Niter+1))
est$delta = array( dim=c (S, Niter+1))
est$AT-theta = array( dim=c(2,N_iter+1))
est$AT = array( dim=c(S, N-iter+1))
est$epsilon-theta = array( dim=c(2,N_iter+1))
est$epsilon = array( NA, dim=c(S, Niter+1))
est$Gmass = array( NA, dim=c (S, N iter+1))
est$Lambda = array( NA, dim=c (S, LAMBDAD, N iter+1))
est$alpha-theta[,1] = init _model$alpha-theta
est$tau-theta [,1] = init _model$tau-theta
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est$delta-theta [,1] = init model$delta-theta
est$delta [,1] = init _model$delta-theta [1]
est$epsilon [ ,1] = init _model$epsilon _theta [1]
est$epsilon -theta [,1] = init _model$epsilon -theta
est$AT-theta[,1] = initmodel$AT-theta
est$AT[,1] = init model$AT-theta [1]
est$K-tau[1] = initmodel$K-tau
est$k_0[1] = initmodel$k_0
est$sigmaH[1] = init model$sigmaH
## init Z-sigma
for( s in 1:S )
{
est$theta_Z_sigma[s, ,1] = init _model$theta _Z-sigma}
est$ThetaZ-sigma [ ,1] = init _model$ThetaZ-sigma
if( ! is .na(gibbs _params$random-seed) ) { set. seed (gibbsparams$random
_seed) }
proposals = rep(0,4)
for( i in 1:N-iter )
{
accepted = 0
for( s in 1:S )
{### Sample-specific constants
seg . dat = sample. seg . dat {[ s ]]
obs = list ()
obs$HSCNparams sample .HSCNparams [[ s ]]
obs$d = tx-data( sample.HSCN_params [[s ]] , seg . dat [ ,"copy-num"]
)
obs$seg sigma = seg .dat [,"seg-sigma"]
obs$W= seg.dat[,'W']
obs$alphaGRD = sample-GRI [[s]] $alphaGRID
obs$tauGRID = sampleGRID [[ s]] $tau _GRID
obs$sample-k_0_map = sample-k_0_maps [[s]]
obs$sample _DP. c o e f s = sample _DP_ c o e f s [[ s]]
# get a proposal on alpha/tau
new-conf = get-alpha-tau-proposal( est , s, i, conf, obs, gibbs
params, metropparams )
# sample rest of model given proposal
## includes loglik calculation
newconf = sampleconf -point ( new_ conf , est , s , i , Q, obs ,
gibbsparams, metropparams )
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W= new-conf$cluster _W
Z-CN = newconf$cluster _Z_CN
Gmass = sum( (c (1:Q) -1) * W %*% ZCN )
if ( data params$DATATYPE =- " alle le" ){ Gmass = Gmass * 2 }
msg = paste (" alpha: _" , round (new- con f$alpha , 4) , " t au:
round (new_ conf $tau , 4) , " , -Gmass: " , round (Gmass, 4)
loglik :3' , round(new_ conf$loglik ,4) , sep="" )
print (msg)
cur-loglik = est$loglikD[s,i]
MH-ratio = exp(new-conf$loglik - cur-loglik) * new-conf$MH_
correction
log-accept_prob = min( (new-conf$loglik - cur-loglik) + log(new
_conf$MHcorrection) , 0 )
if ( DEBUG == TRUE)
{
est$prop-loglik _D[s ,( i+1)] new-conf$loglik
est$propDP-loglik [s ,( i+1)] = new-conf$cluster _res$loglik
est$prop-seg-logliks [[s]][ ,( i+1)] = new-conf$seg-logliks
est$propZ-sigma-loglik [s,( i+1)] = new-conf$Z-sigma-loglik
est$prop-cluster _Z_CNloglik [s,(i+1)] new-conf$cluster_Z_
CN-loglik
}
if( log(runif( 1,0,1 )) < log-accept-prob ) # accept move
{
chr="O"
est = accept -move( newconf est , s, i )
accepted = accepted + 1
}
else
{
chr="X"
est = reject _move( est , s, i )}
cat(chr)
K-tau-hat[s] = calcK-tau-hat( est$clusterW[[s]] [[( i+l)]] , est$
cluster ZCN[[s ]] [[( i+l)]] , est$tau[s,(i+l)], Q, gibbs-params
$zero-p )
cat( length(unique( est$assign [[s]][ ,(i+1)])) ); cat(" ,,")}
cat (" \n")
est$alpha-theta[,(i+l)] = alpha-theta-posterior( est$alpha[,(i+l)
], gibbs params$pi-alpha-theta )
est$tau-theta[,(i+l)] = alpha-theta-posterior ( est$tau[,(i+l)],
gibbs params$pi-tau-theta )
est$K-tau[(i+l)] = Ktau-post( K-tauhat, gibbsparams$K-tau-theta
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est$k_0[(i+1)] = H-k_0_post( est$k[ ,( i+1)] , gibbsparams$k_0_theta
)
est$sigmaH[(i+1)] = est$sigmaH[i]
stz = apply( matrix(est$thetaZ-sigma[, ,(i+1)] ,nrow-S) , 2, sum )
est$ThetaZ-sigma [1, (i+1)] = rbeta( 1, gibbs -params$pi theta-Z_
sigma [1] + stz [1 , gibbs-params$pi-thetaZ-sigma [2] + stz [2] )
est$ThetaZ-sigma[2 ,(i+1)] = 1 - est$ThetaZ-sigma[1 ,(i+1)]
HP gibbs _params$pi _delta _theta
res = NormInvChi sq-post( est$delta [ ,(i+1)] , IIP[1], HP[2] , IP
[3] , HP[4] )
est$delta-theta[1 ,(i+1)] = res$mu
est$delta-theta [2 ,( i+1)] = res$sigma
HP = gibbsparams$piAT-theta
res = NormInv-Chi sq post( est$AT[, ( i+1)] , HP[1] , HP[2] , HP[3]
HP[4] )
est$ATtheta[1,(i+1)] = res$mu
est$ATtheta [2 ,( i+1)] = res$sigma
HP = gibbs _params$pi _epsilon _theta
res = NormInv _Chi sq_ post( est$epsilon [ ,( i+1)] , HP[1] , HP[2] , HP
[3] , HP[4] )
est $epsilon _theta [1,( i+1)] = res$mu
est $epsilon _theta [2 ,( i+1)] = res$sigma
print( paste("k_0:' , round(est$k_0[i+1],3), sep="" ) )
print( paste("sigmaH:. _, round(est$sigmaH{(i+1)] ,3) Sep="")
print( paste ("K_ tau:-" , round(est$K~tau[(i+1)] ,3) , sep="") )
print ( paste (" Theta _Z_sigma: -" , round ( est $Theta _Z-sigma [ , ( i+1)
] ,3) , sep="") )
print( paste(" delta _theta:." , round(est $delta -theta[ ,(i+1)] ,3)
Sep="") )
print( paste ("AT_ theta:-" , round(est$ATtheta [ ,( i+1)] ,3) , sep=""
) )
print( paste("epsilon-theta:-", round(est$epsilon-theta[,( i+1)] ,3) , sep="") )
print( paste("loglik :., round( sum(est$loglikiD[,(i+1)],na.rm-=T
) , 3) , sep="") )
print ( paste (accepted , "._moves-accepted" , sep="") )}
print ( est$k_0)
print (est$sigma_H)
print (est$K-tau)
print( apply(est$loglik _D, 2, sum, na.rr-T )
print ("Move-acceptances :' )
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print( est$MK$N accept )
print( surn(est $MMK$N-accept [1: i]) )
return( est )
get-span -penalty = function( ZCN, k, eps=le-5 )
{
Z = apply( ZCN, 2, sum, na.rr=T )
Z = Z / sum(Z)
Q = length (Z)
while( Z[i] < eps ) { i i ± 1 }
j = 1
while( rev(Z)[j] < eps ) { j = j + 1}
Nused = Q - (j -1 + i -1)
## BIC penalizes high-complexity solutions less.
# sez gaddy
# H = k * -log (Nused)
# More BIC-like penalty:
H = Nused * -log(k)
return (H)
sampleDP = function( obs, s, i, est , pi-c-mu, pi-c-sigma ){
## get clusters from DP
conf = list ()
k_0_topngmamap = function( k_0, k_0_map )
{
ix = which.min( abs(k_0 - k_0_map[,1]) )
return( k_0_map[ix,2] )
}
usegamma = k__togamnna_map( est$k-0[ i], obs$samplek_0_map )
cluster res = DP-post ( obs$d, use gamma, obs$segsigma, est$assign [[s
]] [7 i] obs$W, pi-c-sigma, pi-c-mu, obs$sampleDP-coefs )
conf$assign = cluster _res$assign
conf$clusterW = cluster res$cW
clusters = unique( conf$assign )
K = length(clusters)
for( j in 1:K )
{
cc = which( conf$assign -= clusters [j] )
conf$assign mu-c[cc] = cluster _res$means[j]
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conf$assign-sigma_c [cc] = cluster _res$sigmas [j
conf$assign _W_c [cc] = cluster -res$cW[ j]
}
conf$k = K
conf$DP-loglik = cluster _res$loglik
conf$c-mu = cluster _res$means
conf$c-stderr = cluster-res$stderrs
return( conf )
}
sample conf _point function( conf , est , s, i, Q, obs, gibbs _params,
metrop-params )
{
## Marginalize over ZCN
WC = conf$clusterW
if( data-params$DATATYPE = "total" )
if( LAMBDAD =1
{
resid = Inf
while( resid > 0.01 )
{
lambda-res = getLambda( conf$tau, WC, est$K-tau[i] ,
gibbs _params$zero _p, first _lambda-guess=NA )
resid = lambda- res$resid
cat (" .")}
m3 = -lambda-res$Lambda * ( (c(1:Q)-1) %*% t(W-C) )
}
i f( LAMBDAD = 2
{
lambda-res = getLambda( conf$tau, WC, est$K-tau[i], Q, gibbs
params$zerop, first _lambda guess=est$Lambda[s , ,(i -1)] )
m31 = -lambda_ res $Lambda [1] * ( (c(1:Q)-1) %*% t(WC) )
ff c( gibbs params$zerop, rep(0, (Q-1) ) )
m32 -lambda-res$Lambda[2] * ( log( (c(1:Q)-1) + ff) - log(
conf$tau))^2 %*% t (WC)
m3 = m31 + m32
I
if ( dataparams$DATATYPE == " alle le " )
{
use-tau = conf$tau / 2
WC = W-C
resid = Inf
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while( resid > 0.01 )
{
lambdares = getLambda( usetau, WC, est$Ktau[i], Q, gibbs-
params$zerop, first _lambda-guess=NA )
resid = lambda-res$resid
cat(".")
}
m3 = -lambda-res$Lambda[1] * ( (c(1:Q)-1) %*% t(W-C) )
}
conf$Lambda = lambda_ res$Lambda
if( lambda-res$resid > 0.01 )
{
cat("! !"
print( lambda-res$resid )
conf$Lambda = NA
}
## Q x K
loc-comb = get -gridpoint _comb( conf, Q, obs$HSCN-params )
res = getSS-combLL( conf, loc comb, est$sigmaH[i] ) ## updates Z
sigma
ml = res$SSLL
conf$Z-sigma = res$Z-sigma
## Sample thetaZ-sigma
sz = apply( conf$Z-sigma, 2, sum)
P-s = dim( conf$Z-sigma ) [1]
conf$theta _Z-sigma = est$thetaZ-sigma [s, ,i
## marginzalize over Z-CN
res = get-seg ANL soft assign( ml, m3, Q, lambda-res$norm-term )
conf$cluster _ZGCN_ loglik = res$loglik
conf$cluster _Z-CN = res$soft -assign
if( !is.finite( conf$cluster-ZCN-loglik ) ) { stop() }
conf = calc-conf-loglik ( conf , est , s, i, obs )
conf$Gmass = sampleGmass( conf )
return( conf )
}
sampleGmass = function( conf )
{
CN = rep( NA, conf$k )
for( k in 1:conf$k )
{
CN[k] = which( rmultinom( 1, 1, conf$cluster _ZCN[k,] ) = 1 ) - 1}
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Gmass = sum( CN * conf$clusterW )
return (Gmass)
}
thetaZ-sigma-gibbs-post = function( pi-theta-Z-sigma, Z-sigma )
{
thetaZsigma = c(0,0)
s1 = pithetaZ-sigma[1] + sum( Z-sigma[ ,1] )
s2 = pi _theta _Z-sigma [2] + sum( Z-sigma[ ,2] )
theta _Zsigma [1] = rbeta( 1, s1 , s2 )
theta _Zsigma [2] = 1 - thetaZ-sigma [1]
return( thetaZ-sigma )
}
calc-conf-loglik = function( conf, est , s, i , obs)
{
# Sample loglik calculation
k = conf$k
p = conf$thetaZ-sigma [1]
x = sum(conf$Zsigma[,1] * conf$clusterW ) * k
Z-sigma-loglik = x*log(p) + (k-x) * log(1-p) # log of un-
normalized binomial density
S = dim( est$thetaZ-sigma ) [1]
theta-Z-sigma-loglik = 0
delta-loglik dnorm( conf$delta , est$delta-theta [1, i], est$delta_
theta[2, i], log=TRUE
AT-loglik = dnorm( conf$AT, est$AT-theta[1,i], est$AT-theta[2,i], log
=TRUE)
epsilon-loglik = dnorm( conf$epsilon , est$epsilon-theta [1 ,i], est$
epsilon _theta [2 , i] log=TRUE )
conf$Z-sigma-loglik = Z-sigma-loglik
alpha-loglik = dnorm( conf$alpha, est$alpha-theta[1,i], est$alpha_
theta [2 , i] log=T)
tau-loglik = dnorm( conf$tau , est$tau-theta [1, i] est$tau-theta [2 , i]
log=T )
H = get -span _penalty( conf$cluster -Z_CN, conf$k )
conf$loglik = H +
conf$cluster _Z_CN_ loglik +
conf$DP-loglik +
Z-sigma-loglik +
thetaZ-sigma-loglik +
delta-loglik +
AT-loglik +
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epsilon-loglik +
alpha-loglik +
tau-loglik
if( is.nan( conf$loglik ) )
{
dump. frames( dumpto="Hmet.framedump", to. file=TRUE
}
return( conf )
}
get gridpoint -comb = function( conf, Q, HSCN-params )
{
res = get-b-and-delta( conf$alpha, conf$tau )
means = get-means( Q, res$delta, res$b, conf$delta, conf$epsilon
HSCNparams )
combX = means
Delta = res$delta
t2 = means [2]
combS = log( (Delta + t2) / t2, 2 )
return( list ("X"=combX, "S"=combS) )
}
accept _move = function( conf , est , s , i )
{
est$alpha[s,(i+1)] = conf$alpha
est$tau[s ,( i+1)] = conf$tau
est$delta[s,(i+1)] = conf$delta
est$AT[s,(i+1)] = conf$AT
est$epsilon[s,(i+1)] = conf$epsilon
est$Gmass[s,(i+1)] = conf$Gmass
est$Lambda[s, ,(i+1)] = conf$Lambda
est$Z-sigma [[s ]] [[ ( i+1)]] = conf$Z-sigma
est$theta-Z-sigma[s,,(i+1)] = conf$thetaZ-sigma
est$assign [[s]][ ,(i+1)] = conf$assign
est$clusterW[[s]] [[( i+1)]] = conf$clusterW
est$clusterZ-CN[[s]][[(i+1)]] = conf$cluster _Z_CN
est$assignmuc [[s]][ , ( i+1)] = conf$assign _mu-c
est$assignWc [[s]][ ,( i+1)] = conf$assignW-c
est$k[s,(i+1)] = conf$k
est$cmu[[s]] = conf$c-mu
est$c-stderr[[s]] = conf$c-stderr
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est$loglik-D[s,(i+1)] = conf$loglik
est$VMC$N-accept[i] = est$V1MC-Naccept [i] + 1
est$DP_ oglik[s,(i+1)] = conf$DP_ oglik
est$Z-sigma-loglik [s ,( i+1)] = conf$Z-sigma-loglik
est$cluster ZCN-loglik [s,(i+1)] = conf$cluster_Z_CN_loglik
est$proptype[s,(i+1)] = conf$type
est$MH-correction [s,(i+1)] = conf$MHlcorrection
clusters = unique( conf$assign )
K = length(clusters)
for( j in 1:K )
{
cc = which( conf$assign = clusters [j] )
est$assign Z-sigma [[s]]( i +1) ,cc , 1] conf$Z-sigma [j , 1]
est$assignZ-sigma [[s]]( i+1) ,cc ,2] = conf$Z-sigma[j ,2]
}
return( est )
}
reject _move = function( est , s , i )
{
est$alpha[s,(i+1)] = est$alpha[s,i]
est$tau [s ,( i+1)] = est$tau[s ,i]
est$delta[s,(i+1)] = est$delta [s, i]
est$AT[s,(i+1)] = est$AT[s,i]
est$epsilon [s,(i+1)] = est$epsilon [s, i]
est$Gmass[s,(i+1)] = est$Gmass[s,i]
est$Lambda[s,,(i+1)] est$Lambda[s,,i]
est$Z-sigma[[s]][[( i+1)]] = est$Z-sigma[[s]] [[i]]
est$thetaZ-sigma[s, ,(i+1)] = est$thetaZ-sigma[s,, i]
est$assign [[s]][ ,(i+1)] = est$assign [[s]][, i]
est$clusterZCN[[s]][[( i+1)]] = est$cluster_Z_CN[[s]][[ i ]]
est$clusterW[[s]][[( i+1)]] = est$clusterW[[s]][[i]]
est$assignmu_c[[s]][,(i+1)] est$assign-mu-c[[s]][ ,i]
est$assignWc [[s]][ ,( i+1)] = est$assignWc [[s]][ , i]
est$assignZCN[[s]][ , ,( i+1)] = est$assignZCN[[s]][, ,i]
est$k[s,(i+1)] = est$k[s,i]
est$loglikD[s ,( i+1)] = est$loglik _D[s , i]
est$DP_ oglik[s,(i+1)] = est$DP_ oglik[s,i]
# est$seglogliks[[s]][,(i+1)] = est$seglogliks[[s]J[, i]
est$Zsigmaloglik [s,(i+1)] = est$Z-sigma-loglik [s,i]
est$clusterZCN-loglik [s,(i+1)] = est$clusterZCN-loglik [s, i]
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est$assign _Z-sigma [[s ]][( i+1) , ,] = est$assign _Z-sigma [[s ]] [ i ,
return( est )
}
calc _sigma _Hlhat = function ( conf, obs )
{
P-s = dim( conf$Z-sigma ) [1]
DF= Ps
sigma-Hhat = array( NA, dim=Ps )
aX = array( NA, dim=P-s )
Z-sigma conf$Z-sigma
assign = conf$assign
comb-post _set = conf$comb post set
K = conf$k
clusters = unique( conf$assign )
for( k in 1:K )
{
cc = which( assign = clusters [k] )
comb-post = combpostset [[k]]
# integrate over mu-c
xx = sapply( obs$d[cc], "-", as.vector(comb-post$X) )
sq-dist = apply( xx^2 * as.vector(comb-post$Y), 2, sum )
Si-sq = sum( as.vector(comb-post$S)^2 * as.vector(comb-post$Y) )
xx = sum(sq-dist * Zsigma[cc,2] / Si-sq) / sum(Zsigma[cc ,2])
sigmaH-hat[cc] = sqrt(xx)}
sigmaH-hat [ is .nan(sigma _HLhat) ] = 0
sigmaH-hat [ sigmaHhat < 0 ] = 0
sigmaH = mean( sigmaH-hat )
return( list ("DF"=DF, "sigma-H_hat "=sigmaH) )
}
sigma _H post = function ( sample _sigma _HAhat, pi sigma _H )
{
DF=sum( sample-sigmaH-hat[,1]
sigma _H.hat = mean( sample-sigma_H_hat [ ,2] )
post = InvChi-sq-post( DF, sigmaH-hat, pi-sigmaH[1], pi-sigmaH[2])
return (post)
}
calcK_ tau-hat = function( W, ZCN, tau, Q, zerop )
#" this is over super-segs
## Calculate sufficient statistic for K-tau
P-s = length(W)
EGmassdist = 0
ff = c( zero-p, rep(O, (Q-1) ) )
for( p in 1:Ps )
{
if( data -params$DATATYPE "total" )
{
EGmass-dist = EGmass-dist +W[p] * sum( ZCN[p,] * ( log( (c
(1:Q)-1) + ff) - log(tau))^2, na.rrn-TRUE )
}
if ( data-params$DATA-TYPE = " allele "
I
E-Gmassdist = E-Gmassdist +W[p] sum( Z-DN[p,] ((c(1:Q)
-1) - tau/2)^2, na.rm-TRUE )
}}
Ktauhat = EGmassdist / tau
return( K-tau-hat )
}
DP_ post = function( data, gamma, sigmax, assigninit , W, pisigma, pi_
mu, stirlingcoef )
{
N = length(data)
assign = assign-init
clusters = array(NA, dim-N+1)
cluster _stats = list (N+1)
cluster prior = list ("mu"=pi _mu$mu-0, "sigma"=pi _sigma$sigma 0)
for( j in 1:(N+1)
{
cluster 
_stats [[j ]] = 0
clusters [j] = sum(assign == j)
}
c-1ik = array(O, dim-+1)
dirty = array(TRUE, dim=N+1)
dirty [ clusters = 0 ] = FALSE
for( n in 1:N)
c-lik = rep(O, length(c-lik)
skip _count = 1
NZ-clusters = which( clusters != 0 )
for( j in 1: length (NZ_ clusters)
I
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c-ix = NZ-clusters [j]
c-dat = (assign = cix)
if( dirty [cx] = TRUE )
{
res = get -cluster _stats ( cdat, data, sigmax, pimu, pi-
sigma )
cluster stats [[c-ix]] = res
dirty [cix] = FALSE}
# if the current point is the only thing in the cluster ...
# This seems to work empirically (as well as theoretically)
if ( sum(cdat) = 1 & c-dat [n] = TRUE )
{
skip -count = skip-count + 1 ## at most = 2
next
}
&# all snps are equal (almost, should use n-probes instead of length
const = sum(W[c-dat]) / (1 - W[n] + ganna)
if( c-dat[n] == FALSE )
{
c-res = cluster stats [[cix]]
}
else
{
# remove the current point from the cluster
# and re-compute cluster stats
cdat [n] = FALSE
c-res = get-cluster stats( cdat data, sigma-x, pi-mu, pi_
sigma )
}
res = cluster_prob( c-res , data[n], sigma-x[n] )
c-lik [c-ix] = const * res$clusterprob
}
# prob to open a new cluster
const = (gamnma) / (1- W[n] + ganna)
cluster _prior$mu = data[n]
cluster -prior$stderr = 0
res = cluster-prob( cluster-prior , data[n] , sigma-x[n] )
h-lik = skip-count * const * res$cluster-prob
new-c._ix = min( which( clusters==0) )
clik [new-c-ix] = h-lik
c-lik [ is .nan(c-lik)] = 0
if ( sum( c-lik ) > 0 )
{
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res = which( rmultinom( 1, 1, c-lik ) = 1 )
}
else
{
print ("DP: - a11 -c-_li k=-0! ! !
res = new-cix
}
## if a point has been assigned to a different cluster..
if( assign [n] != res )
{
clusters [ assign [n] ] clusters [ assign [n] ] - 1
if( clusters [ assign [n] ] > 0 )
{
dirty [ assign [n] ] TRUE
}
else
{
cluster -stats [[ assign [n] ]] 0
}
dirty [ res] = TRUE
clusters [res] = clusters[res] + 1
assign [n] = res
}}
NZ-clusters = unique(assign)
c-mu = rep(0, length(NZ-clusters) )
c-stderr = rep(0, length(NZclusters) )
cW= rep(0, length(NZclusters) )
for( j in 1:length(NZ-clusters) )
{
c-ix = NZ-clusters[j]
c-dat = (assign = c-ix)
if( dirty [c-ix] = TRUE )
{
res = get-cluster _stats( cdat, data, sigma-x, pi-mu, pi-sigma
)
cluster stats [[cix ]] = res
dirty [c-ix] FALSE}
c-res = cluster stats [[c-ix ]]
c-mu[j] = cres$mu
c-stderr [j ] = c-res$stderr
cW[j] =sum( W[c-dat]
DP-loglik = calcDP-loglik( N, length(NZ-clusters), gamma, stirling
coef )
215
return( list("means"=cmu, "stderrs"=c-stderr , "cW'=cW, "assign"=
assign, "loglik"=DP-loglik , "K=length(NZclusters) ) )
}
calcDP-loglik = function( N, K, alpha, coefs )
{
## actually returns the log of the normalized probability
# Escobar and West 1995 for DP loglik. No correction for segment
sizes!
# loglik = log(stirlingcoef[K]) + lgamma(N-1) + K*alpha + Igamma(
alpha) - lgamma(alpha + N)
## Carter and Getz 2008 with seglen correction.
loglik = log(coefs [K]) + K*log(alpha) - log( evaliLpolynom(alpha,
coefs) )
return(loglik)
}
evalNLpolynom = function( alpha, coefs )
{
pows = c(1:length(coefs))
res = sum( coefs * alpha^pows )
return(res)
modDP-conc-post = function( k, N, coefs, gannatheta )
{
### Escobar and West 1995
# eta = rbeta( 1, alphaDP, N)
# new-alpha = rgamma( 1, a-alphaDP[1] - log(eta), a-alphaDP[2] + J -
1 )
N~gmma = 25
gammaGRID = exp( seq( log(O.0005) , log(O.05) , length. out=N-ganma )
for( i in 1:N~gnna
{
gridres[i] = calc _DP_ loglik ( N, k, gannaGRID[ i], coefs ) +
dganna( gamnaGRID[i] , gamatheta [1] , gannatheta
[2] , log=T
}
mx = max(gridres)
nf = sum( exp(grid-res mx) )
griddensity = exp (grid res-mx) / nf
res = which( rmultinom( 1, 1, grid-_density ) )
new-gamnia = grid -density [ res ]
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return (newgamma)
}
cluster prob = function( cres , x, sigma-x )
{
nI dnorm( x, c-res$mu, sqrt(sigma-x^2 + c-res$stderr^2) )
# n1 = dnorm( x, c-res$mu, sigmax )
return( list(" cluster _prob"=n1) )
}
c-sigma-hat = function( c-data, c-mean, c-var )
{
c_SD sqrt( sum( ((c-data-c-mean)^2 + c-var) / c.var) / sum( 1/c-var
) )
return(cSD)
}
get cluster _ stats = function( cix, data, sigmax, pimu, pisigma )
{
c-var = sigma-x[cix]^2
c-dat = data[cix]
N = length(c-dat)
muhat = sum( cdat / cvar ) / sum( 1/cvar )
sigma-hat = c-sigma-hat( c-dat , muhat, c-var )
# new parameters
ybar = mu-hat
s = sigma-hat
# priors
mu_0 = pimu$muO
k_0 = pi-mu$k_0
sigma_0 = pi-sigma$sigma_0
v_0 = pisigma$v_0
mu-n mu_0 * k_0 / (k_0 + N) + y-bar * N / (k0 + N)
k-n = k_0 + N
v-n v_0 + N
if( N > 1 )
{
v-n-sigma-sq = v_0 * sigma_0^2 + (N -1)*s^2 + (y-bar - muO)^2 *(k
_0 * N)/(k_0 + N)
sigma-n = sqrt(v-n-sigma-sq / vn )
}
else
I
sigma-n = sqrt(c-var[1])
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# posterior samples
post-mu = rnorm( 1, mu-n, sqrt( sigma-n^2 / kn) )
dd = rchisq( 1, vn )
post-sigma = sqrt( v-n * sigma-n^2 / dd )
return( list("mu"=postmu, "stderr"=post sigma/sqrt(kn)) )
# return( list ("mu"=post-mu, "stderr"=post-sigma) )}
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